

# CITATION REPORT

List of articles citing

## WAF1, a potential mediator of p53 tumor suppression

DOI: 10.1016/0092-8674(93)90500-p  
Cell, 1993, 75, 817-25.

**Source:** <https://exaly.com/paper-pdf/24044651/citation-report.pdf>

**Version:** 2024-04-23

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2263	Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway. <b>1992</b> , 33, 1307		5
2262	Differential role of diphenyleneiodonium, a flavoenzyme inhibitor, on p53-dependent and -independent cell cycle progression. <b>1992</b> , 33, 1299		
2261	Cell cycle. Dams and sluices. <b>1993</b> , 366, 634-5		104
2260	p53: at the crossroads of molecular carcinogenesis and risk assessment. <b>1993</b> , 262, 1980-1		410
2259	Braking the cycle. <i>Cell</i> , <b>1993</b> , 75, 839-41	56.2	372
2258	The genetics of human cancer: implications for ecotoxicology. <b>1994</b> , 102 Suppl 12, 75-80		7
2257	Cyclin G is a transcriptional target of the p53 tumor suppressor protein.. <b>1994</b> , 13, 4816-4822		319
2256	Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells.. <b>1994</b> , 13, 4823-4830		34
2255	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation.. <b>1994</b> , 13, 3496-3504		150
2254	A temperature-sensitive mutant of human p53.. <b>1994</b> , 13, 2535-2544		98
2253	The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B.. <b>1994</b> , 13, 3772-3781		189
2252	p53 oligomerization and DNA looping are linked with transcriptional activation.. <b>1994</b> , 13, 6011-6020		88
2251	Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein.. <b>1994</b> , 13, 5393-5400		27
2250	Differential regulation of E2F transactivation by cyclin/cdk2 complexes. <b>1994</b> , 8, 1772-86		318
2249	Interactions among regulators of RNA abundance characterized using RNA fingerprinting by arbitrarily primed PCR. <b>1994</b> , 22, 4419-31		46
2248	High-resolution structure of the oligomerization domain of p53 by multidimensional NMR. <b>1994</b> , 265, 386-91		278
2247	Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. <b>1994</b> , 14, 6264-77		546

2246	Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function. <b>1994</b> , 8, 2939-52	546
2245	Molecular biology of human papillomavirus infection and oncogenesis. <b>1994</b> , 103, 248-56	25
2244	Differential cDNA cloning by enzymatic degrading subtraction (EDS). <b>1994</b> , 22, 4381-5	42
2243	Tumor Suppressor and Immediate Early Transcription Factor Genes in Non-small Cell Lung Cancer. <b>1994</b> , 106, 372S-376S	3
2242	Cooperation between mutant p53 and the ras, raf, erbb-2 and fgf-3 oncogenes for transformation of mammary epithelial-cells. <b>1994</b> , 5, 1141-50	
2241	EFFECTS OF MUTANT P53 GENES ON TRANSFORMATION OF HUMAN MAMMARY EPITHELIAL-CELLS. <b>1994</b> , 4, 1077	
2240	Pathogenesis of cancer in view of mutually opposing apoptotic and anti-apoptotic growth signals. <b>1994</b> , 4, 1257-63	2
2239	T-antigen of sv40 blocks p53 transactivation but not p53 specific binding to DNA. <b>1994</b> , 5, 945-53	1
2238	Increased mdm2 expression and immunoreactivity in human pancreatic ductal adenocarcinoma. <b>1994</b> , 5, 1279-84	4
2237	3 distinct regions of chromosome-6 are targets of loss of heterozygosity in human ovarian carcinomas. <b>1994</b> , 5, 1043-8	4
2236	Effect of actinomycin-d on the cell-cycle progression and the expression of p53, waf1/cip1, gadd45, and mdm-2 genes in human oral keratinocytes - implication of human papillomavirus infection. <b>1994</b> , 5, 1023-30	
2235	Nuclear exclusion of p53 controls DNA-synthesis through reduction in the expression of p21 inhibitor of cyclin-dependent kinase-2. <b>1994</b> , 5, 1059-64	
2234	Pathogenesis of ovarian cancers. <b>1994</b> , 1, 181-90	36
2233	Regulation of mdm2 expression by p53: alternative promoters produce transcripts with nonidentical translation potential. <b>1994</b> , 8, 1739-49	253
2232	Cell cycle analysis of the activity, subcellular localization, and subunit composition of human CAK (CDK-activating kinase). <b>1994</b> , 127, 467-78	222
2231	Loss of cell cycle controls in apoptotic lymphoblasts of the bursa of Fabricius. <b>1994</b> , 5, 763-72	12
2230	p53 domains: structure, oligomerization, and transformation. <b>1994</b> , 14, 5182-91	137
2229	Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. <b>1994</b> , 14, 2713-21	262

2228	Cyclin D1-mediated inhibition of repair and replicative DNA synthesis in human fibroblasts. <b>1994</b> , 8, 1627-39	246
2227	Cancer genes: From mouse to man. <b>1994</b> , 5, 135-146	1
2226	The SAD1/RAD53 protein kinase controls multiple checkpoints and DNA damage-induced transcription in yeast. <b>1994</b> , 8, 2401-15	404
2225	Interactions between papillomavirus proteins and tumor suppressor gene products. <b>1994</b> , 64, 1-24	45
2224	Altered cell cycle regulation in the lens of HPV-16 E6 or E7 transgenic mice: implications for tumor suppressor gene function in development. <b>1994</b> , 8, 1285-99	342
2223	An inhibitor of yeast cyclin-dependent protein kinase plays an important role in ensuring the genomic integrity of daughter cells. <b>1994</b> , 14, 3320-8	150
2222	Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. <b>1994</b> , 14, 4889-901	249
2221	Defect in Radiation Signal Transduction in Ataxia-telangiectasia. <b>1994</b> , 66, S151-S156	18
2220	p53, a potential target for tumor-directed T cells. <b>1994</b> , 40, 171-8	75
2219	Detection of P53 tumor-suppressor-gene protein in bladder tumors and prostate cancer: possible clinical implications. <b>1994</b> , 12, 345-51	13
2218	Tumor suppressor genes in molecular medicine. <b>1994</b> , 72, 619-30	8
2217	A Drosophila gene encoding a DEAD box RNA helicase can suppress loss of wee1/mik1 function in Schizosaccharomyces pombe. <b>1994</b> , 245, 654-7	13
2216	Control of cell proliferation during plant development. <b>1994</b> , 26, 1289-303	25
2215	Molecular determinants of soft tissue sarcoma proliferation. <b>1994</b> , 10, 315-22	6
2214	Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. <b>1994</b> , 174, 23-31	44
2213	Tumor suppressor genes and their roles in breast cancer. <b>1994</b> , 32, 19-38	38
2212	Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 RNA in human cells. <b>1994</b> , 11, 59-64	124
2211	The regulation of p53 function: Steiner Award Lecture. <b>1994</b> , 57, 623-7	141

2210	TP53 gene mutations and CCND1 gene amplification in head and neck squamous cell carcinoma cell lines. <b>1994</b> , 59, 383-7	38
2209	Cell cycle control and cancer chemotherapy. <b>1994</b> , 54, 440-52	66
2208	From genetics to chemistry: tumor suppressor genes and drug discovery. <b>1994</b> , 1, 7-9	5
2207	Cell cycle control and cancer. <b>1994</b> , 266, 1821-8	1890
2206	The G1/S cell-cycle checkpoint in eukaryotic cells. <b>1994</b> , 1198, 215-30	12
2205	Malignant transformation of keratinocytes by human papillomaviruses. <b>1994</b> , 21, 193-9	7
2204	Apoptosis and its role in human disease. <b>1994</b> , 12, 487-93	173
2203	Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. <b>1994</b> , 8, 27-32	980
2202	Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. <b>1994</b> , 8, 171-6	292
2201	The p21 inhibitor of cyclin-dependent kinases controls DNA replication by interaction with PCNA. <b>1994</b> , 369, 574-8	1499
2200	p53-dependent apoptosis in the absence of transcriptional activation of p53-target genes. <b>1994</b> , 370, 220-3	814
2199	Tumour biology. p53, guardian of Rb. <b>1994</b> , 371, 21-2	154
2198	Cell cycle. Stifled by inhibitions. <b>1994</b> , 371, 204-5	76
2197	Differential effects by the p21 CDK inhibitor on PCNA-dependent DNA replication and repair. <b>1994</b> , 371, 534-7	580
2196	Overexpression of p53 and long-term survival in colon carcinoma. <b>1994</b> , 70, 293-6	70
2195	Solution structure of the tetrameric minimum transforming domain of p53. <b>1994</b> , 1, 877-90	242
2194	Close correlation between the dephosphorylation of p53 and growth suppression by transforming growth factor-beta 1 in nasopharyngeal carcinoma cells transduced with adenovirus early region genes. <b>1994</b> , 85, 459-63	10
2193	Cancer genetics. Is p53 the only real tumor suppressor gene?. <b>1994</b> , 4, 137-9	19

2192	Allosteric activation of latent p53 tetramers. <b>1994</b> , 4, 865-75		292
2191	Cip1 blocks the initiation of DNA replication in <i>Xenopus</i> extracts by inhibition of cyclin-dependent kinases. <b>1994</b> , 4, 876-83		126
2190	Cip1 inhibits DNA replication but not PCNA-dependent nucleotide excision-repair. <b>1994</b> , 4, 1062-8		137
2189	Negative control of cell proliferation in eukaryotes. <b>1994</b> , 27, 373-394		10
2188	Inhibition of cyclin-dependent kinases by purine analogues. <b>1994</b> , 224, 771-86		504
2187	Cyclic AMP-induced G1 phase arrest mediated by an inhibitor (p27Kip1) of cyclin-dependent kinase 4 activation. <i>Cell</i> , <b>1994</b> , 79, 487-96	56.2	712
2186	p53-dependent inhibition of cyclin-dependent kinase activities in human fibroblasts during radiation-induced G1 arrest. <i>Cell</i> , <b>1994</b> , 76, 1013-23	56.2	1317
2185	G1 phase progression: cycling on cue. <i>Cell</i> , <b>1994</b> , 79, 551-5	56.2	2505
2184	Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. <i>Cell</i> , <b>1994</b> , 79, 573-82	56.2	1959
2183	Cloning of p27Kip1, a cyclin-dependent kinase inhibitor and a potential mediator of extracellular antimitogenic signals. <i>Cell</i> , <b>1994</b> , 78, 59-66	56.2	1928
2182	p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21. <i>Cell</i> , <b>1994</b> , 78, 67-74	56.2	1842
2181	Apoptosis, senescence, immortalization and cancer. <b>1994</b> , 30, 301-15		6
2180	TGF-beta receptors and actions. <b>1994</b> , 1222, 71-80		245
2179	The role of the p53 protein in the apoptotic response. <b>1994</b> , 345, 277-80		50
2178	Mechanisms of action of the p53 tumor suppressor and prospects for cancer gene therapy by reconstitution of p53 function. <b>1994</b> , 716, 265-80; discussion 280-2		18
2177	Multiple pathways leading to genomic instability and tumorigenesis. <b>1994</b> , 726, 165-77		18
2176	Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. <b>1994</b> , 266, 1376-80		831
2175	Functions of human papillomavirus E6 and E7 oncoproteins. <b>1994</b> , 2, 170-4		37

2174	Arresting developments in cell-cycle control. <b>1994</b> , 19, 143-5	69
2173	Oncogenes and cell death. <b>1994</b> , 4, 120-9	229
2172	Tumor suppressor genes. <b>1994</b> , 4, 135-41	188
2171	DNA amplification: new insights into its mechanism. <b>1994</b> , 103, 73-81	20
2170	Cell cycle checkpoints. <b>1994</b> , 6, 872-6	149
2169	DNA damage triggers a prolonged p53-dependent G1 arrest and long-term induction of Cip1 in normal human fibroblasts. <b>1994</b> , 8, 2540-51	931
2168	Crystal structure of a p53 tumor suppressor-DNA complex: understanding tumorigenic mutations. <b>1994</b> , 265, 346-55	2093
2167	Cyclins and cancer: wheels within wheels. <b>1994</b> , 343, 931-2	10
2166	Disrupted dichotomous intracellular control of human papillomavirus infection in cancer of the cervix. <b>1994</b> , 343, 955-7	78
2165	p53 tagged sites from human genomic DNA. <b>1994</b> , 3, 1537-42	167
2164	Cancer genetics. <b>1994</b> , 4, 109-19	12
2163	p53 and Rb: their cellular roles. <b>1994</b> , 6, 853-8	71
2162	Cdk inhibitors: on the threshold of checkpoints and development. <b>1994</b> , 6, 847-52	288
2161	Signal transduction and growth control in normal and cancer cells. <b>1994</b> , 4, 1-4	52
2160	Genetics of growth arrest and cell death: key determinants of tissue homeostasis. <b>1994</b> , 30A, 2001-12	15
2159	Potential diagnostic, prognostic, and therapeutic implications of mutations in the p53 tumor suppressor gene in lung cancer. <b>1994</b> , 11, 151-152	1
2158	European School of Oncology Task Force Report. New approaches in cancer pharmacology: drug design and development (Part 2). <b>1994</b> , 30A, 1148-60	1
2157	A cell cycle regulator potentially involved in genesis of many tumor types. <b>1994</b> , 264, 436-40	2450

2156	p21-containing cyclin kinases exist in both active and inactive states. <b>1994</b> , 8, 1750-8	506
2155	Myc-mediated apoptosis requires wild-type p53 in a manner independent of cell cycle arrest and the ability of p53 to induce p21waf1/cip1. <b>1994</b> , 8, 2817-30	406
2154	Mediation of c-Myc-induced apoptosis by p53. <b>1994</b> , 265, 2091-3	648
2153	Identification of p53 mutations in endometrial adenocarcinoma by polymerase chain reaction-single-strand conformation polymorphism. <b>1994</b> , 1, 234-7	5
2152	p53: tumor suppression through control of the cell cycle. <b>1994</b> , 106, 1708-11	22
2151	The structure, function, and regulation of papillomaviral genes in infection and cervical cancer. <b>1994</b> , 44, 305-56	48
2150	Southwestern internal medicine conference: hereditary predisposition to colorectal cancer: new insights. <b>1994</b> , 308, 295-308	3
2149	The retinoblastoma tumor suppressor protein. <b>1994</b> , 64, 25-85	182
2148	Dissecting molecular carcinogenesis: development of transgenic mouse models by epidermal gene targeting. <b>1994</b> , 64, 247-96	13
2147	Role of androgens in prostatic cancer. <b>1994</b> , 49, 433-502	102
2146	Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. <b>1994</b> , 91, 10079-83	95
2145	Inducible growth arrest: new mechanistic insights. <b>1994</b> , 91, 1985-6	18
2144	A cell cycle-regulated inhibitor of cyclin-dependent kinases. <b>1994</b> , 91, 5291-5	251
2143	Cdk-interacting protein 1 directly binds with proliferating cell nuclear antigen and inhibits DNA replication catalyzed by the DNA polymerase delta holoenzyme. <b>1994</b> , 91, 8655-9	369
2142	Specific sequences from the carboxyl terminus of human p53 gene product form anti-parallel tetramers in solution. <b>1994</b> , 91, 8974-8	61
2141	Overexpression of human cyclin D1 reduces the transforming growth factor beta (TGF-beta) type II receptor and growth inhibition by TGF-beta 1 in an immortalized human esophageal epithelial cell line. <b>1994</b> , 91, 11576-80	63
2140	Transformation by homeobox genes can be mediated by selective transcriptional repression.. <b>1994</b> , 13, 5967-5976	17
2139	Growth arrest by induction of p53 in DNA damaged keratinocytes is bypassed by human papillomavirus 16 E7. <b>1994</b> , 91, 4382-6	202



2138	Senescence of immortal human fibroblasts by the introduction of normal human chromosome 6. <b>1994</b> , 91, 5498-502	75
2137	Relief of p53-mediated transcriptional repression by the adenovirus E1B 19-kDa protein or the cellular Bcl-2 protein. <b>1994</b> , 91, 8940-4	142
2136	Gene regulation by temperature-sensitive p53 mutants: identification of p53 response genes. <b>1994</b> , 91, 10640-4	65
2135	Mutations and altered expression of p16INK4 in human cancer. <b>1994</b> , 91, 11045-9	457
2134	Sequence-specific transcriptional activation is essential for growth suppression by p53. <b>1994</b> , 91, 1998-2002	324
2133	Hepatitis B virus X protein inhibits p53 sequence-specific DNA binding, transcriptional activity, and association with transcription factor ERCC3. <b>1994</b> , 91, 2230-4	578
2132	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. <b>1994</b> , 14, 6764-72	32
2131	A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. <b>1994</b> , 14, 3683-94	300
2130	Senescence-like growth arrest induced by hydrogen peroxide in human diploid fibroblast F65 cells. <b>1994</b> , 91, 4130-4	519
2129	p53-dependent G1 arrest involves pRB-related proteins and is disrupted by the human papillomavirus 16 E7 oncoprotein. <b>1994</b> , 91, 5320-4	289
2128	Oncogenic capacity of the E2F1 gene. <b>1994</b> , 91, 12823-7	222
2127	Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. <b>1994</b> , 14, 7805-15	102
2126	Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene. <b>1994</b> , 14, 8483-92	48
2125	Modulation of p53-mediated transcriptional repression and apoptosis by the adenovirus E1B 19K protein. <b>1995</b> , 15, 1060-70	186
2124	The human papilloma virus 16E6 gene sensitizes human mammary epithelial cells to apoptosis induced by DNA damage. <b>1995</b> , 92, 7829-33	72
2123	Single cell monitoring of growth arrest and morphological changes induced by transfer of wild-type p53 alleles to glioblastoma cells. <b>1995</b> , 92, 1008-12	48
2122	A proliferative p53-responsive element mediates tumor necrosis factor alpha induction of the human immunodeficiency virus type 1 long terminal repeat. <b>1995</b> , 15, 3450-9	32
2121	Astrocytes derived from p53-deficient mice provide a multistep in vitro model for development of malignant gliomas. <b>1995</b> , 15, 4249-59	84

2120	p53 stimulates transcription from the human transforming growth factor alpha promoter: a potential growth-stimulatory role for p53. <b>1995</b> , 15, 4694-701	71
2119	Platelet-derived growth factor induces apoptosis in growth-arrested murine fibroblasts. <b>1995</b> , 92, 9500-4	62
2118	G1 phase arrest induced by Wilms tumor protein WT1 is abrogated by cyclin/CDK complexes. <b>1995</b> , 92, 4517-21	75
2117	Biological response to phorbol ester determined by alternative G1 pathways. <b>1995</b> , 92, 4793-7	55
2116	PAK1, a gene that can regulate p53 activity in yeast. <b>1995</b> , 92, 6062-6	22
2115	An apoptotic defect in lens differentiation caused by human p53 is rescued by a mutant allele. <b>1995</b> , 92, 6142-6	70
2114	SCT1 mutants suppress the camptothecin sensitivity of yeast cells expressing wild-type DNA topoisomerase I. <b>1995</b> , 92, 6299-303	63
2113	Wild-type p53 protein undergoes cytoplasmic sequestration in undifferentiated neuroblastomas but not in differentiated tumors. <b>1995</b> , 92, 4407-11	363
2112	Phosphorylated and unphosphorylated forms of human single-stranded DNA-binding protein are equally active in simian virus 40 DNA replication and in nucleotide excision repair. <b>1995</b> , 92, 4636-40	65
2111	p53 controls both the G2/M and the G1 cell cycle checkpoints and mediates reversible growth arrest in human fibroblasts. <b>1995</b> , 92, 8493-7	718
2110	The C-terminal domain of p53 recognizes DNA damaged by ionizing radiation. <b>1995</b> , 92, 9455-9	167
2109	Cloning and characterization of the <i>Xenopus</i> cyclin-dependent kinase inhibitor p27XIC1. <b>1995</b> , 92, 10187-91	95
2108	Regulation of p53-mediated apoptosis and cell cycle arrest by Steel factor. <b>1995</b> , 15, 6953-60	59
2107	The p53-mediated G1 checkpoint is retained in tumorigenic rat embryo fibroblast clones transformed by the human papillomavirus type 16 E7 gene and EJ-ras. <b>1995</b> , 15, 1446-54	26
2106	Cyclin E restores p53 activity in contact-inhibited cells. <b>1995</b> , 15, 3926-33	28
2105	Discrimination of DNA binding sites by mutant p53 proteins. <b>1995</b> , 15, 5196-202	39
2104	Exit from G0 and entry into the cell cycle of cells expressing p21Sdi1 antisense RNA. <b>1995</b> , 92, 4352-6	123
2103	Identification of human and mouse p19, a novel CDK4 and CDK6 inhibitor with homology to p16ink4. <b>1995</b> , 15, 2682-8	301

2102	Genetic alterations in human gastrointestinal cancers. The application to molecular diagnosis. <b>1995</b> , 75, 1410-7	110
2101	Transforming growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent mechanism. <b>1995</b> , 92, 5545-9	784
2100	Mitogen-responsive nuclear factors that mediate growth control signals in vascular myocytes. <b>1995</b> , 30, 585-592	21
2099	Sensitivity and cellular response to different anticancer agents of a human ovarian cancer cell line expressing wild-type, mutated or no p53. <b>1995</b> , 6, 589-93	18
2098	Role of cysteine residues in regulation of p53 function. <b>1995</b> , 15, 3892-903	264
2097	Cell cycle control mechanisms and their role in cardiac growth. <b>1995</b> , 30, 557-569	36
2096	Differential regulation of cyclin A, cyclin B and p21 concentrations in a growth-restricted human fibroblast cell line. <b>1995</b> , 312 ( Pt 3), 693-8	8
2095	Cyclins and cyclin-dependent kinases: a biochemical view. <b>1995</b> , 308 ( Pt 3), 697-711	481
2094	Molecular genetics of exocrine pancreatic neoplasms. <b>1995</b> , 75, 857-69	50
2093	p53: DNA damage, DNA repair, and apoptosis. <b>1996</b> , 127, 65-95	36
2092	p53 expression and the result of adjuvant therapy of breast cancer. <b>1995</b> , 34, 767-70	30
2091	[Detection of genetic alterations in sporadic breast tumors]. <b>1995</b> , 35 Suppl 1, 63-7	2
2090	Tumor suppressor p53 mutations and breast cancer: a critical analysis. <b>1995</b> , 66, 71-141	68
2089	V(D)J recombination and double-strand break repair. <b>1995</b> , 58, 29-85	49
2088	The p53 tumor suppressor gene. <b>1995</b> , 3, 55-141	0
2087	Temperature sensitivity for conformation is an intrinsic property of wild-type p53. <b>1995</b> , 71, 227-31	41
2086	Loss of cyclin-dependent kinase inhibitor genes and chromosome 9 karyotypic abnormalities in human bladder cancer cell lines. <b>1995</b> , 72, 1214-8	25
2085	Molecular alterations in head and neck squamous cell carcinoma. <b>1995</b> , 20, 291-8	4

2084	Simultaneous use of the PCR-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer. <b>1995</b> , 104, 319-24	11
2083	Human TAFII31 protein is a transcriptional coactivator of the p53 protein. <b>1995</b> , 92, 5154-8	278
2082	Involvement of the cell-cycle inhibitor Cip1/WAF1 and the E1A-associated p300 protein in terminal differentiation. <b>1995</b> , 92, 5451-5	312
2081	The carboxyl-terminal domain of the p53 protein regulates sequence-specific DNA binding through its nonspecific nucleic acid-binding activity. <b>1995</b> , 92, 5729-33	91
2080	14-3-3 proteins associate with cdc25 phosphatases. <b>1995</b> , 92, 7892-6	238
2079	Increased activity of p53 in senescing fibroblasts. <b>1995</b> , 92, 8348-52	264
2078	Four p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA. <b>1995</b> , 92, 8591-5	123
2077	Multiple genetic loci within 11p15 defined by Beckwith-Wiedemann syndrome rearrangement breakpoints and subchromosomal transferable fragments. <b>1995</b> , 92, 12456-60	93
2076	p53 inhibits DNA replication in vitro in a DNA-binding-dependent manner. <b>1995</b> , 15, 6554-60	32
2075	Wild-type human p53 transactivates the human proliferating cell nuclear antigen promoter. <b>1995</b> , 15, 6785-93	104
2074	Gas1-induced growth suppression requires a transactivation-independent p53 function. <b>1995</b> , 15, 7152-60	87
2073	Wild-type human p53 and a temperature-sensitive mutant induce Fas/APO-1 expression. <b>1995</b> , 15, 3032-40	638
2072	Inhibition of cellular proliferation by the Wilms' tumor suppressor WT1 is associated with suppression of insulin-like growth factor I receptor gene expression. <b>1995</b> , 15, 3516-22	111
2071	MyoD-induced expression of p21 inhibits cyclin-dependent kinase activity upon myocyte terminal differentiation. <b>1995</b> , 15, 3823-9	356
2070	Cell-cycle regulators and cancer. <b>1995</b> , 11, 136-40	254
2069	Modulation of cell kinetics and cell cycle status by treating CD34+ chronic myeloid leukaemia cells with p53 antisense phosphorothioate oligonucleotides. <b>1995</b> , 90, 8-14	18
2068	Structural integrity of the cyclin-dependent kinase inhibitor genes, p15, p16 and p18 in myeloid leukaemias. <b>1995</b> , 91, 139-49	55
2067	Screening for germline mutations of the p53 gene in familial breast cancer patients. <b>1995</b> , 25, 132-7	7

2066	A small peptide inhibitor of DNA replication defines the site of interaction between the cyclin-dependent kinase inhibitor p21WAF1 and proliferating cell nuclear antigen. <b>1995</b> , 5, 275-82	258
2065	Time, telomeres and tumours: is cellular senescence more than an anticancer mechanism?. <b>1995</b> , 5, 293-7	112
2064	Functions of pRb and p53: what's the connection?. <b>1995</b> , 5, 448-50	20
2063	D-type cyclins. <b>1995</b> , 20, 187-90	805
2062	p53 gene mutations and photocarcinogenesis. <b>1995</b> , 62, 218-30	129
2061	Protein p53 modulates transcription from a promoter containing its binding site in a concentration-dependent manner. <b>1995</b> , 234, 827-31	11
2060	Mutations of the p53 gene in male breast cancer. <b>1995</b> , 75, 2233-8	65
2059	Molecular biology of cervical cancer and its precursors. <b>1995</b> , 76, 1902-13	104
2058	Molecular basis of endometrial cancer. <b>1995</b> , 76, 2034-40	84
2057	Characterization of a murine p53ser246 mutant equivalent to the human p53ser249 associated with hepatocellular carcinoma and aflatoxin exposure. <b>1995</b> , 13, 104-11	14
2056	Overexpression of MDM-2 mRNA and mutation of the p53 tumor suppressor gene in bladder carcinoma cell lines. <b>1995</b> , 13, 173-81	30
2055	Delay of dimethylbenz[a]anthracene-induced mammary tumorigenesis in transgenic mice by apoptosis induced by an unusual mutant p53 protein. <b>1995</b> , 14, 75-83	22
2054	UV irradiation of chromosomal DNA and its effect upon MPF and meiosis in mammalian oocytes. <b>1995</b> , 41, 503-12	38
2053	The initiation of senescence and its relationship to embryonic cell differentiation. <b>1995</b> , 17, 257-60	6
2052	Cyclin-dependent protein kinases: key regulators of the eukaryotic cell cycle. <b>1995</b> , 17, 471-80	789
2051	Tumour suppressors, kinases and clamps: how p53 regulates the cell cycle in response to DNA damage. <b>1995</b> , 17, 501-8	279
2050	Human papillomavirus E6 and E7: proteins which deregulate the cell cycle. <b>1995</b> , 17, 509-18	113
2049	Origins of G1 arrest in senescent human fibroblasts. <b>1995</b> , 17, 537-43	123

2048	Stopped for repairs. <b>1995</b> , 17, 545-8	68
2047	Life and death by p53. <b>1995</b> , 17, 923-30	88
2046	Decreased cytotoxic effects of doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 genes. <b>1995</b> , 61, 397-401	34
2045	Absence of mutations and identification of two polymorphisms in the SSCP and sequence analysis of p21CKI gene in malignant gliomas. <b>1995</b> , 62, 115-7	17
2044	Expression of the cyclin-dependent kinase inhibitors p16INK4, p15INK4B and p21WAF1/CIP1 in human breast cancer. <b>1995</b> , 63, 584-91	71
2043	Expression of p21WAF1/CIP1 is heterogeneous and unrelated to proliferation index in human ovarian carcinoma. <b>1995</b> , 63, 611-5	50
2042	Adenovirus-mediated gene transfer of wild-type p53 results in melanoma cell apoptosis in vitro and in vivo. <b>1995</b> , 63, 673-9	53
2041	ras, p53 and HPV status in benign and malignant prostate tumors. <b>1995</b> , 64, 124-9	43
2040	Detection of TP53 gene mutation in human meningiomas: a study using immunohistochemistry, polymerase chain reaction/single-strand conformation polymorphism and DNA sequencing techniques on paraffin-embedded samples. <b>1995</b> , 64, 223-8	49
2039	Alterations of CDKN2 (p16) in non-small cell lung cancer. <b>1995</b> , 14, 164-70	43
2038	The p53 gene and its role in human brain tumors. <b>1995</b> , 15, 308-27	156
2037	p53 protein immunoreactivity in extrahepatic bile duct and gallbladder cancer: Correlation with tumor grade and survival. <b>1995</b> , 22, 774-779	72
2036	Bcl-2 protooncogene expression in cervical carcinoma cell lines containing inactive p53. <b>1995</b> , 57, 509-21	58
2035	Apoptosis and the cell cycle. <b>1995</b> , 58, 160-74	316
2034	Differential regulation of p34cdc2 and p33cdk2 by transforming growth factor-beta 1 in murine mammary epithelial cells. <b>1995</b> , 58, 517-26	10
2033	Retrovirally mediated wild-type p53 restores S-phase modulation without inducing WAF1 mRNA in breast carcinoma cells containing mutant p53. <b>1995</b> , 59, 537-44	4
2032	Okadaic acid, cAMP, and selected nutrients inhibit hepatocyte proliferation at different stages in G1: modulation of the cAMP effect by phosphatase inhibitors and nutrients. <b>1995</b> , 163, 232-40	29
2031	The pathophysiology and management of spine metastasis from lung cancer. <b>1995</b> , 23, 109-20	6

2030	Interferon modulates the messenger RNA of G1-controlling genes to suppress the G1-to-S transition in Daudi cells. <b>1995</b> , 152, 149-58	16
2029	Poly(ADP-ribosyl)ation as a fail-safe, transcription-independent, suicide mechanism in acutely DNA-damaged cells: a hypothesis. <b>1995</b> , 34, 251-4	11
2028	Apoptosis, cancer and the p53 tumour suppressor gene. <b>1995</b> , 14, 149-61	133
2027	P53, cell cycle control and apoptosis: implications for cancer. <b>1995</b> , 14, 3-15	392
2026	Cell cycle regulation in response to DNA damage in mammalian cells: a historical perspective. <b>1995</b> , 14, 17-29	88
2025	Genetic instability as a consequence of inappropriate entry into and progression through S-phase. <b>1995</b> , 14, 59-73	73
2024	Protein kinases in human breast cancer. <b>1995</b> , 35, 105-14	44
2023	Comparative analysis of Homo sapiens and Mus musculus cyclin-dependent kinase (CDK) inhibitor genes p16 (MTS1) and p15 (MTS2). <b>1995</b> , 41, 795-802	15
2022	Molecular mechanisms of virus-induced carcinogenesis: the interaction of viral factors with cellular tumor suppressor proteins. <b>1995</b> , 73, 529-38	32
2021	Inhibitors of cyclin-dependent kinase and cancer. <b>1995</b> , 73, 509-14	41
2020	Identification of a PstI polymorphism in the p21Cip1/Waf1 cyclin-dependent kinase inhibitor gene. <b>1995</b> , 95, 459-60	11
2019	Cloning and expression of a Xenopus gene that prevents mitotic catastrophe in fission yeast. <b>1995</b> , 246, 387-96	21
2018	Molecular biology of gastric cancer. <b>1995</b> , 19, 484-8; discussion 489-90	135
2017	Role of tumor suppressor genes in determining radiation-induced G1 arrest and transformation in human cells. <b>1995</b> , 3, 268-271	
2016	MDM2 and CDK4 gene amplification in Ewing's sarcoma. <b>1995</b> , 175, 211-7	85
2015	Demonstration of DNA damage/repair in individual cells using in situ end labelling: association of p53 with sites of DNA damage. <b>1995</b> , 176, 19-26	66
2014	p53 gene point mutations in relation to p53 nuclear protein accumulation in colorectal cancers. <b>1995</b> , 176, 45-53	61
2013	p53 protein expression in colorectal adenomas: an immunohistochemical study using an antigen retrieval system. <b>1995</b> , 27, 517-23	10

2012	Assessment of cell proliferation in pathology--what next?. <b>1995</b> , 26, 105-12	51
2011	Inhibition by differentiation-inducing agents of wild-type p53-dependent apoptosis in HL-60 cells. <b>1995</b> , 86, 217-23	11
2010	Tumor suppressor genes: prospects for cancer therapies. <b>1995</b> , 13, 127-31	3
2009	A mutant p53 transgene accelerates tumour development in heterozygous but not nullizygous p53-deficient mice. <b>1995</b> , 9, 305-11	204
2008	p53 modulation of TFIIH-associated nucleotide excision repair activity. <b>1995</b> , 10, 188-95	468
2007	Molecular foundations of cancer: new targets for intervention. <b>1995</b> , 1, 309-20	93
2006	p53 activates expression of HIC-1, a new candidate tumour suppressor gene on 17p13.3. <b>1995</b> , 1, 570-7	376
2005	Constraining the cell cycle: regulating cell division and differentiation by gene therapy. <b>1995</b> , 1, 1004-6	8
2004	The p21 cyclin-dependent kinase inhibitor suppresses tumorigenicity in vivo. <b>1995</b> , 1, 1052-6	177
2003	Principles of CDK regulation. <b>1995</b> , 374, 131-4	2906
2002	Separate domains of p21 involved in the inhibition of Cdk kinase and PCNA. <b>1995</b> , 374, 386-8	509
2001	Cell-cycle inhibition by independent CDK and PCNA binding domains in p21Cip1. <b>1995</b> , 375, 159-61	498
2000	Increased and altered DNA binding of human p53 by S and G2/M but not G1 cyclin-dependent kinases. <b>1995</b> , 376, 88-91	334
1999	Radiation-induced cell cycle arrest compromised by p21 deficiency. <b>1995</b> , 377, 552-7	1119
1998	Induction of the growth inhibitor IGF-binding protein 3 by p53. <b>1995</b> , 377, 646-9	786
1997	Rescue of early embryonic lethality in mdm2-deficient mice by deletion of p53. <b>1995</b> , 378, 203-6	1214
1996	Evaluation of p53 protein expression as a marker for long-term prognosis in colorectal carcinoma. <b>1995</b> , 71, 1257-62	57
1995	TP53 gene mutations and protein accumulation in primary vaginal carcinomas. <b>1995</b> , 72, 129-33	11



1994	Multiple polymorphisms, but no mutations, in the WAF1/CIP1 gene in human brain tumours. <b>1995</b> , 72, 1230-3	57
1993	p53 protein expression in sequential biopsies of oral dysplasias and in situ carcinomas. <b>1995</b> , 24, 18-22	66
1992	Cell cycle regulators in the keratinocyte (cyclin-cdk). <b>1995</b> , 4, 1-8	7
1991	The specificity of p53 mutation spectra in sunlight induced human cancers. <b>1995</b> , 28, 115-24	115
1990	Characterization of a new human glioblastoma cell line that expresses mutant p53 and lacks activation of the PDGF pathway. <b>1995</b> , 31, 207-14	9
1989	Genetic analysis of cellular senescence. <b>1995</b> , 1242, 29-41	21
1988	Signaling by the transforming growth factor-beta receptors. <b>1995</b> , 1242, 115-36	16
1987	Molecular analysis of the Cip1/Waf1 (p21) gene in diverse types of human tumors. <b>1995</b> , 1263, 275-80	35
1986	Progress against cancer. <b>1995</b> , 121, 633-47	8
1985	Role of p53 in leukemogenesis of chronic myeloid leukemia. <b>1995</b> , 13, 445-52	29
1984	Recessive oncogenes: current status. <b>1995</b> , 1, 7-22	7
1983	Multiple mechanisms account for genomic instability and molecular mutation in neoplastic transformation. <b>1995</b> , 41, 644-657	43
1982	NGF regulates the PC12 cell cycle machinery through specific inhibition of the Cdk kinases and induction of cyclin D1. <b>1995</b> , 15, 6200-12	167
1981	Nerve growth factor-induced growth arrest and induction of p21Cip1/WAF1 in NIH-3T3 cells expressing TrkA. <b>1995</b> , 270, 30841-4	32
1980	Irreversible repression of DNA synthesis in Fanconi anemia cells is alleviated by the product of a novel cyclin-related gene. <b>1995</b> , 15, 305-14	27
1979	The tumour suppressor gene product APC blocks cell cycle progression from G0/G1 to S phase.. <b>1995</b> , 14, 5618-5625	121
1978	Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1.. <b>1995</b> , 14, 555-563	122
1977	Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product.. <b>1995</b> , 14, 503-511	240

1976	Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression.. <b>1995</b> , 14, 1392-1401	77
1975	Suppression of the yeast mutation rft1-1 by human p53. <b>1995</b> , 270, 22556-64	13
1974	Loss of p53 function through PAX-mediated transcriptional repression.. <b>1995</b> , 14, 5638-5645	160
1973	The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding.. <b>1995</b> , 14, 512-519	98
1972	Deleted in oral cancer-1 (doc-1), a novel oral tumor suppressor gene. <b>1995</b> , 9, 1362-70	79
1971	Negative feedback regulation of wild-type p53 biosynthesis.. <b>1995</b> , 14, 4442-4449	205
1970	Alternatively spliced forms in the carboxy-terminal domain of the p53 protein regulate its ability to promote annealing of complementary single strands of nucleic acids. <b>1995</b> , 15, 497-504	111
1969	Molecular biology and colorectal cancer: genetic alterations, inherited syndromes, and applications to colon cancer screening. <b>1995</b> , 13, 182-9	2
1968	DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective.. <b>1995</b> , 14, 4994-5005	79
1967	Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1.. <b>1995</b> , 14, 6184-6192	69
1966	A direct effect of activated human p53 on nuclear DNA replication.. <b>1995</b> , 14, 2099-2105	57
1965	Cdk2. <b>1995</b> , 188-190	
1964	Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53.. <b>1995</b> , 14, 1382-1391	84
1963	Genetics of Colorectal and Breast Cancer. <b>1995</b> , 15, 957-971	4
1962	The Molecular Biology of Brain Tumors. <b>1995</b> , 13, 701-721	7
1961	Regulation of Transcription Functions of the p53 Tumor Suppressor by the mdm-2 Oncogene. <b>1995</b> , 1, 142-152	169
1960	Taxol-Induced Mitotic Block Triggers Rapid Onset of a p53-Independent Apoptotic Pathway. <b>1995</b> , 1, 506-526	221
1959	Systemic gene therapy with p53 reduces growth and metastases of a malignant human breast cancer in nude mice. <b>1995</b> , 6, 395-405	132

1958	p57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. <b>1995</b> , 9, 650-62	731
1957	To pop or not to pop: p53 as a critical modulator of tumour responsiveness to therapy in vivo?. <b>1995</b> , 14, 222-5	1
1956	Induction of G1 arrest by down-regulation of cyclin D3 in T cell hybridomas. <b>1995</b> , 182, 401-8	30
1955	Expression of the E2F1 transcription factor overcomes type beta transforming growth factor-mediated growth suppression. <b>1995</b> , 92, 483-7	148
1954	Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. <b>1995</b> , 4, 1089-92	96
1953	Ultraviolet light induces expression of p53 and p21 in human skin: effect of sunscreen and constitutive p21 expression in skin appendages. <b>1995</b> , 105, 402-6	120
1952	The Genetics of Cancer. <b>1995</b> ,	2
1951	Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. <b>1995</b> , 23, 3710-7	125
1950	p53 transcriptional activation mediated by coactivators TAFII40 and TAFII60. <b>1995</b> , 267, 100-4	407
1949	Use of semiquantitative reverse transcription-polymerase chain reaction to study gene expression in normal human skin fibroblasts following low dose-rate irradiation. <b>1995</b> , 67, 135-43	15
1948	p53 is phosphorylated in vitro and in vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. <b>1995</b> , 270, 5511-8	188
1947	Kip/Cip and Ink4 Cdk inhibitors cooperate to induce cell cycle arrest in response to TGF-beta. <b>1995</b> , 9, 1831-45	742
1946	Correlation of terminal cell cycle arrest of skeletal muscle with induction of p21 by MyoD. <b>1995</b> , 267, 1018-21	1034
1945	Growth factor modulation of p53-mediated growth arrest versus apoptosis. <b>1995</b> , 9, 600-11	272
1944	Inhibition of nucleotide excision repair by the cyclin-dependent kinase inhibitor p21. <b>1995</b> , 270, 22008-16	120
1943	Functional analysis of the transforming growth factor beta responsive elements in the WAF1/Cip1/p21 promoter. <b>1995</b> , 270, 28623-8	373
1942	Applications of molecular biology to biomedicine and toxicology. <b>1995</b> , 13, 1-51	8
1941	The WT1 gene product stabilizes p53 and inhibits p53-mediated apoptosis. <b>1995</b> , 9, 2143-56	195

1940	Raf1 interaction with Cdc25 phosphatase ties mitogenic signal transduction to cell cycle activation. <b>1995</b> , 9, 1046-58	190
1939	Early events in DNA replication require cyclin E and are blocked by p21CIP1. <b>1995</b> , 130, 755-69	186
1938	Both p16 and p21 families of cyclin-dependent kinase (CDK) inhibitors block the phosphorylation of cyclin-dependent kinases by the CDK-activating kinase. <b>1995</b> , 270, 18195-7	145
1937	Modulation of interleukin-6-induced plasma protein secretion in hepatoma cells by p53 species. <b>1995</b> , 270, 23159-65	18
1936	Inhibitors of mammalian G1 cyclin-dependent kinases. <b>1995</b> , 9, 1149-63	2652
1935	p53 binds single-stranded DNA ends through the C-terminal domain and internal DNA segments via the middle domain. <b>1995</b> , 23, 362-9	151
1934	Two distinct signaling pathways activate the latent DNA binding function of p53 in a casein kinase II-independent manner. <b>1995</b> , 270, 18165-74	84
1933	Irradiation induces WAF1 expression through a p53-independent pathway in KG-1 cells. <b>1995</b> , 270, 19181-7	47
1932	Molecular cloning and characterization of the bovine and porcine outer dense fibers cDNA and organization of the bovine gene. <b>1995</b> , 376, 431-5	7
1931	Iron deprivation results in an increase in p53 expression. <b>1995</b> , 376, 627-30	23
1930	A p53-independent pathway for activation of WAF1/CIP1 expression following oxidative stress. <b>1995</b> , 270, 29386-91	186
1929	Regulation of p53-Dependent Apoptosis by E1A and E1B. <b>1995</b> , 33-58	6
1928	Cyclins and cyclin-dependent kinases: theme and variations. <b>1995</b> , 66, 181-212	122
1927	Expression of mutant p53 protein and CD44 variant proteins in colorectal tumorigenesis. <b>1995</b> , 36, 76-80	48
1926	p53, Rb and bcl-2 expression during the cell cycle: a study in phytohaemagglutinin stimulated lymphocytes and microwave irradiated lymphoid tissue sections. <b>1995</b> , 48, 151-9	16
1925	Effect of adenovirus-2 early region-4 products on e1-transformation. <b>1995</b> , 6, 663-8	1
1924	P53 and its implication in apoptosis (review). <b>1995</b> , 6, 1129-35	10
1923	Similarity of the DNA-damage responsiveness and growth-suppressive properties of waf1/cip1 and gadd45. <b>1995</b> , 6, 937-46	4

1922 DEFINITION OF THE P53 BINDING-SITE ON THE TMS1 PROTEIN. **1995**, 7, 171

1921 Overexpression of wild-type p53 overrides the mitogenic effect of ri-alpha subunit of protein-kinase-a in human breast cells. **1995**, 7, 331-6 1

1920 The first intron of human h-ras is regulated by p53 - mediation of specific activation by a p53-binding element. **1995**, 7, 1021-8

1919 Absence of somatic mutations in the coding region of the waf1/cip1 gene in human breast, lung and ovarian carcinomas - a polymorphism at codon-31. **1995**, 6, 187-9 7

1918 Status of the mdm-2 and waf-1 genes in mouse epidermal jb6 variants harboring wild-type p53 - a p53-independent induction of waf-1. **1995**, 6, 465-71 1

1917 CHARACTERIZATION OF A NEW P53-MUTATED AND HPV-NEGATIVE HUMAN SQUAMOUS-CELL CERVICAL CARCINOMA-DERIVED CELL-LINE. **1995**, 6, 681

1916 The gene encoding the p53-regulated inhibitor of cdks (pic1) is not expressed in the molt-4 leukemia-cell line with p53 truncated at the carboxyl-terminus, and harbors a nucleotide substitution at codon-31 in several other cancer cell-lines. **1995**, 6, 871-6

1915 The aberrant p53 protein (review). **1995**, 6, 1209-26 2

1914 Differential-effects of transforming growth-factor-Beta-1 on protein-levels of p21 waf and cdk-2 and on cdk-2 kinase-activity in human rd and ccl64 mink lung-cells. **1995**, 7, 337-41 1

1913 P53-independent induction of p21(waf1) pathway is preserved during tumor progression. **1995**, 7, 889-93 3

1912 Specific recognition of a transcriptional element within the human h-ras protooncogene by the p53 tumor-suppressor. **1995**, 7, 1029-34 2

1911 High-frequency of loss of expression and allelic deletion of the apc and mcc genes in human prostate-cancer. **1995**, 6, 111-7 6

1910 Radiation-induced irreversible g(0) g(1) block is abolished in human-diploid fibroblasts transfected with the human papilloma-virus e6 gene - implication of the p53-cip1 waf1 pathway. **1995**, 6, 233-6 2

1909 Coordinated effects of insulin-like growth factor I on inhibitory pathways of cell cycle progression in cultured cardiac muscle cells. **1995**, 136, 5240-3 14

1908 Discovery of Tumor Suppressor Gene Function. **1995**, 57, 200-201 1

1907 Human cyclin E, a nuclear protein essential for the G1-to-S phase transition. **1995**, 15, 2612-24 1020

1906 Inhibition of myogenic differentiation in proliferating myoblasts by cyclin D1-dependent kinase. **1995**, 267, 1022-4 445

1905 p53-independent expression of p21Cip1 in muscle and other terminally differentiating cells. **1995**, 267, 1024-7 957

1904	p53-independent death and p53-induced protection against apoptosis in fibroblasts treated with chemotherapeutic drugs. <b>1995</b> , 72, 952-7	45
1903	Identification of a novel p53 promoter element involved in genotoxic stress-inducible p53 gene expression. <b>1995</b> , 15, 4489-96	97
1902	Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. <b>1995</b> , 15, 2672-81	560
1901	Tumor suppressor genes and clonal evolution in B-CLL. <b>1995</b> , 18, 41-9	14
1900	p53 expression in non-Hodgkin's lymphomas: a marker of p53 inactivation?. <b>1995</b> , 17, 35-42	21
1899	Deletion of the p16 and p15 genes in human bladder tumors. <b>1995</b> , 87, 1524-9	157
1898	Up-regulation of p21WAF1/CIP1 in psoriasis and after the application of irritants and tape stripping. <b>1995</b> , 105, 274-9	27
1897	Screening for colorectal cancer. <b>1995</b> , 332, 861-7	138
1896	Induction of p53 in mouse cells decreases mutagenesis by UV radiation. <b>1995</b> , 16, 2295-300	32
1895	p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. <b>1995</b> , 6 Suppl 3, S9-13	40
1894	Cell cycle and cancer. <b>1995</b> , 87, 1499-501	78
1893	Effects of tumor necrosis factor-alpha on antimutagenicity and cell cycle-related proteins in MCF-7 cells. <b>1995</b> , 270, 18367-73	58
1892	Potential role of WAF1/Cip1/p21 as a mediator of TGF-beta cytoinhibitory effect. <b>1995</b> , 270, 4971-4	192
1891	A functional p53-responsive intronic promoter is contained within the human mdm2 gene. <b>1995</b> , 23, 2584-92	248
1890	Advances in cancer gene therapy. <b>1995</b> , 32, 289-341	20
1889	RACH2, a novel human gene that complements a fission yeast cell cycle checkpoint mutation. <b>1995</b> , 6, 1411-21	17
1888	Essential role for p53-mediated transcription in E1A-induced apoptosis. <b>1995</b> , 9, 2184-92	182
1887	Wild Type p53 Stimulates Expression from the Human Multidrug Resistance Promoter in a p53-negative Cell Line. <b>1995</b> , 270, 1894-1898	45

1886	Cellular aging in vitro. <b>1995</b> , 5, 369-381	4
1885	UV irradiation and heat shock mediate JNK activation via alternate pathways. <b>1995</b> , 270, 26071-7	176
1884	p53: a cell cycle regulator activated by DNA damage. <b>1995</b> , 66, 143-80	87
1883	Inhibition of poly(ADP-ribose) polymerase increases (+/-)-anti-benzo [a]pyrene diolepoxide-induced micronuclei formation and p53 accumulation in isolated human peripheral blood lymphocytes. <b>1995</b> , 16, 2765-71	12
1882	Activation of the p21 pathway of growth arrest and apoptosis by the beta 4 integrin cytoplasmic domain. <b>1995</b> , 270, 22673-6	95
1881	p53-dependent and p53-independent activation of apoptosis in mammary epithelial cells reveals a survival function of EGF and insulin. <b>1995</b> , 128, 1185-96	153
1880	p53-dependent repression of CDK4 translation in TGF-beta-induced G1 cell-cycle arrest. <b>1995</b> , 9, 204-17	133
1879	Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation. <b>1995</b> , 6, 1197-213	229
1878	p107 uses a p21CIP1-related domain to bind cyclin/cdk2 and regulate interactions with E2F. <b>1995</b> , 9, 1740-52	213
1877	Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of transforming growth factor beta 1. <b>1995</b> , 92, 3239-43	124
1876	Induction of apoptosis in HeLa cells by trans-activation-deficient p53. <b>1995</b> , 9, 2170-83	429
1875	Inhibition of cyclin-dependent kinases by p21. <b>1995</b> , 6, 387-400	836
1874	The C-terminal region of p21SDI1/WAF1/CIP1 is involved in proliferating cell nuclear antigen binding but does not appear to be required for growth inhibition. <b>1995</b> , 270, 17060-3	80
1873	p53-dependent growth arrest of REF52 cells containing newly amplified DNA. <b>1995</b> , 92, 3224-8	34
1872	Prolonged induction of p21Cip1/WAF1/CDK2/PCNA complex by epidermal growth factor receptor activation mediates ligand-induced A431 cell growth inhibition. <b>1995</b> , 131, 235-42	113
1871	The Role of Apoptosis in Development, Tissue Homeostasis and Malignancy. <b>1995</b> ,	3
1870	p53 Mutational Status and Survival of Human Breast Cancer MCF-7 Cell Variants after Exposure to X Rays or Fission Neutrons. <b>1995</b> , 142, 256	23
1869	CDC25 phosphatases as potential human oncogenes. <b>1995</b> , 269, 1575-7	446

1868 Cell regulation. **1995**, 7, 239-98

1867	Cyclin dependent kinase regulation. <b>1995</b> , 7, 773-80		240
1866	Roles of p53 mutation in cell line establishment and identification of the minimum transactivation and transform suppression domains. <b>1995</b> , 31B, 129-35		3
1865	Cyclin kinase inhibitors add a new dimension to cell cycle control. <b>1995</b> , 31B, 291-8		18
1864	Infrequent MDM2 gene amplification and absence of gross WAF1 gene alterations in nasopharyngeal carcinoma. <b>1995</b> , 31B, 328-32		16
1863	The role of inducible transcription factors in apoptotic nerve cell death. <b>1995</b> , 21, 1-28		160
1862	Role of poly(ADP-ribose) polymerase in cell-cycle checkpoint mechanisms following gamma-irradiation. <b>1995</b> , 77, 462-5		56
1861	Transcriptional repression in normal human keratinocytes by wild-type and mutant p53. <b>1995</b> , 91, 85-92		3
1860	Growth arrest associated changes of mRNA levels in breast cancer cells measured by semi-quantitative RT-PCR: potential early indicators of treatment response. <b>1995</b> , 97, 107-16		21
1859	A splice donor site mutation results in the insertion of five extra amino acids into P53 from SEWA mouse sarcoma cells. <b>1995</b> , 162, 231-4		1
1858	p53 expression and DNA ploidy of cartilage lesions. <b>1995</b> , 26, 620-4		61
1857	Molecular and cell biological studies of ageing and their application to considerations of T lymphocyte immunosenescence. <b>1995</b> , 79, 1-32		58
1856	Mice lacking p21CIP1/WAF1 undergo normal development, but are defective in G1 checkpoint control. <i>Cell</i> , <b>1995</b> , 82, 675-84	56.2	1875
1855	Absence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes. <i>Cell</i> , <b>1995</b> , 82, 29-36	56.2	113
1854	p19Skp1 and p45Skp2 are essential elements of the cyclin A-CDK2 S phase kinase. <i>Cell</i> , <b>1995</b> , 82, 915-25	56.2	426
1853	The retinoblastoma protein and cell cycle control. <i>Cell</i> , <b>1995</b> , 81, 323-30	56.2	4192
1852	Tumor suppressor p53 is a direct transcriptional activator of the human bax gene. <i>Cell</i> , <b>1995</b> , 80, 293-9	56.2	3503
1851	DNA polymerase epsilon links the DNA replication machinery to the S phase checkpoint. <i>Cell</i> , <b>1995</b> , 80, 29-39	56.2	373



1850	Development of a panel of monochromosomal somatic cell hybrids for rapid gene mapping. <b>1995</b> , 59, 233-41	80
1849	Characterisation of epitopes on human p53 using phage-displayed peptide libraries: insights into antibody-peptide interactions. <b>1995</b> , 248, 58-78	172
1848	Clinical applications of the p53 tumor suppressor gene. <b>1995</b> , 237, 79-90	11
1847	Induction of p53 and apoptosis by delta 12-PGJ2 in human hepatocarcinoma SK-HEP-1 cells. <b>1995</b> , 368, 348-52	29
1846	Studies of specific gene induction during apoptosis of cell lines conditionally immortalized by SV40. <b>1995</b> , 374, 384-6	7
1845	Precise mapping of the tms1 binding site on p53. <b>1995</b> , 377, 155-8	11
1844	Recombinant adenovirus vector expressing wild-type p53 is a potent inhibitor of prostate cancer cell proliferation. <b>1995</b> , 46, 843-8	37
1843	Molecular genetics of colorectal cancer. <b>1995</b> , 768, 101-10	46
1842	The spectrum of mutations at the p53 locus. Evidence for tissue-specific mutagenesis, selection of mutant alleles, and a "gain of function" phenotype. <b>1995</b> , 768, 111-28	82
1841	Low incidence of p53 mutations in European hepatocellular carcinomas with heterogeneous mutation as a rare event. <b>1995</b> , 23, 412-9	28
1840	p53-dependent and independent expression of p21 during cell growth, differentiation, and DNA damage. <b>1995</b> , 9, 935-44	850
1839	Uncoupling cell fate determination from patterned cell division in the Drosophila eye. <b>1995</b> , 270, 983-5	131
1838	p53 mutations, O6-alkylguanine DNA alkyltransferase activity, and sensitivity to procarbazine in human brain tumors. <b>1995</b> , 75, 1339-42	40
1837	Cell-mediated cytotoxicity can be regulated by p53 tumor suppressor gene activity in vitro. <b>1995</b> , 84, 175-85	5
1836	Cellular effects of olomoucine, an inhibitor of cyclin-dependent kinases. <b>1995</b> , 83, 105-20	104
1835	Effect of donor age on the phosphorylation of the retinoblastoma gene product in cultured human keratinocytes. <b>1995</b> , 9, 59-63	1
1834	Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. <b>1995</b> , 9, 639-49	661
1833	Potential for pharmacological intervention in Werner syndrome. <b>1995</b> , 7, 449-58	2

1832	p53 trans-dominantly suppresses tumor formation of human breast cancer cells mediated by retroviral bulk infection without marker gene selection: an expeditious in vitro protocol with implications towards gene therapy. <b>1995</b> , 14, 153-7		9
1831	p53 and its 14 kDa C-terminal domain recognize primary DNA damage in the form of insertion/deletion mismatches. <i>Cell</i> , <b>1995</b> , 81, 1013-20	56.2	357
1830	Activation of p53 sequence-specific DNA binding by short single strands of DNA requires the p53 C-terminus. <i>Cell</i> , <b>1995</b> , 81, 1021-9	56.2	339
1829	Pharmacology and toxicology of phosphorothioate oligonucleotides in the mouse, rat, monkey and man. <b>1995</b> , 82-83, 425-30		21
1828	A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma. <b>1995</b> , 269, 1281-4		971
1827	Prediction of recurrence in B-C stages of colorectal cancer by p53 nuclear overexpression in comparison with standard pathological features. <b>1995</b> , 21, 635-9		17
1826	The genetics of cell cycle checkpoints. <b>1995</b> , 5, 5-11		127
1825	Biochemical properties and biological effects of p53. <b>1995</b> , 5, 84-90		161
1824	Mammalian antiproliferative signals and their targets. <b>1995</b> , 5, 91-6		113
1823	Oncogenes and cell proliferation. <b>1995</b> , 5, 115-50		
1822	Risk assessment of environmental chemicals. <b>1995</b> , 35, 341-68		36
1821	The prognostic value of NCAM, p53 and cyclin D1 in resected non-small cell lung cancer. <b>1996</b> , 14, 207-17		27
1820	Endometrial effects of RU486 in primates--antiproliferative action despite signs of estrogen action and increased cyclin-B expression. <b>1996</b> , 59, 179-90		31
1819	Prediction of biologic aggressiveness in colorectal cancer by p53/k-ras-2 topographic genotyping. <b>1996</b> , 1, 5-28		24
1818	The cellular and molecular pathogenesis of colorectal cancer. <b>1996</b> , 25, 737-54		29
1817	Ionizing radiation-induced phosphorylation of RPA p34 is deficient in ataxia telangiectasia and reduced in aged normal fibroblasts. <b>1996</b> , 39, 43-52		35
1816	The mammalian cell cycle in normal and abnormal growth. <b>1996</b> , 25, 491-502		6
1815	The genetic program of genital human papillomaviruses in infection and cancer. <b>1996</b> , 23, 735-58		31

1814	Clinical implications of the p53 gene. <b>1996</b> , 47, 285-301	144
1813	Expression of p53 protein in melanoma progression. <b>1996</b> , 12, 97-103	13
1812	Probing Protein/Protein Interactions with Mass Spectrometry and Isotopic Labeling: Analysis of the p21/Cdk2 Complex. <b>1996</b> , 118, 5320-5321	55
1811	Evidence for Activities Inhibiting In Trans Initiation of DNA Replication in Extract Prepared from Irradiated Cells. <b>1996</b> , 145, 408	11
1810	Analysis of the K-ras and p53 Pathways in X-Ray-Induced Lung Tumors in the Rat. <b>1996</b> , 145, 449	18
1809	Low expression of the WAF1/CIP1 gene product, p21, in enzyme-altered foci induced in rat liver by diethylnitrosamine or phenobarbital. <b>1996</b> , 104, 21-6	18
1808	p53 accumulation in the organs of low-dose X-ray-irradiated mice. <b>1996</b> , 104, 79-84	26
1807	p53 involves cytosine arabinoside-induced apoptosis in cultured cerebellar granule neurons. <b>1996</b> , 203, 1-4	104
1806	Excitotoxic lesion of rat brain with quinolinic acid induces expression of p53 messenger RNA and protein and p53-inducible genes Bax and Gadd-45 in brain areas showing DNA fragmentation. <b>1996</b> , 74, 1143-60	100
1805	Vectors for a 'double-tagging' assay for protein-protein interactions: localization of the CDK2-binding domain of human p21. <b>1996</b> , 173, 147-54	2
1804	Antitopoisomerase drug action and resistance. <b>1996</b> , 32A, 958-66	159
1803	Apoptosis and chemotherapy resistance. <b>1996</b> , 32A, 921-6	150
1802	Cell division and the nervous system: regulating the cycle from neural differentiation to death. <b>1996</b> , 19, 62-8	137
1801	Gamma-radiation-induced cell death in the fetal rat brain possesses molecular characteristics of apoptosis and is associated with specific messenger RNA elevations. <b>1996</b> , 35, 19-30	42
1800	Apoptosis: a programmed cell death involved in ovarian and uterine physiology. <b>1996</b> , 67, 85-102	79
1799	ATF/CREB site mediated transcriptional activation and p53 dependent repression of the cyclin A promoter. <b>1996</b> , 385, 34-8	37
1798	Clonal nature of spontaneously immortalized 3T3 cells. <b>1996</b> , 229, 7-13	14
1797	Structural aspects of the p53 protein in relation to gene evolution: a second look. <b>1996</b> , 260, 623-37	186

1796	How phosphorylation regulates the activity of p53. <b>1996</b> , 263, 103-13	85
1795	The exit from G(0) into the cell cycle requires and is controlled by sarco(endo)plasmic reticulum Ca <sup>2+</sup> pump. <b>1996</b> , 329, 65-72	27
1794	The cdk2 binding domain of p27Kip correlates with the inhibition of the kinase activity of cdk2/cyclin complexes. <b>1996</b> , 220, 703-9	9
1793	DNA-dependent protein kinase inhibitor (OK-1035) suppresses p21 expression in HCT116 cells containing wild-type p53 induced by adriamycin. <b>1996</b> , 221, 207-12	32
1792	Specific in vitro binding of p53 to the promoter region of the human mismatch repair gene hMSH2. <b>1996</b> , 221, 722-8	71
1791	Effect of aging on regulation of sdi-1 in rat hepatocytes. <b>1996</b> , 225, 122-7	6
1790	Heat shock-mediated cell cycle arrest is accompanied by induction of p21 CKI. <b>1996</b> , 225, 759-63	32
1789	Proteasome-dependent regulation of p21WAF1/CIP1 expression. <b>1996</b> , 227, 564-9	212
1788	P21waf-1/cip-1/sdi-1 is expressed at G1 phase in primary culture of hepatocytes from old rats, presumably preventing the cells from entering the S phase of the cell cycle. <b>1996</b> , 228, 819-24	5
1787	Suppression of actinomycin D-induced apoptosis by the NS3 protein of hepatitis C virus. <b>1996</b> , 229, 825-31	76
1786	Characterization of the human p57KIP2 gene: alternative splicing, insertion/deletion polymorphisms in VNTR sequences in the coding region, and mutational analysis. <b>1996</b> , 97, 625-31	66
1785	p16ink4a gene and hematological malignancies. <b>1996</b> , 22, 11-24	25
1784	The induction of p53 and WAF1/CIP1 in chronic lymphocytic leukemia cells treated with 2-chlorodeoxyadenosine. <b>1996</b> , 74, 143-7	22
1783	Cloning differentially expressed mRNAs. <b>1996</b> , 14, 1685-91	130
1782	Expression of cyclin E in colorectal adenomas and adenocarcinomas: correlation with expression of Ki-67 antigen and p53 protein. <b>1996</b> , 429, 13-9	45
1781	Antisense oncogene and tumor suppressor gene therapy of cancer. <b>1996</b> , 74, 191-204	18
1780	Mutational analysis of the human cyclin-dependent kinase inhibitor p27kip1 in primary breast carcinomas. <b>1996</b> , 97, 91-4	62
1779	Receptor protein tyrosine kinase DDR is up-regulated by p53 protein. <b>1996</b> , 398, 165-9	24

1778	The WAF1-mediated p53 growth-suppressor pathway is intact in the coronary arteries of heart transplant recipients. <b>1996</b> , 27, 324-9		9
1777	The role of p53 mutation and protein expression in primary and recurrent adenoid cystic carcinoma. <b>1996</b> , 27, 567-72		47
1776	Immunohistochemical detection of p21waf1/cip1/sdi1 and p53 proteins in formalin-fixed, paraffin-embedded tissue sections of colorectal carcinoma. <b>1996</b> , 27, 912-6		20
1775	p53 and p21(WAF1/CIP1/SDI1) gene products in Barrett esophagus and adenocarcinoma of the esophagus and esophagogastric junction. <b>1996</b> , 27, 1211-20		57
1774	Uterine papillary serous carcinoma evolves via a p53-driven pathway. <b>1996</b> , 27, 1295-300		73
1773	Mice lacking p27(Kip1) display increased body size, multiple organ hyperplasia, retinal dysplasia, and pituitary tumors. <i>Cell</i> , <b>1996</b> , 85, 707-20	56.2	1403
1772	A syndrome of multiorgan hyperplasia with features of gigantism, tumorigenesis, and female sterility in p27(Kip1)-deficient mice. <i>Cell</i> , <b>1996</b> , 85, 733-44	56.2	1327
1771	The tumor suppressor gene Brca1 is required for embryonic cellular proliferation in the mouse. <i>Cell</i> , <b>1996</b> , 85, 1009-23	56.2	574
1770	p53 Protein exhibits 3'-to-5' exonuclease activity. <i>Cell</i> , <b>1996</b> , 85, 1089-99	56.2	234
1769	Structure of the C-terminal region of p21(WAF1/CIP1) complexed with human PCNA. <i>Cell</i> , <b>1996</b> , 87, 297-306	56.2	665
1768	Dacapo, a cyclin-dependent kinase inhibitor, stops cell proliferation during Drosophila development. <i>Cell</i> , <b>1996</b> , 87, 1225-35	56.2	282
1767	The role of DNA repair in the prevention of cancer. <b>1996</b> , 17, 235-283		5
1766	p53 Phosphorylation: biochemical and functional consequences. <b>1997</b> , 60, 1-11		73
1765	p53 functional loss in a colon cancer cell line with two missense mutations (218leu and 248trp) on separate alleles. <b>1996</b> , 98, 183-191		11
1764	High-risk HPV-positive human cancer cell lines show different sensitivity to cisplatin-induced apoptosis correlated with the p21Waf1/Cip1 level. <b>1996</b> , 108, 15-23		18
1763	Ginsenoside-Rh2 blocks the cell cycle of SK-HEP-1 cells at the G1/S boundary by selectively inducing the protein expression of p27kip1. <b>1996</b> , 110, 193-200		64
1762	p21ras in carcinogenesis. <b>1996</b> , 192, 658-68		10
1761	The role of p53 in cell cycle regulation. <b>1996</b> , 192, 669-75		84

1760	Cdk inhibitors in development and cancer. <b>1996</b> , 6, 56-64	375
1759	Polymorphisms in P21CIP1/WAF1 are not correlated with TP53 status in sporadic ovarian tumours. <b>1996</b> , 32A, 2360-3	10
1758	Effects of 1,25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. <b>1996</b> , 58, 395-401	159
1757	Modulation of DNA topoisomerase I activity by p53. <b>1996</b> , 35, 5778-86	94
1756	p53: puzzle and paradigm. <b>1996</b> , 10, 1054-72	1871
1755	Translational control of p27Kip1 accumulation during the cell cycle. <b>1996</b> , 271, 1861-4	791
1754	Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. <b>1996</b> , 272, 719-22	714
1753	Blockage by adenovirus E4orf6 of transcriptional activation by the p53 tumor suppressor. <b>1996</b> , 272, 1470-3	277
1752	Structure of the p53 tumor suppressor bound to the ankyrin and SH3 domains of 53BP2. <b>1996</b> , 274, 1001-5	477
1751	Abrogation of p53 function affects gadd gene responses to DNA base-damaging agents and starvation. <b>1996</b> , 15, 805-15	86
1750	Regulation of transcription factor activity during cellular aging. <b>1996</b> , 74, 523-34	28
1749	P21Waf1/Cip1/Sdi1 and p53 expression in association with DNA strand breaks in idiopathic pulmonary fibrosis. <b>1996</b> , 154, 477-83	267
1748	Cyclin-dependent protein kinases and the regulation of the eukaryotic cell cycle. 179-201	3
1747	. <b>1996</b> ,	49
1746	Imprinting of the gene encoding a human cyclin-dependent kinase inhibitor, p57KIP2, on chromosome 11p15. <b>1996</b> , 93, 3026-30	266
1745	Biological and clinical importance of the p53 tumor suppressor gene. <b>1996</b> , 42, 858-868	156
1744	Regulators of Life and Death: The Bcl-2 Gene Family. <b>1996</b> , 6, 312-336	15
1743	Induction of the WAF1/CIP1 protein and apoptosis in human T-cell leukemia virus type I-transformed lymphocytes after treatment with adriamycin by using a p53-independent pathway. <b>1996</b> , 93, 265-8	77

1742	Regional mapping of the human platelet-activating factor receptor gene (PTAFR) to 1p35-->p34.3 by fluorescence in situ hybridization. <b>1996</b> , 72, 205-7	9
1741	Cross talk between cell death and cell cycle progression: BCL-2 regulates NFAT-mediated activation. <b>1996</b> , 93, 9545-52	303
1740	The tumour suppressor gene p53 as a regulator of proliferative life-span and tumour progression. <b>1996</b> , 5, 139-53	16
1739	A novel role for the budding yeast RAD9 checkpoint gene in DNA damage-dependent transcription.. <b>1996</b> , 15, 3912-3922	81
1738	Sensitivity and selectivity of the DNA damage sensor responsible for activating p53-dependent G1 arrest. <b>1996</b> , 93, 4827-32	311
1737	Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system.. <b>1996</b> , 15, 6178-6188	242
1736	Functional interactions between p53 and the TFIIH complex are affected by tumour-associated mutations.. <b>1996</b> , 15, 1615-1624	116
1735	Cell type-specific inhibition of p53-mediated apoptosis by mdm2.. <b>1996</b> , 15, 1596-1606	151
1734	Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis.. <b>1996</b> , 15, 3693-3701	165
1733	p53-dependent cell cycle arrest induced by N-acetyl-L-leuciny-L-leuciny-L-norleucinal in platelet-derived growth factor-stimulated human fibroblasts. <b>1996</b> , 93, 10815-9	64
1732	Isolation of 10 differentially expressed cDNAs in p53-induced apoptosis: activation of the vertebrate homologue of the drosophila seven in absentia gene. <b>1996</b> , 93, 3953-7	140
1731	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant.. <b>1996</b> , 15, 827-838	232
1730	Role of the p21 cyclin-dependent kinase inhibitor in limiting intimal cell proliferation in response to arterial injury. <b>1996</b> , 93, 7905-10	221
1729	The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors.. <b>1996</b> , 15, 2748-2759	153
1728	BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. <b>1996</b> , 93, 14094-9	176
1727	Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E.. <b>1996</b> , 15, 4182-4193	254
1726	Identification of a novel p53 functional domain that is necessary for efficient growth suppression. <b>1996</b> , 93, 15335-40	374
1725	Genotoxic drugs induce interaction of the c-Abl tyrosine kinase and the tumor suppressor protein p53. <b>1996</b> , 271, 26457-60	62

1724	p53-dependent association between cyclin G and the B' subunit of protein phosphatase 2A. <b>1996</b> , 16, 6593-602	95
1723	Cytoplasmic sequestration of wild-type p53 protein impairs the G1 checkpoint after DNA damage. <b>1996</b> , 16, 1126-37	234
1722	Regulation of p16CDKN2 expression and its implications for cell immortalization and senescence. <b>1996</b> , 16, 859-67	626
1721	Adenovirus E1A proteins inhibit activation of transcription by p53. <b>1996</b> , 16, 2101-9	71
1720	C/EBPalpha regulation of the growth-arrest-associated gene gadd45. <b>1996</b> , 16, 3878-83	58
1719	Inhibition of p53-mediated growth arrest by overexpression of cyclin-dependent kinases. <b>1996</b> , 16, 4445-55	31
1718	A mutation in mouse rad51 results in an early embryonic lethal that is suppressed by a mutation in p53. <b>1996</b> , 16, 7133-43	623
1717	Inhibition of cell proliferation by the Mad1 transcriptional repressor. <b>1996</b> , 16, 2796-801	119
1716	Rat embryo fibroblasts immortalized with simian virus 40 large T antigen undergo senescence upon its inactivation. <b>1996</b> , 16, 5127-38	37
1715	Inhibition of G1 cyclin-dependent kinase activity during growth arrest of human breast carcinoma cells by prostaglandin A2. <b>1996</b> , 16, 762-70	104
1714	Induction of inositol 1,4,5 trisphosphate receptor genes by ionizing radiation. <b>1996</b> , 69, 539-46	12
1713	Transcriptional activation of the human epidermal growth factor receptor promoter by human p53. <b>1996</b> , 16, 6009-19	159
1712	mdm-2 inhibits the G1 arrest and apoptosis functions of the p53 tumor suppressor protein. <b>1996</b> , 16, 2445-52	318
1711	Regulation of the p21Sdi1/Cip1/Waf1 DNA Synthesis Inhibitor in Senescent Human Diploid Fibroblasts. <b>1996</b> , 15, 315-329	1
1710	Ras induces anchorage-independent growth by subverting multiple adhesion-regulated cell cycle events. <b>1996</b> , 16, 3370-80	85
1709	Functional interaction between DP-1 and p53. <b>1996</b> , 16, 5888-95	54
1708	p21 Disrupts the interaction between cdk2 and the E2F-p130 complex. <b>1996</b> , 16, 737-44	77
1707	A mutant p53 that discriminates between p53-responsive genes cannot induce apoptosis. <b>1996</b> , 16, 4961-71	276



1706	Wild-type p53 induces diverse effects in 32D cells expressing different oncogenes. <b>1996</b> , 16, 487-95	31
1705	Anchorage-dependent transcription of the cyclin A gene. <b>1996</b> , 16, 4632-8	122
1704	Protective role of p21(Waf1/Cip1) against prostaglandin A2-mediated apoptosis of human colorectal carcinoma cells. <b>1996</b> , 16, 6654-60	147
1703	Cyclin-mediated inhibition of muscle gene expression via a mechanism that is independent of pRB hyperphosphorylation. <b>1996</b> , 16, 7043-53	116
1702	Id2 specifically alters regulation of the cell cycle by tumor suppressor proteins. <b>1996</b> , 16, 2570-8	200
1701	Inhibition of E2F activity by the cyclin-dependent protein kinase inhibitor p21 in cells expressing or lacking a functional retinoblastoma protein. <b>1996</b> , 16, 2987-97	126
1700	The p53-binding protein 53BP2 also interacts with Bc12 and impedes cell cycle progression at G2/M. <b>1996</b> , 16, 3884-92	138
1699	Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function. <b>1996</b> , 16, 4952-60	255
1698	YY1 and NF1 both activate the human p53 promoter by alternatively binding to a composite element, and YY1 and E1A cooperate to amplify p53 promoter activity. <b>1996</b> , 16, 5933-45	92
1697	The cyclin-dependent kinase inhibitor p21 (WAF1) is required for survival of differentiating neuroblastoma cells. <b>1996</b> , 16, 1335-41	221
1696	Repression of p27kip1 synthesis by platelet-derived growth factor in BALB/c 3T3 cells. <b>1996</b> , 16, 4327-36	158
1695	Involvement of the cyclin-dependent kinase inhibitor p16 (INK4a) in replicative senescence of normal human fibroblasts. <b>1996</b> , 93, 13742-7	769
1694	Chapter 25. Cell Cycle Control and Cancer. <b>1996</b> , 31, 241-248	6
1693	Regulation of gene expression and transcription factor binding activity during cellular aging. <b>1996</b> , 5, 130-8	24
1692	Reactive oxygen species are downstream mediators of p53-dependent apoptosis. <b>1996</b> , 93, 11848-52	494
1691	Transcriptional activation of the human proliferating-cell nuclear antigen promoter by p53. <b>1996</b> , 93, 895-9	113
1690	The TGF $\beta$ receptors and signaling pathways. <b>1996</b> , 1, 395-432	1
1689	TP53 mutation analyses on breast carcinomas: a study of paraffin-embedded archival material. <b>1996</b> , 74, 555-61	30

1688	Sporadic CDKN2 (MTS1/p16ink4) gene alterations in human ovarian tumours. <b>1996</b> , 74, 1069-73	22
1687	p53 mutation is associated with high S-phase fraction in primary fallopian tube adenocarcinoma. <b>1996</b> , 74, 1157-60	11
1686	p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapse-free survival. <b>1996</b> , 74, 208-15	96
1685	Cell cycle control in fission yeast and mammals: identification of new regulatory mechanisms. <b>1996</b> , 69, 17-62	29
1684	Mechanisms of programmed cell death in Caenorhabditis elegans and vertebrates. <b>1996</b> , 32, 139-74	15
1683	Evidence of gene deletion of p21 (WAF1/CIP1), a cyclin-dependent protein kinase inhibitor, in thyroid carcinomas. <b>1996</b> , 74, 1336-41	31
1682	Structural studies of p21Waf1/Cip1/Sdi1 in the free and Cdk2-bound state: conformational disorder mediates binding diversity. <b>1996</b> , 93, 11504-9	483
1681	Identification of putative downstream genes of Oct-3, a pluripotent cell-specific transcription factor. <b>1996</b> , 1, 239-52	49
1680	Reversal of the temperature-shift-induced growth restriction of a temperature-sensitive simian virus 40 T-antigen-transformed human fibroblast cell line by treatment with retinoic acid. <b>1996</b> , 317 ( Pt 3), 707-11	6
1679	Nitric oxide-induced apoptosis: p53-dependent and p53-independent signalling pathways. <b>1996</b> , 319 ( Pt 1), 299-305	243
1678	Cyclin from sea urchins to HeLas: making the human cell cycle. <b>1996</b> , 24, 15-33	31
1677	G1 arrest and down-regulation of cyclin E/cyclin-dependent kinase 2 by the protein kinase inhibitor staurosporine are dependent on the retinoblastoma protein in the bladder carcinoma cell line 5637. <b>1996</b> , 93, 5941-6	58
1676	Wild-type and mutant p53 differentially regulate transcription of the insulin-like growth factor I receptor gene. <b>1996</b> , 93, 8318-23	326
1675	Mammalian cells resistant to tumor suppressor genes. <b>1996</b> , 93, 8390-4	9
1674	Activation of the human homologue of the Drosophila sina gene in apoptosis and tumor suppression. <b>1996</b> , 93, 9039-42	92
1673	The melanoma differentiation associated gene mda-7 suppresses cancer cell growth. <b>1996</b> , 93, 9160-5	254
1672	p53 protein expression in non-Hodgkin's lymphoma. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1. <b>1996</b> , 49, M278-82	4
1671	p53 gene alterations and protein accumulation in colorectal cancer. <b>1996</b> , 49, M85-90	7

1670	Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids.. <b>1996</b> , 15, 1734-1741	100
1669	Cancer cell cycles. <b>1996</b> , 274, 1672-7	4404
1668	Alterations of the p15, p16, and p18 genes in osteosarcoma. <b>1996</b> , 86, 136-42	100
1667	bcl-2 protein downregulation is not required for differentiation of multidrug resistant HL60 leukemia cells. <b>1996</b> , 20, 101-7	50
1666	Induced differentiation, the cell cycle, and the treatment of cancer. <b>1996</b> , 69, 97-102	39
1665	Replicative senescence: considerations relating to the stability of heterochromatin domains. <b>1996</b> , 31, 281-93	68
1664	SV40-mediated immortalization of human fibroblasts. <b>1996</b> , 31, 303-10	53
1663	Differential CDK-inhibitor gene expression in aging human diploid fibroblasts. <b>1996</b> , 31, 311-25	89
1662	Studies demonstrating the complexity of regulation and action of the growth inhibitory gene SDI1. <b>1996</b> , 31, 327-35	9
1661	Models of initiation of replicative senescence by loss of telomeric DNA. <b>1996</b> , 31, 235-43	37
1660	The role of DNA damage in cellular aging: is it time for a reassessment?. <b>1996</b> , 31, 61-8	9
1659	From telomere loss to p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. <b>1996</b> , 31, 295-301	176
1658	Redox regulation of transcriptional activators. <b>1996</b> , 21, 335-48	562
1657	Characterization of the GADD45 response to ionizing radiation in WI-L2-NS cells, a p53 mutant cell line. <b>1996</b> , 352, 79-86	14
1656	Chromosome changes caused by alterations of p53 expression. <b>1996</b> , 354, 129-38	41
1655	Viruses as pacemakers in the evolution of defence mechanisms against cancer. <b>1996</b> , 12, 4-6	12
1654	Negative regulation of cell growth by TGF beta. <b>1996</b> , 1242, 185-99	32
1653	Effects of p53 mutation on tumor progression: recent insights from mouse tumor models. <b>1996</b> , 1242, 171-6	8

1652	p53 in growth control and neoplasia. <b>1996</b> , 1287, 77-102	198
1651	Retroviral insertional mutagenesis as a strategy to identify cancer genes. <b>1996</b> , 1287, 29-57	92
1650	Ubiquitin in signal transduction and cell transformation. <b>1996</b> , 1288, F21-9	10
1649	Why are there so many CDK inhibitors?. <b>1996</b> , 1288, 01-5	19
1648	Pterygia and limbal epithelial cells: Relationship and molecular mechanisms. <b>1996</b> , 15, 297-329	10
1647	Lessons from the p53 mutant mouse. <b>1996</b> , 122, 319-27	29
1646	The p53 gene is a potent determinant of chemosensitivity and radiosensitivity in gastric and colorectal cancers. <b>1996</b> , 122, 360-5	95
1645	Immunohistochemical study of Cell Cycle Modulators in G(1)-S Transition in Clinical Breast Cancer Tissue. <b>1996</b> , 3, 93-104	3
1644	Curable and non-curable malignancies: lessons from paediatric cancer. <b>1996</b> , 13, 15-21	9
1643	A mutation in a thioredoxin reductase homolog suppresses p53-induced growth inhibition in the fission yeast <i>Schizosaccharomyces pombe</i> . <b>1996</b> , 252, 518-29	22
1642	Mammary tumors induced by human adenovirus type 9: a role for the viral early region 4 gene. <b>1996</b> , 39, 57-67	18
1641	Regulation of the cell cycle following DNA damage in normal and Ataxia telangiectasia cells. <b>1996</b> , 52, 316-28	12
1640	Role of protein kinase activity in apoptosis. <b>1996</b> , 52, 979-94	59
1639	The p53 tumour suppressor gene: a mediator of a G1 growth arrest and of apoptosis. <b>1996</b> , 52, 1001-7	61
1638	Cyclin-dependent kinase inhibitors (CKIs) and hematological malignancies. <b>1996</b> , 38, 313-23	17
1637	In vitro properties of a newly established medulloblastoma cell line, MCD-1. <b>1996</b> , 29, 107-26	11
1636	Human and plant proliferating-cell nuclear antigen have a highly conserved binding site for the p53-inducible gene product p21WAF1. <b>1996</b> , 237, 854-61	19
1635	Molecular pathogenesis of adenoma and differentiated adenocarcinoma of the stomach. <b>1996</b> , 46, 834-41	32

1634	Loss of an HLA haplotype in pancreas cancer tissue and its corresponding tumor derived cell line. <b>1996</b> , 47, 372-81	76
1633	Development of intestinal cell culture models for drug transport and metabolism studies. <b>1996</b> , 22, 3-52	51
1632	Apoptosis and gastrointestinal pharmacology. <b>1996</b> , 72, 149-69	60
1631	Oncogenes and tumor suppressor genes in cutaneous malignant melanoma. <b>1996</b> , 63, 412-8	3
1630	Subcellular distribution of p21 and PCNA in normal and repair-deficient cells following DNA damage. <b>1996</b> , 6, 189-99	126
1629	E2F-1 but not E2F-4 can overcome p16-induced G1 cell-cycle arrest. <b>1996</b> , 6, 474-83	69
1628	Molecular biology of the cell cycle: Potential for therapeutic applications in radiation oncology. <b>1996</b> , 6, 284-294	19
1627	Regulation of cellular proliferation effects on alteration of normal signaling pathways. <b>1996</b> , 27, 20-24	
1626	Colorectal cancer: Molecular genetic studies and their future clinical applications. <b>1996</b> , 27, 35-40	6
1625	Multiple genetic abnormalities of 11p15 in Wilms' tumor. <b>1996</b> , 27, 484-9	17
1624	p21/WAF1/CIP1 expression in normal mucosa and in adenomas and adenocarcinomas of the colon: its relationship with differentiation. <b>1996</b> , 179, 248-53	79
1623	MDM2 and p21WAF1/CIP1, wild-type p53-induced proteins, are regularly expressed by Sternberg-Reed cells in Hodgkin's disease. <b>1996</b> , 180, 58-64	21
1622	Expression of cyclin-dependent kinase inhibitor p21WAF1/CIP1 in non-neoplastic mucosa and neoplasia of the stomach: relationship with p53 status and proliferative activity. <b>1996</b> , 180, 122-8	70
1621	Molecular analysis of the cyclin-dependent kinase inhibitor family: p16(CDKN2/MTS1/INK4A), p18(INK4C) and p27(Kip1) genes in neuroblastomas. <b>1996</b> , 77, 570-5	42
1620	Radiation therapy tolerance limits. For one or for all?--Janeway Lecture. <b>1996</b> , 77, 2379-85	52
1619	Radioresistance and p53 status of T2 laryngeal carcinoma. Analysis by immunohistochemistry and denaturing gradient gel electrophoresis. <b>1996</b> , 78, 991-7	17
1618	The helix-loop-helix protein Id-1 and a retinoblastoma protein binding mutant of SV40 T antigen synergize to reactivate DNA synthesis in senescent human fibroblasts. <b>1996</b> , 18, 161-72	64
1617	Ionizing radiation and the cell cycle: A review. <b>1996</b> , 4, 147-158	1

1616	Mutation in p53 and de-regulation of p53-related gene expression in three human cell lines immortalized with 4-nitroquinoline 1-oxide or 60Co gamma rays. <b>1996</b> , 66, 698-702	11
1615	Overexpression of bax sensitizes human breast cancer MCF-7 cells to radiation-induced apoptosis. <b>1996</b> , 67, 101-5	128
1614	Wild-type p53-induced apoptosis in a Burkitt lymphoma cell line is inhibited by interferon gamma. <b>1996</b> , 67, 106-12	17
1613	In vitro evaluation of a p53-expressing adenovirus as an anti-cancer drug. <b>1996</b> , 67, 386-92	171
1612	Reduced messenger RNA expression level of p21 CIP1 in human colorectal carcinoma tissues and its association with p53 gene mutation. <b>1996</b> , 69, 259-64	23
1611	Inhibition of hepatitis-B-virus core promoter by p53: implications for carcinogenesis in hepatocytes. <b>1996</b> , 67, 892-7	16
1610	Radio-induced modulation of transforming growth factor beta1 sensitivity in a p53 wild-type human colorectal-cancer cell line. <b>1996</b> , 68, 126-31	9
1609	Mutations and polymorphisms in the p53, p21 and p16 genes in oral carcinomas of Indian betel quid chewers. <b>1996</b> , 68, 420-3	53
1608	Abrogation of apoptosis induced by DNA-damaging agents in human bladder-cancer cell lines with p21/WAF1/CIP1 and/or p53 gene alterations. <b>1996</b> , 68, 501-5	39
1607	Cellular responses of HPV-positive cancer cells to genotoxic anti-cancer agents: repression of E6/E7-oncogene expression and induction of apoptosis. <b>1996</b> , 68, 506-13	81
1606	Molecular analysis of the cyclin-dependent kinase inhibitor genes p15INK4b/MTS2, p16INK4/MTS1, p18 and p19 in human cancer cell lines. <b>1996</b> , 68, 605-11	35
1605	Characterization of senescence- and apoptosis-dependent forms of terminin as derived from a precursor found in replicating and nonreplicating cells. <b>1996</b> , 60, 107-20	6
1604	Tumor necrosis factor alpha: posttranscriptional stabilization of WAF1 mRNA in p53-deficient human leukemic cells. <b>1996</b> , 166, 568-76	43
1603	Sodium butyrate inhibits the phosphorylation of the retinoblastoma gene product in mouse fibroblasts by a transcription-dependent mechanism. <b>1996</b> , 166, 631-6	27
1602	Differential regulation of p27 and cyclin D1 by TGF-beta and EGF in C3H 10T1/2 mouse fibroblasts. <b>1996</b> , 168, 510-20	37
1601	c-Myc inactivation by mutant Max alters growth and morphology of NCI-H-630 colon cancer cells. <b>1996</b> , 169, 200-8	6
1600	TP53 and MYC gene alterations independently predict poor prognosis in breast cancer patients. <b>1996</b> , 16, 170-9	58
1599	Molecular cytogenetic characterization and physical mapping of 12q13-15 amplification in human cancers. <b>1996</b> , 17, 205-14	47

1598	Separate amplified regions encompassing CDK4 and MDM2 in human sarcomas. <b>1996</b> , 17, 254-9	86
1597	Induction of p53 and p21/WAF1/CIP1 expression by nitric oxide and their association with apoptosis in human cancer cells. <b>1996</b> , 16, 20-31	118
1596	p53 transactivation through various p53-responsive elements. <b>1996</b> , 16, 101-8	11
1595	Mutational analysis of the p21/WAF1/CIP1/SDI1 coding region in human tumor cell lines. <b>1996</b> , 16, 221-8	22
1594	The role of cdc2, cdc25 and cyclin A genes in the maintenance of immortalization and growth arrest in a rat embryonic fibroblast conditional cell line. <b>1996</b> , 20, 159-67	3
1593	The metastatic phenotype--prognostic implications. <b>1996</b> , 24, 71-96	11
1592	Infectious agents and environmental factors in lymphoid malignancies. <b>1996</b> , 10, 89-94	6
1591	Early ovarian cancer: A review of its genetic and biologic factors, detection, and treatment. <b>1996</b> , 20, 86-137	1
1590	Protéine p53: sentinelle du ghome. <b>1996</b> , 1996, 29-36	
1589	The expression of retinoblastoma protein in epidermis is induced by ultraviolet B exposure. <b>1996</b> , 135, 406-411	0
1588	D-type cyclin expression is decreased and p21 and p27 CDK inhibitor expression is increased when tsBN462 CCG1/TAFII250 mutant cells arrest in G1 at the restrictive temperature. <b>1996</b> , 1, 687-705	26
1587	Molecular and cellular biomarkers for field cancerization and multistep process in head and neck tumorigenesis. <b>1996</b> , 15, 53-76	40
1586	Synchronization in mammalian system: An introduction. <b>1996</b> , 18, 75-81	
1585	Infrequent but significant p21/WAF1/CIP1 gene alteration in synchronous or metachronous transitional cell carcinoma. <b>1996</b> , 1, 69-74	11
1584	The role of the cell cycle in genitourinary carcinoma. <b>1996</b> , 14, 310-7	2
1583	Purification and crystallization of cyclin-dependent kinase inhibitor p21. <b>1996</b> , 5, 1928-30	4
1582	MTS1 gene mutations in archival oral squamous cell carcinomas. <b>1996</b> , 25, 541-6	10
1581	Tumor suppressor p53 down-regulates tissue-specific expression of tyrosinase gene in human melanoma cell lines. <b>1996</b> , 9, 85-91	18

1580	Simultaneously detected aberrant p53 tumor suppressor protein and HPV-DNA localize mostly in separate keratinocytes in anogenital and common warts. <b>1996</b> , 5, 72-8	7
1579	Disturbance of the cell cycle with colchicine enhances the growth advantage of diethylnitrosamine-initiated hepatocytes in rats. <b>1996</b> , 87, 5-9	11
1578	Cloning of mouse DAN cDNA and its down-regulation in transformed cells. <b>1996</b> , 87, 58-61	20
1577	Absence of a mutation of the p21/WAF1 gene in human lung and pancreatic cancers. <b>1996</b> , 87, 275-8	29
1576	Inhibition of cell growth by transforming growth factor beta 1 is associated with p53-independent induction of p21 in gastric carcinoma cells. <b>1996</b> , 87, 377-84	33
1575	p53 antisense oligonucleotide inhibits growth of human colon tumor and normal cell lines. <b>1996</b> , 87, 735-42	18
1574	Simultaneous measurement of unscheduled and replicating DNA synthesis by means of a new cell culture insert DNA retention method: rapid induction of replicating DNA synthesis in response to genotoxic carcinogens. <b>1996</b> , 87, 805-15	3
1573	Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines. <b>1996</b> , 87, 824-30	42
1572	A comparative study of glioma cell lines for p16, p15, p53 and p21 gene alterations. <b>1996</b> , 87, 900-7	18
1571	Target of skin tumorigenesis: cyclin D1-cdk4. <b>1996</b> , 35, 609-13	5
1570	Immunohistochemical detection of CDK4 and 9 16INK4 proteins in cutaneous malignant melanoma. <b>1996</b> , 134, 269-275	40
1569	Expression of p21waf1/Cip1, MDM2 and p53 in vivo: analysis of cytological preparations. <b>1996</b> , 7, 340-51	4
1568	Use of a cDNA microarray to analyse gene expression patterns in human cancer. <b>1996</b> , 14, 457-60	1672
1567	Identification of BTG2, an antiproliferative p53-dependent component of the DNA damage cellular response pathway. <b>1996</b> , 14, 482-6	346
1566	Loss of normal p53 function confers sensitization to Taxol by increasing G2/M arrest and apoptosis. <b>1996</b> , 2, 72-9	570
1565	H-cadherin, a novel cadherin with growth inhibitory functions and diminished expression in human breast cancer. <b>1996</b> , 2, 776-82	186
1564	Selective radiosensitization of p53-deficient cells by caffeine-mediated activation of p34cdc2 kinase. <b>1996</b> , 2, 1140-3	134
1563	Structure-based rescue of common tumor-derived p53 mutants. <b>1996</b> , 2, 1143-6	86



1562	Evasion of apoptosis by DNA viruses. <b>1996</b> , 74, 527-37	38
1561	Cell-cycle control and its watchman. <b>1996</b> , 381, 643-4	259
1560	A non-enzymatic p21 protein inhibitor of stress-activated protein kinases. <b>1996</b> , 381, 804-6	237
1559	Role for c-Abl tyrosine kinase in growth arrest response to DNA damage. <b>1996</b> , 382, 272-4	210
1558	Crystal structure of the p27Kip1 cyclin-dependent-kinase inhibitor bound to the cyclin A-Cdk2 complex. <b>1996</b> , 382, 325-31	804
1557	Cooperation of the tumour suppressors IRF-1 and p53 in response to DNA damage. <b>1996</b> , 382, 816-8	301
1556	Relationship between p53 status and radiosensitivity in human tumour cell lines. <b>1996</b> , 73, 581-8	56
1555	A non-random deletion in the p53 gene in oral squamous cell carcinoma. <b>1996</b> , 73, 1381-6	21
1554	Clinical and pathological associations with p53 tumour-suppressor gene mutations and expression of p21WAF1/Cip1 in colorectal carcinoma. <b>1996</b> , 74, 165-71	53
1553	No defect in G1/S cell cycle arrest in irradiated Li-Fraumeni lymphoblastoid cell lines. <b>1996</b> , 74, 698-703	12
1552	Genes involved in cell cycle G1 checkpoint control are frequently mutated in human melanoma metastases. <b>1996</b> , 74, 936-41	21
1551	Expression of p21 (WAF1/CIP1) protein in clinical thyroid tissues. <b>1996</b> , 74, 1269-74	31
1550	Mechanism of PAP I gene induction during hepatocarcinogenesis: clinical implications. <b>1996</b> , 74, 1767-75	16
1549	Involvement of p53 in DNA strand break-induced apoptosis in postmitotic CNS neurons. <b>1996</b> , 8, 1812-21	120
1548	Directional random oligonucleotide primed (DROP) global amplification of cDNA: its application to subtractive cDNA cloning. <b>1996</b> , 24, 4832-5	4
1547	CCAAT/enhancer-binding protein alpha (C/EBP alpha) inhibits cell proliferation through the p21 (WAF-1/CIP-1/SDI-1) protein. <b>1996</b> , 10, 804-15	318
1546	Defect in multiple cell cycle checkpoints in ataxia-telangiectasia postirradiation. <b>1996</b> , 271, 20486-93	105
1545	G0/G1 growth arrest mediated by a region encompassing the basic leucine zipper (bZIP) domain of the Epstein-Barr virus transactivator Zta. <b>1996</b> , 271, 31799-802	54

1544	Transcriptional repression by p53 involves molecular interactions distinct from those with the TATA box binding protein. <b>1996</b> , 24, 4281-8	57
1543	Characterization of a putative p53 binding site in the promoter of the mouse tissue inhibitor of metalloproteinases-3 (TIMP-3) gene: TIMP-3 is not a p53 target gene. <b>1996</b> , 17, 2559-62	19
1542	Wild-type p53 negatively regulates the expression of a microtubule-associated protein. <b>1996</b> , 10, 2971-80	177
1541	Interaction of cyclin-dependent kinase 5 (Cdk5) and neuronal Cdk5 activator in bovine brain. <b>1996</b> , 271, 1538-43	78
1540	p53 stimulates promoter activity of the sgk. serum/glucocorticoid-inducible serine/threonine protein kinase gene in rodent mammary epithelial cells. <b>1996</b> , 271, 12414-22	59
1539	The E1B 19K protein blocks apoptosis by interacting with and inhibiting the p53-inducible and death-promoting Bax protein. <b>1996</b> , 10, 461-77	265
1538	Proteins of the Myc network: essential regulators of cell growth and differentiation. <b>1996</b> , 68, 109-82	600
1537	Cell cycle control by Xenopus p28Kix1, a developmentally regulated inhibitor of cyclin-dependent kinases. <b>1996</b> , 7, 457-69	65
1536	The p53-MDM2 interaction in a cancer-prone family, and the identification of a novel therapeutic target. <b>1996</b> , 35, 429-34	26
1535	Identification of natural monomeric response elements of the nuclear receptor RZR/ROR. They also bind COUP-TF homodimers. <b>1996</b> , 271, 19732-6	86
1534	Genetic determinants of p53-induced apoptosis and growth arrest. <b>1996</b> , 10, 1945-52	374
1533	p202, an interferon-inducible modulator of transcription, inhibits transcriptional activation by the p53 tumor suppressor protein, and a segment from the p53-binding protein 1 that binds to p202 overcomes this inhibition. <b>1996</b> , 271, 27544-55	86
1532	Localisation of apoptosis and expression of apoptosis related proteins in the synovium of patients with rheumatoid arthritis. <b>1996</b> , 55, 442-9	75
1531	The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway. <b>1996</b> , 10, 1219-32	233
1530	Expression of Bcl-xL and loss of p53 can cooperate to overcome a cell cycle checkpoint induced by mitotic spindle damage. <b>1996</b> , 10, 2621-31	196
1529	Cyclin-dependent kinases are inactivated by a combination of p21 and Thr-14/Tyr-15 phosphorylation after UV-induced DNA damage. <b>1996</b> , 271, 13283-91	119
1528	Regulation of mutant p53 temperature-sensitive DNA binding. <b>1996</b> , 271, 25468-78	81
1527	Mutation of phosphoserine 389 affects p53 function in vivo. <b>1996</b> , 271, 29380-5	84

1526	Phosphorylation of p53 at the casein kinase II site selectively regulates p53-dependent transcriptional repression but not transactivation. <b>1996</b> , 24, 1119-26	60
1525	Heterologous expression of the human cyclin-dependent kinase inhibitor p21Cip1 in the fission yeast, <i>Schizosaccharomyces pombe</i> reveals a role for PCNA in the chk1+ cell cycle checkpoint pathway. <b>1996</b> , 7, 651-62	29
1524	p53 regulates the minimal promoter of the human topoisomerase IIalpha gene. <b>1996</b> , 24, 4464-70	81
1523	p53 levels, functional domains, and DNA damage determine the extent of the apoptotic response of tumor cells. <b>1996</b> , 10, 2438-51	542
1522	Allosteric regulation of the thermostability and DNA binding activity of human p53 by specific interacting proteins. CRC Cell Transformation Group. <b>1996</b> , 271, 3917-24	78
1521	Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation. <b>1996</b> , 7, 1587-99	108
1520	Abnormal accumulation of copper in LEC rat liver induces expression of p53 and nuclear matrix-bound p21(waf 1/cip 1). <b>1996</b> , 17, 2157-61	25
1519	Dual roles of ATM in the cellular response to radiation and in cell growth control. <b>1996</b> , 10, 2401-10	318
1518	Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. <b>1996</b> , 122, 627-32	109
1517	Sites and types of UV-induced mutations leading to inactivation of the growth-arresting activity in p21 (sdi1/cip1/waf1) cDNA. <b>1996</b> , 17, 2343-5	5
1516	Induction of p21 mediated by reactive oxygen species formed during the metabolism of aziridinybenzoquinones by HCT116 cells. <b>1996</b> , 271, 31915-21	57
1515	The Atr and Atm protein kinases associate with different sites along meiotically pairing chromosomes. <b>1996</b> , 10, 2423-37	216
1514	Wild-type p53 transgenic mice exhibit altered differentiation of the ureteric bud and possess small kidneys. <b>1996</b> , 10, 836-50	106
1513	Cell Cycle Control of Ovarian Granulosa Cells in Tumors and Cysts. <b>1996</b> , 4, 61-69	2
1512	Alterations of p53 and expression of WAF1/p21 in human thyroid tumors. <b>1996</b> , 6, 1-9	49
1511	anti-Benzo[a]pyrene-7,8-diol-9,10-epoxide Treatment Increases Levels of the Proteins p53 and p21WAF1 in the Human Mammary Carcinoma Cell Line MCF-7. <b>1996</b> , 10, 299-306	17
1510	Abrogation of p27Kip1 by cDNA antisense suppresses quiescence (G0 state) in fibroblasts. <b>1996</b> , 271, 18337-41	172
1509	p53-dependent induction of WAF1 by heat treatment in human glioblastoma cells. <b>1996</b> , 271, 14510-3	64

1508	The role of the transcription factor Sp1 in regulating the expression of the WAF1/CIP1 gene in U937 leukemic cells. <b>1996</b> , 271, 901-6	185
1507	Biochemical characterization of p16INK4- and p18-containing complexes in human cell lines. <b>1996</b> , 271, 15942-9	47
1506	Decorin-induced growth suppression is associated with up-regulation of p21, an inhibitor of cyclin-dependent kinases. <b>1996</b> , 271, 18961-5	188
1505	Paclitaxel activation of the GADD153 promoter through a cellular injury response element containing an essential Sp1 binding site. <b>1996</b> , 271, 20588-93	18
1504	Novel form of p21(WAF1/CIP1/SDI1) protein in phorbol ester-induced G2/M arrest. <b>1996</b> , 271, 29556-60	45
1503	Interference with p53 protein inhibits hematopoietic and muscle differentiation. <b>1996</b> , 134, 193-204	114
1502	Differential modulation of G1 cyclins and the Cdk inhibitor p27kip1 by platelet-derived growth factor and plasma factors in density-arrested fibroblasts. <b>1996</b> , 271, 11253-60	53
1501	Life, death, and the pursuit of apoptosis. <b>1996</b> , 10, 1-15	1041
1500	Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. <b>1996</b> , 10, 142-53	697
1499	Lack of CD54 expression and mutation of p53 gene relate to the prognosis of childhood Burkitt's lymphoma. <b>1996</b> , 21, 449-55	6
1498	Cells arrested in G1 by the v-Abl tyrosine kinase do not express cyclin A despite the hyperphosphorylation of RB. <b>1996</b> , 271, 19637-40	25
1497	Role for cyclin A-dependent kinase in DNA replication in human S phase cell extracts. <b>1996</b> , 271, 31627-37	44
1496	Human Cytomegalovirus Immediate-Early Protein IE2 Tethers a Transcriptional Repression Domain to p53. <b>1996</b> , 271, 3534-3540	91
1495	The absence of p21Cip1/WAF1 alters keratinocyte growth and differentiation and promotes ras-tumor progression. <b>1996</b> , 10, 3065-75	262
1494	The product of the mouse nude locus, Whn, regulates the balance between epithelial cell growth and differentiation. <b>1996</b> , 10, 2212-21	122
1493	Heat shock protein 84 forms a complex with mutant p53 protein predominantly within a cytoplasmic compartment of the cell. <b>1996</b> , 271, 15084-90	87
1492	MCC, a cytoplasmic protein that blocks cell cycle progression from the G0/G1 to S phase. <b>1996</b> , 271, 10341-6	36
1491	Transcriptional activation of the human p21(WAF1/CIP1) gene by retinoic acid receptor. Correlation with retinoid induction of U937 cell differentiation. <b>1996</b> , 271, 31723-8	257

1490	Adenovirus-mediated gene transfer of the tumor suppressor, p53, induces apoptosis in postmitotic neurons. <b>1996</b> , 135, 1085-96	118
1489	The single-stranded DNA end binding site of p53 coincides with the C-terminal regulatory region. <b>1996</b> , 24, 3560-7	53
1488	P53 gene mutations in chronic myelogenous leukemia medullary and extramedullary blast crisis. <b>1996</b> , 24, 175-82	7
1487	A 39 amino acid fragment of the cell cycle regulator p21 is sufficient to bind PCNA and partially inhibit DNA replication in vivo. <b>1996</b> , 24, 1727-33	68
1486	Adhesion-dependent cell cycle progression linked to the expression of cyclin D1, activation of cyclin E-cdk2, and phosphorylation of the retinoblastoma protein. <b>1996</b> , 133, 391-403	416
1485	Elevation in the ratio of Cu/Zn-superoxide dismutase to glutathione peroxidase activity induces features of cellular senescence and this effect is mediated by hydrogen peroxide. <b>1996</b> , 5, 283-92	188
1484	Targeted in vivo expression of the cyclin-dependent kinase inhibitor p21 halts hepatocyte cell-cycle progression, postnatal liver development and regeneration. <b>1996</b> , 10, 245-60	185
1483	Analysis of wild-type and mutant p21WAF-1 gene activities. <b>1996</b> , 16, 1786-93	103
1482	Expression and sequence analysis of the SDI1/WAF1/CIP1/p21 tumor suppressor gene in prostate cancer cell lines. <b>1996</b> , 8, 1237-41	1
1481	Irrelevance of the mutated p53 gene product to tumor rejection antigen in 3-methylcholanthrene-induced fibrosarcomas. <b>1996</b> , 8, 1045-52	
1480	Polymorphisms in the promoter region of the WAF1/CIP1 gene. <b>1996</b> , 9, 559	
1479	UV irradiation leads to transient changes in phosphorylation and stability of tumor suppressor protein p53. <b>1996</b> , 9, 1277-85	
1478	Cyclin-binding motifs are essential for the function of p21CIP1. <b>1996</b> , 16, 4673-82	286
1477	Detection of RB, p16/CDKN2 and p15(INK4B) gene alterations with immunohistochemical studies in human prostate carcinomas. <b>1996</b> , 8, 107-12	2
1476	Role of HPV in tumorigenesis of oral keratinocytes. <b>1996</b> , 8, 21	
1475	No significant changes in the expression of the fas,fasl,bcl-2 and bax genes in apoptosis of an erythroleukemic cell line by p53. <b>1996</b> , 9, 269-77	
1474	WAF1 expression is independent of p53 gene alterations and protein expression in human lung cancer cells. <b>1996</b> , 9, 405-10	
1473	Prognostic significance of the p53 mutation in esophageal cancer. <b>1996</b> , 26, 287-92	24

1472	Functional analysis of a p21WAF1,CIP1,SDI1 mutant (Arg94 --> Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. <b>1996</b> , 271, 15782-6	45
1471	Genetic alterations of cyclins, cyclin-dependent kinases, and Cdk inhibitors in human cancer. <b>1996</b> , 68, 67-108	581
1470	p53 tumor suppressor gene: from the basic research laboratory to the clinic--an abridged historical perspective. <b>1996</b> , 17, 1187-98	206
1469	Continuous infusion of antisense phosphorothioate therapeutics. <b>1996</b> , 1, 201-12	1
1468	Dose rate and mode of exposure are key factors in JNK activation by UV irradiation. <b>1996</b> , 17, 2073-6	26
1467	Drug Resistance. <b>1996</b> ,	3
1466	The family of the small leucine-rich proteoglycans: key regulators of matrix assembly and cellular growth. <b>1997</b> , 32, 141-74	406
1465	P53, MDM-2, BAX and BCL-2 and drug resistance in chronic lymphocytic leukemia. <b>1997</b> , 26, 435-49	63
1464	Prognostic indicators for breast cancer patients with one to three regional lymph node metastases, with special reference to alterations in expression levels of bcl-2, p53 and c-erbB-2 proteins. <b>1997</b> , 27, 371-7	25
1463	Expression of p21WAF1/CIP1 in fetal and adult tissues: simultaneous analysis with Ki67 and p53. <b>1997</b> , 50, 645-53	14
1462	Glucocorticoid inhibition of fibroblast proliferation and regulation of the cyclin kinase inhibitor p21Cip1. <b>1997</b> , 11, 577-86	69
1461	The genetic defect in ataxia-telangiectasia. <b>1997</b> , 15, 177-202	532
1460	Progress in Cell Cycle Research. <b>1997</b> ,	10
1459	Identification of a new cellular protein that can interact specifically with DAN. <b>1997</b> , 16, 985-91	11
1458	Involvement of the Sp3 transcription factor in induction of p21Cip1/WAF1 in keratinocyte differentiation. <b>1997</b> , 272, 1308-14	111
1457	The geranylgeranyltransferase-I inhibitor GGTI-298 arrests human tumor cells in G0/G1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. <b>1997</b> , 272, 27224-9	148
1456	New functional activities for the p21 family of CDK inhibitors. <b>1997</b> , 11, 847-62	1057
1455	Inhibition of protein phosphatase activity induces p53-dependent apoptosis in the absence of p53 transactivation. <b>1997</b> , 272, 15220-6	94

1454	Inactivation of the cyclin D-dependent kinase in the rat fibroblast cell line, 3Y1, induced by contact inhibition. <b>1997</b> , 272, 8065-70	51
1453	The MDM2 C-terminal region binds to TAFII250 and is required for MDM2 regulation of the cyclin A promoter. <b>1997</b> , 272, 30651-61	63
1452	Ionizing radiation induces apoptosis and elevates cyclin A1-Cdk2 activity before but not after the midblastula transition in Xenopus. <b>1997</b> , 8, 1195-206	99
1451	Damage and replication checkpoint control in fission yeast is ensured by interactions of Crb2, a protein with BRCT motif, with Cut5 and Chk1. <b>1997</b> , 11, 3387-400	209
1450	Cyclin-dependent kinase regulation during G1 phase and cell cycle regulation by TGF-beta. <b>1997</b> , 71, 165-207	108
1449	DNA damage induces phosphorylation of the amino terminus of p53. <b>1997</b> , 11, 3471-81	633
1448	Butyrate activates the WAF1/Cip1 gene promoter through Sp1 sites in a p53-negative human colon cancer cell line. <b>1997</b> , 272, 22199-206	313
1447	Analysis of phosphorylation of pRB and its regulatory proteins in breast cancer. <b>1997</b> , 50, 407-12	13
1446	Dietary Fat and Cancer. <b>1997</b> ,	
1445	Pathways of p53-dependent apoptosis. <b>1997</b> , 53, 139-73	6
1444	Mechanisms of Apoptosis. <b>1997</b> , 20, 183-229	1
1443	p53 activates Fanconi anemia group C gene expression. <b>1997</b> , 6, 277-83	17
1442	Characterization of p53 and p21 functional interactions in glioma cells en route to apoptosis. <b>1997</b> , 89, 1036-44	108
1441	p21: structure and functions associated with cyclin-CDK binding. <b>1997</b> , 3, 125-34	44
1440	Proteolytic cleavage of the mdm2 oncoprotein during apoptosis. <b>1997</b> , 272, 22966-73	99
1439	Cyclin E-CDK2 is a regulator of p27Kip1. <b>1997</b> , 11, 1464-78	705
1438	Antioxidant-induced nuclear translocation of CCAAT/enhancer-binding protein beta. A critical role for protein kinase A-mediated phosphorylation of Ser299. <b>1997</b> , 272, 30356-61	107
1437	Apoptosis, neurotrophic factors and neurodegeneration. <b>1997</b> , 8, 223-65	38

1436	Redox state regulates binding of p53 to sequence-specific DNA, but not to non-specific or mismatched DNA. <b>1997</b> , 25, 1289-95	68
1435	Nuclear and non-nuclear targets of genotoxic agents in the induction of gene expression. Shared principles in yeast, rodents, man and plants. <b>1997</b> , 378, 1217-29	57
1434	Brca2 is required for embryonic cellular proliferation in the mouse. <b>1997</b> , 11, 1242-52	222
1433	Human p53 binds Holliday junctions strongly and facilitates their cleavage. <b>1997</b> , 272, 7532-9	115
1432	Characterization of the mitogen-activated protein kinase kinase 4 (MKK4)/c-Jun NH2-terminal kinase 1 and MKK3/p38 pathways regulated by MEK kinases 2 and 3. MEK kinase 3 activates MKK3 but does not cause activation of p38 kinase in vivo. <b>1997</b> , 272, 14489-96	93
1431	A novel, nerve growth factor-activated pathway involving nitric oxide, p53, and p21WAF1 regulates neuronal differentiation of PC12 cells. <b>1997</b> , 272, 24002-7	125
1430	Oocyte polarity and cell determination in early mammalian embryos. <b>1997</b> , 3, 863-905	188
1429	Interaction of p53 with the human Rad51 protein. <b>1997</b> , 25, 3868-74	179
1428	Human p53 restores DNA synthesis control in fission yeast. <b>1997</b> , 378, 1361-71	8
1427	P53. <b>1997</b> , 446-463	1
1426	Persistent DNA damage inhibits S-phase and G2 progression, and results in apoptosis. <b>1997</b> , 8, 1129-42	120
1425	Activation of p53-p21waf1 pathway in response to disruption of cell-matrix interactions. <b>1997</b> , 272, 29091-8	66
1424	Expression of wild-type p53 is required for efficient global genomic nucleotide excision repair in UV-irradiated human fibroblasts. <b>1997</b> , 272, 28073-80	259
1423	p53 Oncoprotein Expression and Gene Mutations in Some Keratoacanthomas. <b>1997</b> , 133, 189	13
1422	p53 regulates apoptosis in human retinoblastoma. <b>1997</b> , 115, 213-9	54
1421	Architectural accommodation in the complex of four p53 DNA binding domain peptides with the p21/waf1/cip1 DNA response element. <b>1997</b> , 272, 14830-41	59
1420	Extended Abstracts. <b>1997</b> , 25, 674-696	
1419	Drug Toxicity in Embryonic Development I. <b>1997</b> ,	1



1418	Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. <b>1997</b> , 17, 3850-7	370
1417	Activation of Raf kinase by phorbol ester does not correlate with enhanced phosphorylation or transactivation activity of tumor suppressor protein p53. <b>1997</b> , 10, 649-57	
1416	Control of cell cycle regulatory proteins and modulation of STAT1 proteins by IFN-gamma in human prostatic JCA-1 cells. <b>1997</b> , 10, 835-9	
1415	Acute leukemia. <b>1997</b> , 11, 657	
1414	Loss of heterozygosity on chromosome 17p13 (p53) and 13q14 (Rb1) in squamous cell carcinoma of head and neck. <b>1997</b> , 10, 1235-40	
1413	Altered P53 conformation. <b>1997</b> , 11, 1087-94	2
1412	Levels of p21(WAF1/CIP1) do not affect radiation-induced cell death in human breast epithelial cells. <b>1997</b> , 11, 1349-53	0
1411	Growth suppression induced by antitumor drug vitamin K-3 in human hepatoma HepG2 cells is accompanied by downregulation of proliferating cell nuclear antigen expression. <b>1997</b> , 10, 1015-9	
1410	p53 protein accumulation and genetic alterations in human giant cell tumors of bone (osteoclastomas). <b>1997</b> , 10, 1087-92	1
1409	Induction of cdk2 after gamma-ray irradiation is dependent on p53 status. <b>1997</b> , 10, 1257-60	
1408	Adenovirus-mediated p53 gene therapy in nasopharyngeal cancer. <b>1997</b> , 11, 221-226	8
1407	Correlation between reduced p21(WAF1/CIP1) expression and abnormal p53 expression in esophageal carcinomas. <b>1997</b> , 11, 703-8	2
1406	Molecular analysis of INK4 genes in breast carcinomas. <b>1997</b> , 11, 737-44	1
1405	Aberrant expression of p53 and retinoblastoma gene products in human esophageal squamous cell carcinoma. <b>1997</b> , 11, 1109-14	1
1404	Regulation of p53 by metal ions and by antioxidants: dithiocarbamate down-regulates p53 DNA-binding activity by increasing the intracellular level of copper. <b>1997</b> , 17, 5699-706	159
1403	Ubiquitination of p53 and p21 is differentially affected by ionizing and UV radiation. <b>1997</b> , 17, 355-63	299
1402	Gastric carcinoma: clinical, pathogenic, and molecular aspects. <b>1997</b> , 90, 735-49	15
1401	DNA binding specificity of proteins derived from alternatively spliced mouse p53 mRNAs. <b>1997</b> , 25, 1319-26	8

1400	Absence of p53 mutations in malignant mesotheliomas. <b>1997</b> , 16, 9-13	74
1399	Inhaled asbestos fibers induce p53 expression in the rat lung. <b>1997</b> , 16, 479-85	42
1398	Repression of p53-mediated transcription by MDM2: a dual mechanism. <b>1997</b> , 11, 1974-86	213
1397	Expression of p27Kip1 in osteoblast-like cells during differentiation with parathyroid hormone. <b>1997</b> , 138, 1995-2004	57
1396	The DNA repair endonuclease XPG binds to proliferating cell nuclear antigen (PCNA) and shares sequence elements with the PCNA-binding regions of FEN-1 and cyclin-dependent kinase inhibitor p21. <b>1997</b> , 272, 24522-9	183
1395	Differential interaction of the cyclin-dependent kinase (Cdk) inhibitor p27Kip1 with cyclin A-Cdk2 and cyclin D2-Cdk4. <b>1997</b> , 272, 25863-72	214
1394	The subcellular locations of p15(Ink4b) and p27(Kip1) coordinate their inhibitory interactions with cdk4 and cdk2. <b>1997</b> , 11, 492-503	258
1393	Identification of several human homologs of hamster DNA damage-inducible transcripts. Cloning and characterization of a novel UV-inducible cDNA that codes for a putative RNA-binding protein. <b>1997</b> , 272, 26720-6	77
1392	DNA bending is essential for the site-specific recognition of DNA response elements by the DNA binding domain of the tumor suppressor protein p53. <b>1997</b> , 272, 14842-9	79
1391	A benzo[a]pyrene-induced cell cycle checkpoint resulting in p53-independent G1 arrest in 3T3 fibroblasts. <b>1997</b> , 272, 2762-9	55
1390	Proteasome- and p53-dependent masking of signal transducer and activator of transcription (STAT) factors. <b>1997</b> , 272, 4659-62	33
1389	p53-dependent regulation of MDR1 gene expression causes selective resistance to chemotherapeutic agents. <b>1997</b> , 94, 11037-42	136
1388	Early growth response-1-dependent apoptosis is mediated by p53. <b>1997</b> , 272, 20131-8	138
1387	Induction of the cyclin-dependent kinase inhibitor p21(Sdi1/Cip1/Waf1) by nitric oxide-generating vasodilator in vascular smooth muscle cells. <b>1997</b> , 272, 10050-7	133
1386	1-(5-Isoquinolinesulfonyl)-2-methylpiperazine induces apoptosis in human neuroblastoma cells, SH-SY5Y, through a p53-dependent pathway. <b>1997</b> , 272, 4252-60	55
1385	Mitosis-specific negative regulation of epidermal growth factor receptor, triggered by a decrease in ligand binding and dimerization, can be overcome by overexpression of receptor. <b>1997</b> , 272, 18656-65	48
1384	Inhibition of CDK activity and PCNA-dependent DNA replication by p21 is blocked by interaction with the HPV-16 E7 oncoprotein. <b>1997</b> , 11, 2090-100	387
1383	p21CIP1-mediated inhibition of cell proliferation by overexpression of the gax homeodomain gene. <b>1997</b> , 11, 1674-89	143

1382	Cooperating oncogenes converge to regulate cyclin/cdk complexes. <b>1997</b> , 11, 663-77	184
1381	Activation of adenomatous polyposis coli (APC) gene expression by the DNA-alkylating agent N-methyl-N'-nitro-N-nitrosoguanidine requires p53. <b>1997</b> , 272, 30619-22	73
1380	Differential expression of proteins related to START checkpoint of the cell cycle in human stomach, lung, cervix and liver cancers. <b>1997</b> , 29, 123-128	
1379	Cell cycle checkpoint control. <b>1997</b> , 29, 1-11	2
1378	The mdm2 proto-oncogene. <b>1997</b> , 26, 227-38	46
1377	Virus-induced apoptosis. <b>1997</b> , 41, 295-336	50
1376	Identification of a novel transcriptional regulatory element common to the p53 and interferon regulatory factor 1 genes. <b>1997</b> , 272, 29801-9	10
1375	p53-dependent response in UV-induced transformation. <b>1997</b> , 18, 2319-25	2
1374	Purification and analysis of CIP/KIP proteins. <b>1997</b> , 283, 230-44	13
1373	Cellular response to DNA damage from a potent carcinogen involves stabilization of p53 without induction of p21(waf1/cip1). <b>1997</b> , 18, 2313-8	34
1372	Decrease in the frequency of X-ray-induced mutation by wild-type p53 protein in human osteosarcoma cells. <b>1997</b> , 18, 695-700	11
1371	Control of differentiation, transformation, and apoptosis in granulosa cells by oncogenes, oncoviruses, and tumor suppressor genes. <b>1997</b> , 18, 435-61	100
1370	Activities and response to DNA damage of latent and active sequence-specific DNA binding forms of mouse p53. <b>1997</b> , 94, 8982-7	19
1369	Wild-type p53 triggers a rapid senescence program in human tumor cells lacking functional p53. <b>1997</b> , 94, 9648-53	252
1368	p53CP, a putative p53 competing protein that specifically binds to the consensus p53 DNA binding sites: a third member of the p53 family?. <b>1997</b> , 94, 14753-8	49
1367	The ataxia-telangiectasia gene product, a constitutively expressed nuclear protein that is not up-regulated following genome damage. <b>1997</b> , 94, 1840-5	132
1366	Wip1, a novel human protein phosphatase that is induced in response to ionizing radiation in a p53-dependent manner. <b>1997</b> , 94, 6048-53	449
1365	The murine C'-terminally alternatively spliced form of p53 induces attenuated apoptosis in myeloid cells. <b>1997</b> , 17, 713-22	21

1364	Proteolysis by calpains: a possible contribution to degradation of p53. <b>1997</b> , 17, 2806-15	152
1363	Inhibition of DNA topoisomerase II alpha gene expression by the p53 tumor suppressor. <b>1997</b> , 17, 389-97	138
1362	Constitutive activation of gene expression by thyroid hormone receptor results from reversal of p53-mediated repression. <b>1997</b> , 17, 7195-207	28
1361	Molecular mechanisms of myogenic coactivation by p300: direct interaction with the activation domain of MyoD and with the MADS box of MEF2C. <b>1997</b> , 17, 1010-26	325
1360	Transforming growth factor beta stabilizes p15INK4B protein, increases p15INK4B-cdk4 complexes, and inhibits cyclin D1-cdk4 association in human mammary epithelial cells. <b>1997</b> , 17, 2458-67	168
1359	c-Rel arrests the proliferation of HeLa cells and affects critical regulators of the G1/S-phase transition. <b>1997</b> , 17, 6526-36	90
1358	p53 is phosphorylated by CDK7-cyclin H in a p36MAT1-dependent manner. <b>1997</b> , 17, 7220-9	150
1357	Induction of senescence-like phenotypes by forced expression of hic-5, which encodes a novel LIM motif protein, in immortalized human fibroblasts. <b>1997</b> , 17, 1224-35	91
1356	Complex formation between p53 and replication protein A inhibits the sequence-specific DNA binding of p53 and is regulated by single-stranded DNA. <b>1997</b> , 17, 2194-201	51
1355	Regulation of the expression of cyclin-dependent kinase inhibitor p21 by E2A and Id proteins. <b>1997</b> , 17, 5888-96	276
1354	The viral oncoprotein E1A blocks transforming growth factor beta-mediated induction of p21/WAF1/Cip1 and p15/INK4B. <b>1997</b> , 17, 2030-7	81
1353	Inactivation of the cyclin-dependent kinase Cdc28 abrogates cell cycle arrest induced by DNA damage and disassembly of mitotic spindles in <i>Saccharomyces cerevisiae</i> . <b>1997</b> , 17, 2723-34	45
1352	p53 transactivation and protein accumulation are independently regulated by UV light in different phases of the cell cycle. <b>1997</b> , 17, 3074-80	31
1351	Ectopic expression of cyclin D1 but not cyclin E induces anchorage-independent cell cycle progression. <b>1997</b> , 17, 5640-7	52
1350	The CDK7-cycH-p36 complex of transcription factor IIH phosphorylates p53, enhancing its sequence-specific DNA binding activity in vitro. <b>1997</b> , 17, 5923-34	136
1349	Transcriptional activation by p53 of the human type IV collagenase (gelatinase A or matrix metalloproteinase 2) promoter. <b>1997</b> , 17, 6330-8	240
1348	Transformed cells require continuous activity of RNA polymerase II to resist oncogene-induced apoptosis. <b>1997</b> , 17, 7306-16	79
1347	Thrombopoietin-induced differentiation of a human megakaryoblastic leukemia cell line, CMK, involves transcriptional activation of p21(WAF1/Cip1) by STAT5. <b>1997</b> , 17, 2933-43	181

1346	WAF1 retards S-phase progression primarily by inhibition of cyclin-dependent kinases. <b>1997</b> , 17, 4877-82	173
1345	A dominant-negative cyclin D1 mutant prevents nuclear import of cyclin-dependent kinase 4 (CDK4) and its phosphorylation by CDK-activating kinase. <b>1997</b> , 17, 7362-74	157
1344	Analysis of IFN-gamma-induced cell cycle arrest and cell death in hepatocytes. <b>1997</b> , 121, 677-83	72
1343	Raf-induced proliferation or cell cycle arrest is determined by the level of Raf activity with arrest mediated by p21Cip1. <b>1997</b> , 17, 5598-611	590
1342	Comparison of immunofluorometry and immunohistochemistry for the detection of p53 protein in lung cancer specimens. <b>1997</b> , 107, 308-16	6
1341	p21(Waf1/Cip1) and p53 protein expression in breast cancer. <b>1997</b> , 107, 684-91	77
1340	Das Wachstumssuppressorprotein p53, seine zellulären Partner und das Prostatakarzinom. <b>1997</b> , 28, 371-376	
1339	High-intensity Raf signal causes cell cycle arrest mediated by p21Cip1. <b>1997</b> , 17, 5588-97	424
1338	CCAAT/enhancer binding protein alpha regulates p21 protein and hepatocyte proliferation in newborn mice. <b>1997</b> , 17, 7353-61	214
1337	Role of p53 in apoptosis. <b>1997</b> , 41, 429-60	49
1336	Extension of the replicative life span of human diploid fibroblasts by inhibition of the p33ING1 candidate tumor suppressor. <b>1997</b> , 17, 2014-9	127
1335	Enhancement of DNA repair in human skin cells by thymidine dinucleotides: evidence for a p53-mediated mammalian SOS response. <b>1997</b> , 94, 12627-32	184
1334	Principles of Cell Cycle Control. <b>1997</b> , 819-842	
1333	Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. <b>1997</b> , 76, 884-9	88
1332	p21WAF1 mutations and human malignancies. <b>1997</b> , 26, 35-41	31
1331	Role of the Extracellular Matrix and Cytoskeleton in the Regulation of Cyclins, Cyclindependent Kinase Inhibitors, and Anchorage-Dependent Growth. <b>1997</b> , 24, 57-75	
1330	Inhibition of growth and induction of differentiation of metastatic melanoma cells in vitro by genistein: chemosensitivity is regulated by cellular p53. <b>1997</b> , 75, 1559-66	55
1329	Loss of p21WAF1/CIP1 expression correlates with disease progression in gastric carcinoma. <b>1997</b> , 75, 1617-20	51

1328	Overexpression of p53 mRNA in colorectal cancer and its relationship to p53 gene mutation. <b>1997</b> , 75, 528-36	28
1327	Tumor suppressor genes and human cancer. <b>1997</b> , 36, 45-135	24
1326	P53 expression in altered limbal basal cells of pingueculae, pterygia, and limbal tumors. <b>1997</b> , 16, 1179-92	125
1325	G1 cyclins and control of the cell division cycle in normal and transformed cells. <b>1997</b> , 15, 143-52	33
1324	The initiation of simian virus 40 DNA replication in vitro. <b>1997</b> , 32, 503-68	124
1323	The apoptotic and transcriptional transactivation activities of p53 can be dissociated. <b>1997</b> , 75, 351-358	29
1322	Recent insights into the functions of the retinoblastoma susceptibility gene product. <b>1997</b> , 15, 243-54	39
1321	p53 and ATM: cell cycle, cell death, and cancer. <b>1997</b> , 71, 1-25	222
1320	The human papillomavirus E7 oncoprotein can uncouple cellular differentiation and proliferation in human keratinocytes by abrogating p21Cip1-mediated inhibition of cdk2. <b>1997</b> , 11, 2101-11	353
1319	Reference List. <b>1997</b> , 7, S363-S388	
1318	Rb and p53 Gene Deletions in Lung Adenocarcinomas from Irradiated and Control Mice. <b>1997</b> , 148, 81	13
1317	Spectra of X-Ray-Induced and Spontaneous Intragenic HPRT Mutations in Closely Related Human Cells Differentially Expressing the p53 Tumor Suppressor Gene. <b>1997</b> , 147, 138	7
1316	Differential Activation of p53 Targets in Cells Treated with Ultraviolet Radiation That Undergo Both Apoptosis and Growth Arrest. <b>1997</b> , 148, 115	39
1315	Abundance of alpha 1(I) and alpha 1(III) procollagen and p21 mRNAs in fibroblasts cultured from fetal and postnatal dermis. <b>1997</b> , 97, 131-42	13
1314	Cytogenetics and molecular genetics in multiple myeloma. <b>1997</b> , 11, 1-25	39
1313	Molecular Epidemiology in Environmental Health: The Potential of Tumor Suppressor Gene p53 as a Biomarker. <b>1997</b> , 105, 155	4
1312	Molecular Analysis of the INK4 Family of Genes in Prostate Carcinomas. <b>1997</b> , 157, 1995-1999	23
1311	P53 synthesis and phosphorylation in the aging diet-restricted rat following retinoic acid administration. <b>1997</b> , 97, 15-34	8

1310	Expression and sequence analysis of the p21(WAF1/CIP1) gene in renal cancers. <b>1997</b> , 49, 481-6	10
1309	Granule cell apoptosis and protein expression in hippocampal dentate gyrus after forebrain ischemia in the rat. <b>1997</b> , 150, 93-102	50
1308	Transforming growth factor-beta3 protection of epithelial cells from cycle-selective chemotherapy in vitro. <b>1997</b> , 53, 1149-59	24
1307	Analysis of proliferation markers and p53 expression in gliomas of astrocytic origin: relationships and prognostic value. <b>1997</b> , 86, 121-30	83
1306	ATM-dependent telomere loss in aging human diploid fibroblasts and DNA damage lead to the post-translational activation of p53 protein involving poly(ADP-ribose) polymerase. <b>1997</b> , 16, 6018-33	311
1305	Immunohistochemical detection of p21WAF1/CIP1 and p53 proteins in formalin-fixed paraffin-embedded tissue sections of squamous cell carcinoma of the skin. <b>1997</b> , 14, 233-9	8
1304	Gene regulation by reactive oxygen species. <b>1997</b> , 35, 123-48	71
1303	Oxidative damage to DNA: formation, measurement, and biological significance. <b>1997</b> , 131, 1-87	103
1302	Cytotoxic Effects of Recombinant Adenovirus p53 and Cell Cycle Regulator Genes (p21 sup WAF1/CIP1 and p16 sup CDKN4) in Human Prostate Cancers. <b>1997</b> , 158, 636-641	65
1301	Subtractive cloning: past, present, and future. <b>1997</b> , 66, 751-83	121
1300	Inactivation of cyclin-dependent kinase inhibitor genes and development of human acute leukemias. <b>1997</b> , 25, 23-35	12
1299	A general strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites. <b>1997</b> , 275, 657-61	357
1298	Tying it all together: epigenetics, genetics, cell cycle, and cancer. <b>1997</b> , 277, 1948-9	162
1297	Human DNA-(cytosine-5) methyltransferase-PCNA complex as a target for p21WAF1. <b>1997</b> , 277, 1996-2000	748
1296	The role of NAD(P)H:quinone oxidoreductase in quinone-mediated p21 induction in human colon carcinoma cells. <b>1997</b> , 346, 241-51	14
1295	Characterisation of DNA binding and transcriptional regulatory function of an endogenous mutant p53 in MDA-468 human breast cancer cells. <b>1997</b> , 232, 14-9	9
1294	Oligomerization is not essential for growth suppression by p53 in p53-deficient osteosarcoma Saos-2 cells. <b>1997</b> , 232, 54-60	18
1293	Abrogation of G1 arrest after DNA damage is associated with constitutive overexpression of Mdm2, Cdk4, and Irf1 mRNAs in the BALB/c 3T3 A31 variant 1-1 clone. <b>1997</b> , 233, 216-20	1

1292	Functional expression of human p21(WAF1/CIP1) gene in rat glioma cells suppresses tumor growth in vivo and induces radiosensitivity. <b>1997</b> , 233, 329-35	43
1291	Changes in BRCA2 expression during progression of the cell cycle. <b>1997</b> , 234, 247-51	23
1290	Rat TAFII31 gene is induced upon programmed cell death in differentiated PC12 cells deprived of NGF. <b>1997</b> , 234, 230-4	8
1289	Activation of the p21(Waf1/Cip1) promoter by the ets oncogene family transcription factor E1AF. <b>1997</b> , 236, 79-82	36
1288	Loss of cell adhesion to substratum up-regulates p21Cip1/WAF1 expression in BALB/c 3T3 fibroblasts. <b>1997</b> , 238, 169-72	10
1287	Regulation of cell cycle-related genes in rat hepatocytes by transforming growth factor beta1. <b>1997</b> , 238, 539-43	27
1286	Cell cycle-dependent phosphorylation of p27 cyclin-dependent kinase (Cdk) inhibitor by cyclin E/Cdk2. <b>1997</b> , 240, 386-90	60
1285	Histone deacetylase inhibitor activates the WAF1/Cip1 gene promoter through the Sp1 sites. <b>1997</b> , 241, 142-50	272
1284	Early ultraviolet B-induced G1 arrest and suppression of the malignant phenotype by wild-type p53 in human squamous cell carcinoma cells. <b>1997</b> , 233, 135-44	28
1283	Retinoic acid inhibition of cell cycle progression in MCF-7 human breast cancer cells. <b>1997</b> , 234, 293-9	106
1282	p53 Induces myocyte apoptosis via the activation of the renin-angiotensin system. <b>1997</b> , 234, 57-65	122
1281	Inhibition of mouse thymidylate synthase promoter activity by the wild-type p53 tumor suppressor protein. <b>1997</b> , 234, 270-6	42
1280	Involvement of p53 and WAF1/CIP1 in gamma-irradiation-induced apoptosis of retinoblastoma cells. <b>1997</b> , 236, 51-6	26
1279	Bifunctional effects of a protein kinase inhibitor (H-7) on heat-induced p53-dependent WAF1 accumulation. <b>1997</b> , 237, 186-91	8
1278	Chromosome localization and structure of the murine cyclin G1 gene promoter sequence. <b>1997</b> , 45, 297-303	13
1277	In vitro structure-function analysis of the beta-strand 326-333 of human p53. <b>1997</b> , 273, 873-81	30
1276	Gene expression profiles in normal and cancer cells. <b>1997</b> , 276, 1268-72	1217
1275	The molecular genetics of astrocytomas: current understanding and future applications. <b>1997</b> , 4, 114-21	3



1274	Induction of cell cycle arrest and B cell terminal differentiation by CDK inhibitor p18(INK4c) and IL-6. <b>1997</b> , 6, 47-56		137
1273	14-3-3sigma is a p53-regulated inhibitor of G2/M progression. <b>1997</b> , 1, 3-11		1062
1272	Differential roles of p300 and PCAF acetyltransferases in muscle differentiation. <b>1997</b> , 1, 35-45		373
1271	Oncogenes and antioncogenes in the development of HPV associated tumors. <b>1997</b> , 15, 207-15		5
1270	A role for p53 in DNA end rejoining by human cell extracts. <b>1997</b> , 385, 21-9		31
1269	Regulation of CDK/cyclin complexes during the cell cycle. <b>1997</b> , 29, 559-73		153
1268	Murine hepatic p53, RB, and CDK inhibitory protein expression following acute 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) exposure. <b>1997</b> , 34, 1557-68		12
1267	A study of p53 protein, proliferating cell nuclear antigen, and p21 in Hodgkin's disease at presentation and relapse. <b>1997</b> , 28, 549-55		15
1266	The role of p53, p21WAF1/C1PI, and bcl-2 in radioresistant colorectal carcinoma. <b>1997</b> , 28, 1189-95		38
1265	Lonely no more: p53 finds its kin in a tumor suppressor haven. <i>Cell</i> , <b>1997</b> , 90, 829-32	56.2	75
1264	Tumor suppression at the mouse INK4a locus mediated by the alternative reading frame product p19ARF. <i>Cell</i> , <b>1997</b> , 91, 649-59	56.2	1400
1263	Activation of p53 sequence-specific DNA binding by acetylation of the p53 C-terminal domain. <i>Cell</i> , <b>1997</b> , 90, 595-606	56.2	2184
1262	Monoallelically expressed gene related to p53 at 1p36, a region frequently deleted in neuroblastoma and other human cancers. <i>Cell</i> , <b>1997</b> , 90, 809-19	56.2	1442
1261	Characterization of the yeast transcriptome. <i>Cell</i> , <b>1997</b> , 88, 243-51	56.2	924
1260	p53, the cellular gatekeeper for growth and division. <i>Cell</i> , <b>1997</b> , 88, 323-31	56.2	6389
1259	Mutation analysis of p53 gene in childhood malignant solid tumors. <b>1997</b> , 32, 1175-80		68
1258	The induction of apoptosis in proliferating human fibroblasts by oxygen radicals is associated with a p53- and p21WAF1CIP1 induction. <b>1997</b> , 404, 6-10		50
1257	Regulation of the DNA binding of p53 by its interaction with protein kinase CK2. <b>1997</b> , 408, 99-104		28

1256	Oncoprotein MDM2 is a ubiquitin ligase E3 for tumor suppressor p53. <b>1997</b> , 420, 25-7	1465
1255	Similarity of apoptosis induction by 2-chlorodeoxyadenosine and cisplatin in human mononuclear blood cells. <b>1997</b> , 76, 1448-54	16
1254	Expression of Bax, Bcl-2, Waf-1, and PCNA gene products in an immortalized human endothelial cell line undergoing p53-mediated apoptosis. <b>1997</b> , 2, 442-54	5
1253	Cloning and chromosome mapping of the feline genes p21WAF1 and p27Kip1. <b>1997</b> , 198, 141-7	4
1252	Dynamic interrelationships between DNA replication, methylation, and repair. <b>1997</b> , 61, 1220-4	20
1251	Lack of mutation in the WAF1/CIP1 gene during bovine leukemia virus-induced leukemogenesis. <b>1997</b> , 59, 311-22	
1250	Type of inducing signal regulates transactivation by p53. <b>1997</b> , 1358, 314-20	2
1249	17 beta-Estradiol-mediated growth inhibition of MDA-MB-468 cells stably transfected with the estrogen receptor: cell cycle effects. <b>1997</b> , 133, 49-62	33
1248	Decreased expression and rare somatic mutation of the CIP1/WAF1 gene in human hepatocellular carcinoma. <b>1997</b> , 111, 191-7	29
1247	Induction of cyclin-dependent kinase inhibitor, p21WAF1, by treatment with 3,4-dihydro-6-[4-(3,4)-dimethoxybenzoyl]-1-piperazinyl]-2(1H)-quinoline (vesnarinone) in a human salivary cancer cell line with mutant p53 gene. <b>1997</b> , 112, 181-9	20
1246	Introduction of p21(Waf1/Cip1) gene into a carcinoma cell line of the uterine cervix with inactivated p53. <b>1997</b> , 116, 233-9	7
1245	Antisense-mediated regulation of Annexin VII gene expression during the transition from growth to differentiation in Dictyostelium discoideum. <b>1997</b> , 189, 49-56	22
1244	Cloning and characterization of rat p27Kip1, a cyclin-dependent kinase inhibitor. <b>1997</b> , 191, 211-8	9
1243	Molecular advances in pancreatic cancer. <b>1997</b> , 58, 550-6	32
1242	The p53 tumor suppressor targets a novel regulator of G protein signaling. <b>1997</b> , 94, 7868-72	78
1241	Role of surveillance endoscopy, biopsy and biomarkers in early detection of Barrett's adenocarcinoma. <b>1997</b> , 10, 165-71	7
1240	Disruption of the MyoD/p21 Pathway in Rhabdomyosarcoma. <b>1997</b> , 1, 135-41	8
1239	A proline-rich motif in p53 is required for transactivation-independent growth arrest as induced by Gas1. <b>1997</b> , 94, 4675-80	82

1238	Contributions of the Molecular Biologist in Gastrointestinal Cancer and Precancer Screening: Current Possibilities and Future Prospects. <b>1997</b> , 7, 147-164	1
1237	Differential Regulation of the p21/WAF-1 and mdm2 Genes after High-Dose UV Irradiation: p53-Dependent and p53-Independent Regulation of the mdm2 Gene. <b>1997</b> , 3, 441-451	136
1236	Transcription Abnormalities Potentiate Apoptosis of Normal Human Fibroblasts. <b>1997</b> , 3, 852-863	47
1235	Molecular Interactions of Aging and Cancer. <b>1997</b> , 13, 69-77	4
1234	The influence of the proliferating cell nuclear antigen-interacting domain of p21(CIP1) on DNA synthesis catalyzed by the human and <i>Saccharomyces cerevisiae</i> polymerase delta holoenzymes. <b>1997</b> , 272, 2373-81	47
1233	Cell cycle control in pediatric neuro-oncology. <b>1997</b> , 26, 226-35	1
1232	Expression of p24, a novel p21Waf1/Cip1/Sdi1-related protein, correlates with measurement of the finite proliferative potential of rodent embryo fibroblasts. <b>1997</b> , 94, 151-6	20
1231	Molecular epidemiology in environmental health: the potential of tumor suppressor gene p53 as a biomarker. <b>1997</b> , 105 Suppl 1, 155-63	19
1230	Loss of p21 increases sensitivity to ionizing radiation and delays the onset of lymphoma in atm-deficient mice. <b>1997</b> , 94, 14590-5	145
1229	p53 and WAF1 are induced and Rb protein is hypophosphorylated during cell growth inhibition by the thymidylate synthase inhibitor ZD1694 (Tomudex). <b>1997</b> , 51, 630-6	13
1228	Molecular and genetic advances in gastrointestinal cancer: state of the art. <b>1997</b> , 15, 275-301	3
1227	Apoptosis in tumorigenesis and cancer therapy. <b>1997</b> , 2, d353-79	41
1226	Estrogenic regulation of a novel 34 kDa protein associated with cyclin B1 in MCF-7 breast cancer cells. <b>1997</b> , 4, 15-21	2
1225	Nerve growth factor induces transcription of the p21 WAF1/CIP1 and cyclin D1 genes in PC12 cells by activating the Sp1 transcription factor. <b>1997</b> , 17, 6122-32	144
1224	rhoB encoding a UV-inducible Ras-related small GTP-binding protein is regulated by GTPases of the Rho family and independent of JNK, ERK, and p38 MAP kinase. <b>1997</b> , 272, 30637-44	71
1223	Conformation-dependent phosphorylation of p53. <b>1997</b> , 94, 1686-91	113
1222	Nuclear Signalling of Melatonin. <b>1997</b> , 23, 25-35	10
1221	Topographical association between the cyclin-dependent kinases inhibitor P21, p53 accumulation, and cellular proliferation in human atherosclerotic tissue. <b>1997</b> , 17, 2218-24	81

1220	p53 and MDM2 in the Development and Progression of Bladder Cancer. <b>1997</b> , 32, 487-493	43
1219	Deletions and Loss of Expression of P16INK4a and P21Waf1 Genes Are Associated With Aggressive Variants of Mantle Cell Lymphomas. <b>1997</b> , 89, 272-280	204
1218	p53 Abnormalities in B-Cell Prolymphocytic Leukemia. <b>1997</b> , 89, 2015-2023	101
1217	Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH) <sub>2</sub> Vitamin D <sub>3</sub> , and Granulocyte-Macrophage Colony-Stimulating Factor. <b>1997</b> , 90, 4578-4587	69
1216	Polyploidization and Functional Maturation Are Two Distinct Processes During Megakaryocytic Differentiation: Involvement of Cyclin-Dependent Kinase Inhibitor p21 in Polyploidization. <b>1997</b> , 89, 3980-3990 <sup>69</sup>	69
1215	Retinoid Induced Apoptosis in Leukemia Cells Through a Retinoic Acid Nuclear Receptor-Independent Pathway. <b>1997</b> , 89, 4470-4479	126
1214	Apoptosis of Late-Stage Erythroblasts in Megaloblastic Anemia: Association With DNA Damage and Macrocyte Production. <b>1997</b> , 89, 4617-4623	74
1213	Human Non-Hodgkin's Lymphomas Overexpress a Wild-Type Form of p53 Which Is a Functional Transcriptional Activator of the Cyclin-Dependent Kinase Inhibitor p21. <b>1997</b> , 89, 2523-2528	28
1212	Thrombopoietin Upregulates the Promoter Conformation of p53 in a Proliferation-Independent Manner Coincident With a Decreased Expression of Bax: Potential Mechanisms for Survival Enhancing Effects. <b>1997</b> , 90, 4394-4402	26
1211	Upregulation of the Elongation Factor-1 Gene by p53 in Association With Death of an Erythroleukemic Cell Line. <b>1997</b> , 90, 1373-1378	49
1210	Mechanisms of induction of skin cancer by UV radiation. <b>1997</b> , 2, d538-51	110
1209	PCNA, Ki-67, p53, bcl-2 and prognosis in intraoral squamous cell carcinoma of the head and neck. <b>1997</b> , 14, 101-10	22
1208	p53-independent apoptosis induced by paclitaxel through an indirect mechanism. <b>1997</b> , 94, 9679-83	139
1207	Sequence of Events in Lung Carcinogenesis. <b>1997</b> , 86-102	
1206	Current Concepts in Neuro-Oncology: The Cell Cycle-A Review. <b>1997</b> ,	
1205	Cellular localization and chromosome mapping of a novel candidate tumor suppressor gene (ING1). <b>1997</b> , 76, 176-8	52
1204	p21 (WAF1/Cip1/Sdi1/Pic1) mRNA is expressed in neuroblastoma cell lines but not in Ewing's sarcoma and primitive neuroectodermal tumor cell lines. <b>1997</b> , 39, 590-4	3
1203	Overexpression of cyclin-dependent kinase-activating CDC25B phosphatase in human gastric carcinomas. <b>1997</b> , 88, 947-52	71

1202	Expressions of cell cycle regulators in human colorectal cancer cell lines. <b>1997</b> , 88, 855-60	34
1201	Regulation of Cell-Cycle Progression and Cell Death in Breast Cancer. <b>1997</b> , 3, 15-25	6
1200	Wild-type p53 gene transfer: a novel therapeutic strategy for neointimal hyperplasia after arterial injury. <b>1997</b> , 811, 395-400	10
1199	Adenovirus-mediated transfer of cyclin-dependent kinase inhibitor-p21 suppresses neointimal formation in the balloon-injured rat carotid arteries in vivo. <b>1997</b> , 811, 401-11	27
1198	Retinoic acid modulates the anti-proliferative effect of 1,25-dihydroxyvitamin D3 in cultured human epidermal keratinocytes. <b>1997</b> , 109, 46-54	45
1197	Potential molecular targets for manipulating the radiation response. <b>1997</b> , 37, 639-53	96
1196	Transfection of p53-knockout mouse fibroblasts with wild-type p53 increases the thermosensitivity and stimulates apoptosis induced by heat stress. <b>1997</b> , 38, 1089-95	27
1195	Apoptosis in the rat mammary gland and ventral prostate: detection of cell death-associated genes using a coincident-expression cloning approach. <b>1997</b> , 4, 114-24	18
1194	Mutation of CDKN2 is infrequently detected in myelodysplastic syndrome. <b>1997</b> , 11, 1391-2	2
1193	p21(WAF1/CIP1) response to genotoxic agents in wild-type TP53 expressing breast primary tumours. <b>1997</b> , 14, 45-52	28
1192	Further characterisation of the p53 responsive element--identification of new candidate genes for trans-activation by p53. <b>1997</b> , 14, 85-94	130
1191	PACT: cloning and characterization of a cellular p53 binding protein that interacts with Rb. <b>1997</b> , 14, 145-55	58
1190	Induction of Cip/Kip and Ink4 cyclin dependent kinase inhibitors by interferon-alpha in hematopoietic cell lines. <b>1997</b> , 14, 415-23	100
1189	Activation of p53 transcriptional activity by 1,10-phenanthroline, a metal chelator and redox sensitive compound. <b>1997</b> , 14, 385-93	67
1188	Induction of apoptosis in human lung cancer cells after wild-type p53 activation by methoxyestradiol. <b>1997</b> , 14, 379-84	120
1187	Cell cycle arrest defect in Li-Fraumeni Syndrome: a mechanism of cancer predisposition?. <b>1997</b> , 14, 277-82	33
1186	Inhibition of the growth of WI-38 fibroblasts by benzyloxycarbonyl-Leu-Leu-Tyr diazomethyl ketone: evidence that cleavage of p53 by a calpain-like protease is necessary for G1 to S-phase transition. <b>1997</b> , 14, 255-63	70
1185	PCNA: structure, functions and interactions. <b>1997</b> , 14, 629-40	689

1184	p21(Waf1/Cip1) protects against p53-mediated apoptosis of human melanoma cells. <b>1997</b> , 14, 929-35	279
1183	Induction of BCL2 family member MCL1 as an early response to DNA damage. <b>1997</b> , 14, 1031-9	74
1182	The tumor suppressor p53 is subject to both nuclear import and export, and both are fast, energy-dependent and lectin-inhibited. <b>1997</b> , 14, 1407-17	79
1181	Differentiation induced by RB expression and apoptosis induced by p53 expression in an osteosarcoma cell line. <b>1997</b> , 14, 1389-96	34
1180	p53 induced by ionizing radiation mediates DNA end-jointing activity, but not apoptosis of thyroid cells. <b>1997</b> , 14, 1511-9	67
1179	Failure of HPV E6 to rapidly degrade p53 in human HeLa x PNET cell hybrids. <b>1997</b> , 14, 1669-78	10
1178	Inhibition of p53-mediated transactivation and cell cycle arrest by E1A through its p300/CBP-interacting region. <b>1997</b> , 14, 1047-57	155
1177	Role of p21Waf1/Cip1/Sdi1 in cell death and DNA repair as studied using a tetracycline-inducible system in p53-deficient cells. <b>1997</b> , 14, 1875-82	105
1176	Tolerance of high levels of wild-type p53 in transformed epithelial cells dependent on auto-regulation by mdm-2. <b>1997</b> , 14, 1859-68	67
1175	Polyomavirus large T antigen overcomes p53 dependent growth arrest. <b>1997</b> , 14, 1923-31	26
1174	Vascular permeability factor/vascular endothelial growth factor (VPF/VEGF) delays and induces escape from senescence in human dermal microvascular endothelial cells. <b>1997</b> , 14, 2025-32	118
1173	Dissociation between cell cycle arrest and apoptosis can occur in Li-Fraumeni cells heterozygous for p53 gene mutations. <b>1997</b> , 14, 2137-47	46
1172	Cells lacking CIP1/WAF1 genes exhibit preferential sensitivity to cisplatin and nitrogen mustard. <b>1997</b> , 14, 2127-36	150
1171	The role of p27Kip1 in gamma interferon-mediated growth arrest of mammary epithelial cells and related defects in mammary carcinoma cells. <b>1997</b> , 14, 2111-22	74
1170	A recombinant adenovirus expressing p27Kip1 induces cell cycle arrest and loss of cyclin-Cdk activity in human breast cancer cells. <b>1997</b> , 14, 2283-9	180
1169	Homologous regions of Fen1 and p21Cip1 compete for binding to the same site on PCNA: a potential mechanism to co-ordinate DNA replication and repair. <b>1997</b> , 14, 2313-21	140
1168	HPV-16 oncogenes E6 and E7 are mutagenic in normal human oral keratinocytes. <b>1997</b> , 14, 2347-53	38
1167	Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. <b>1997</b> , 14, 2533-42	87

1166	Identification of a p130 domain mediating interactions with cyclin A/cdk 2 and cyclin E/cdk 2 complexes. <b>1997</b> , 14, 2395-406	56
1165	Comparison of VEGF, VEGF-B, VEGF-C and Ang-1 mRNA regulation by serum, growth factors, oncoproteins and hypoxia. <b>1997</b> , 14, 2475-83	382
1164	SAGE transcript profiles for p53-dependent growth regulation. <b>1997</b> , 15, 1079-85	171
1163	Apparent protection from instability of repeat sequences in cancer-related genes in replication error positive gastrointestinal cancers. <b>1997</b> , 14, 2613-8	15
1162	Regulation of DNA binding and transactivation in p53 by nuclear localization and phosphorylation. <b>1997</b> , 14, 2511-20	29
1161	The p53 activation and apoptosis induced by DNA damage are reversibly inhibited by salicylate. <b>1997</b> , 14, 2503-10	44
1160	K-ras modulates the cell cycle via both positive and negative regulatory pathways. <b>1997</b> , 14, 2595-607	61
1159	The carboxy terminus of p53 mimics the polylysine effect of protein kinase CK2-catalyzed MDM2 phosphorylation. <b>1997</b> , 14, 2683-8	67
1158	Radiation-induced apoptosis is not enhanced by expression of either p53 or BAX in SW626 ovarian cancer cells. <b>1997</b> , 14, 2753-8	20
1157	Resistance to p53-mediated growth arrest and apoptosis in Hep 3B hepatoma cells. <b>1997</b> , 15, 63-70	45
1156	In vivo evidence for binding of p53 to consensus binding sites in the p21 and GADD45 genes in response to ionizing radiation. <b>1997</b> , 15, 87-99	77
1155	p53-mediated accumulation of hypophosphorylated pRb after the G1 restriction point fails to halt cell cycle progression. <b>1997</b> , 15, 337-45	26
1154	Heat shock induces transient p53-dependent cell cycle arrest at G1/S. <b>1997</b> , 15, 561-8	86
1153	Unmasking by soluble IL-6 receptor of IL-6 effect on metastatic melanoma: growth inhibition and differentiation of B16-F10.9 tumor cells. <b>1997</b> , 15, 569-77	21
1152	P53 associates with trk tyrosine kinase. <b>1997</b> , 15, 245-56	29
1151	Oncogenes belonging to the CSF-1 transduction pathway direct p53 tumor suppressor effects to monocytic differentiation in 32D cells. <b>1997</b> , 15, 607-11	5
1150	Induction of p27Kip1 degradation and anchorage independence by Ras through the MAP kinase signaling pathway. <b>1997</b> , 15, 629-37	169
1149	Loss of p21CIP1/WAF1 does not recapitulate accelerated malignant conversion caused by p53 loss in experimental skin carcinogenesis. <b>1997</b> , 15, 685-90	18

1148	Regulation of tumor suppressor proteins, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. <b>1997</b> , 15, 991-5	59
1147	The polyproline region of p53 is required to activate apoptosis but not growth arrest. <b>1997</b> , 15, 887-98	248
1146	Identification of an additional p53-responsive site in the human epidermal growth factor receptor gene promotor. <b>1997</b> , 15, 1095-101	40
1145	Ethanol upregulates the expression of p21 WAF1/CIP1 and prolongs G1 transition via a p53-independent pathway in human epithelial cells. <b>1997</b> , 15, 1143-9	25
1144	Resistance to radiation-induced apoptosis in Bcl-2-expressing cells is reversed by depleting cellular thiols. <b>1997</b> , 15, 1461-70	200
1143	Cytostatic effect of TNFalpha on cancer cells is independent of p21WAF1. <b>1997</b> , 15, 1605-9	11
1142	The p53 targets mdm2 and Fas are not required as mediators of apoptosis in vivo. <b>1997</b> , 15, 1527-34	61
1141	Involvement of p21(WAF1/Cip1), CDK4 and Rb in activin A mediated signaling leading to hepatoma cell growth inhibition. <b>1997</b> , 15, 1705-11	67
1140	p53 expression overcomes p21WAF1/CIP1-mediated G1 arrest and induces apoptosis in human cancer cells. <b>1997</b> , 15, 1903-9	74
1139	Retinoic acid and the cyclin dependent kinase inhibitors synergistically alter proliferation and morphology of U343 astrocytoma cells. <b>1997</b> , 15, 2037-48	57
1138	p53-induced apoptosis in the human T-ALL cell line CCRF-CEM. <b>1997</b> , 15, 2429-37	33
1137	A fluorescent p53GFP fusion protein facilitates its detection in mammalian cells while retaining the properties of wild-type p53. <b>1997</b> , 15, 2241-7	16
1136	DNA-conformation is an important determinant of sequence-specific DNA binding by tumor suppressor p53. <b>1997</b> , 15, 857-69	59
1135	Cell cycle re-entry following chemically-induced cell cycle synchronization leads to elevated p53 and p21 protein levels. <b>1997</b> , 15, 2749-53	30
1134	Involvement of p21 in mitotic exit after paclitaxel treatment in MCF-7 breast adenocarcinoma cell line. <b>1997</b> , 15, 2867-75	82
1133	Identification of RB18A, a 205 kDa new p53 regulatory protein which shares antigenic and functional properties with p53. <b>1997</b> , 15, 3013-24	46
1132	p53 in polyoma virus transformed REF52 cells. <b>1997</b> , 15, 3113-9	21
1131	Overexpression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in human cutaneous malignant melanoma. <b>1997</b> , 24, 265-71	43



1130	Attenuation of p53 expression and Bax down-regulation during phorbol ester mediated inhibition of apoptosis. <b>1997</b> , 121, 625-34	21
1129	AP2 inhibits cancer cell growth and activates p21WAF1/CIP1 expression. <b>1997</b> , 15, 78-82	265
1128	Partial rescue of Brca1 (5-6) early embryonic lethality by p53 or p21 null mutation. <b>1997</b> , 16, 298-302	219
1127	Deletion of p21 cannot substitute for p53 loss in rescue of mdm2 null lethality. <b>1997</b> , 16, 336-7	15
1126	On the TRAIL from p53 to apoptosis?. <b>1997</b> , 17, 130-1	43
1125	KILLER/DR5 is a DNA damage-inducible p53-regulated death receptor gene. <b>1997</b> , 17, 141-3	927
1124	Atm selectively regulates distinct p53-dependent cell-cycle checkpoint and apoptotic pathways. <b>1997</b> , 17, 453-6	174
1123	Double indemnity: p53, BRCA and cancer. p53 mutation partially rescues developmental arrest in Brca1 and Brca2 null mice, suggesting a role for familial breast cancer genes in DNA damage repair. <b>1997</b> , 3, 721-2	94
1122	Cell-cycle arrest versus cell death in cancer therapy. <b>1997</b> , 3, 1034-6	317
1121	Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. <b>1997</b> , 3, 1233-41	296
1120	Arrest of the cell cycle by the tumour-suppressor BRCA1 requires the CDK-inhibitor p21WAF1/CiP1. <b>1997</b> , 389, 187-90	473
1119	p73 is a simian [correction of human] p53-related protein that can induce apoptosis. <b>1997</b> , 389, 191-4	844
1118	A model for p53-induced apoptosis. <b>1997</b> , 389, 300-5	2181
1117	Synergistic activation of transcription by CBP and p53. <b>1997</b> , 387, 819-23	541
1116	Binding and modulation of p53 by p300/CBP coactivators. <b>1997</b> , 387, 823-7	616
1115	K-ras and p53 mutations are an independent unfavourable prognostic indicator in patients with non-small-cell lung cancer. <b>1997</b> , 75, 1125-30	117
1114	Spatial association of apoptosis-related gene expression and cellular death in clinical neuroblastoma. <b>1997</b> , 75, 1185-94	38
1113	Induction of p16 during immortalization by HPV 16 and 18 and not during malignant transformation. <b>1997</b> , 75, 1410-6	96

1112	p53 exon 5 mutations as a prognostic indicator of shortened survival in non-small-cell lung cancer. <b>1997, 76, 44-51</b>	47
1111	Nuclear accumulation of p53 correlates significantly with clinical features and inversely with the expression of the cyclin-dependent kinase inhibitor p21(WAF1/CIP1) in pancreatic cancer. <b>1997, 76, 299-305</b>	38
1110	Absence of p21 expression is associated with abnormal p53 in human breast carcinomas. <b>1997, 76, 480-5</b>	32
1109	Up-regulation of p21WAF1 expression in myeloid cells is activated by the protein kinase C pathway. <b>1997, 76, 1554-7</b>	11
1108	Cell-cycle control and renal disease. <b>1997, 52, 294-308</b>	76
1107	Cyclin kinase inhibitors are increased during experimental membranous nephropathy: potential role in limiting glomerular epithelial cell proliferation in vivo. <b>1997, 52, 404-13</b>	97
1106	Cyclin-dependent kinase inhibitors: the age of crystals. <b>1997, 1332, M39-42</b>	5
1105	Involvement of p53 in cell differentiation and development. <b>1997, 1333, F1-27</b>	72
1104	The role of the bcl-2/ced-9 gene family in cancer and general implications of defects in cell death control for tumourigenesis and resistance to chemotherapy. <b>1997, 1333, F151-78</b>	62
1103	Oncoprotein signalling and mitosis. <b>1997, 9, 249-55</b>	46
1102	Modifications of p53 protein and accumulation of p21 and gadd45 mRNA in TGF-beta 1 growth inhibited cells. <b>1997, 9, 291-8</b>	25
1101	Novel candidate biomarkers for dietary chemoprevention of colon cancer. <b>1997, 13, 918-20</b>	
1100	Cell-cycle arrest and inhibition of Cdk4 activity by small peptides based on the carboxy-terminal domain of p21WAF1. <b>1997, 7, 71-80</b>	168
1099	Disruption of mouse ERCC1 results in a novel repair syndrome with growth failure, nuclear abnormalities and senescence. <b>1997, 7, 427-39</b>	287
1098	Regulation of apoptosis resistance and ontogeny of age-dependent diseases. <b>1997, 32, 471-84</b>	50
1097	p53 as a target for anti-cancer immunotherapy. <b>1997, 3, 160-7</b>	26
1096	The Li-Fraumeni syndrome: an inherited susceptibility to cancer. <b>1997, 3, 390-5</b>	66
1095	Redox-mediated regulation of p21(waf1/cip1) expression involves a post-transcriptional mechanism and activation of the mitogen-activated protein kinase pathway. <b>1997, 245, 730-7</b>	83

1094	The retinoblastoma protein: a master regulator of cell cycle, differentiation and apoptosis. <b>1997</b> , 246, 581-601	178
1093	Linking protein kinase C to cell-cycle control. <b>1997</b> , 248, 1-9	179
1092	Expression of p21WAF1/CIP1 in colorectal adenomas and adenocarcinomas and its correlation with p53 protein expression. <b>1997</b> , 47, 470-7	31
1091	Apoptosis and protein expression after focal cerebral ischemia in rat. <b>1997</b> , 765, 301-12	144
1090	Differentiation, differentiation/gene therapy and cancer. <b>1997</b> , 73, 51-65	40
1089	Colorectal carcinogenesis: from chromosomal evolution pathways to molecular pathogenesis. <b>1997</b> , 93, 63-73	22
1088	The expression of MDM2 and other p53-regulated proteins in the tissues of the developing rat. <b>1997</b> , 1350, 306-16	8
1087	Molecular characterization of the cyclin-dependent kinase inhibitor p27 promoter. <b>1997</b> , 1353, 307-17	30
1086	Differential expression of G1 cyclins during human placentogenesis. <b>1997</b> , 18, 9-16	24
1085	Modulation of p53, WAF1/p21 and BCL-2 expression during retinoic acid-induced differentiation of NB4 promyelocytic cells. <b>1997</b> , 21, 439-47	33
1084	Shortened survival after relapse in T-cell acute lymphoblastic leukemia patients with p16/p15 deletions. <b>1997</b> , 21, 549-58	29
1083	Reversible cell cycle arrest with concomitant p21/WAF1 overexpression and mitochondrial destruction by nitric oxide. <b>1997</b> , 42, 779-87	
1082	Regulation of apoptosis and cell cycle arrest by Zac1, a novel zinc finger protein expressed in the pituitary gland and the brain. <b>1997</b> , 16, 2814-25	177
1081	Participation of the human p53 3'UTR in translational repression and activation following gamma-irradiation. <b>1997</b> , 16, 4117-25	98
1080	Induced N- and C-terminal cleavage of p53: a core fragment of p53, generated by interaction with damaged DNA, promotes cleavage of the N-terminus of full-length p53, whereas ssDNA induces C-terminal cleavage of p53. <b>1997</b> , 16, 6008-17	63
1079	Expression of the papillomavirus E2 protein in HeLa cells leads to apoptosis. <b>1997</b> , 16, 504-14	167
1078	Transgenic mice with p53-responsive lacZ: p53 activity varies dramatically during normal development and determines radiation and drug sensitivity in vivo. <b>1997</b> , 16, 1391-400	223
1077	Role of apoptosis and apoptosis-related proteins in the cisplatin-resistant phenotype of human tumor cell lines. <b>1997</b> , 2, 540-8	41

1076	Adriamycin (ADM) induced apoptosis in transitional cell cancer (TCC) cell lines accompanied by p21 WAF1/CIP1 induction. <b>1997</b> , 2, 207-13	9
1075	The treatment with differentiation- and apoptosis-inducing agent, vesnarinone, of a patient with oral squamous cell carcinoma. <b>1997</b> , 2, 313-8	6
1074	Identification of genes induced by interleukin-3 and erythropoietin via the Jak-Stat5 pathway using enhanced differential display-reverse southern. <b>1997</b> , 17, 279-86	9
1073	Regulation of NF-kappaB by cyclin-dependent kinases associated with the p300 coactivator. <b>1997</b> , 275, 523-7	675
1072	Decreased C-MYC and BCL2 expression correlates with methylprednisolone-mediated inhibition of Raji lymphoma growth. <b>1997</b> , 60, 108-15	4
1071	The old and the new in p53 functional regulation. <b>1997</b> , 62, 3-10	8
1070	Induction of growth arrest and DNA damage-inducible genes Gadd45 and Gadd153 in primary rodent embryonic cells following exposure to methylmercury. <b>1997</b> , 147, 31-8	29
1069	Repression of p53 transcriptional activity by the HPV E7 proteins. <b>1997</b> , 227, 255-9	56
1068	Transactivation of prothymosin alpha and c-myc promoters by human papillomavirus type 16 E6 protein. <b>1997</b> , 232, 53-61	46
1067	A comparative analysis of the interactions of the E6 proteins from cutaneous and genital papillomaviruses with p53 and E6AP in correlation to their transforming potential. <b>1997</b> , 239, 132-49	68
1066	Induction of differentiation by wild-type p53 gene in a human glioma cell line. <b>1997</b> , 32, 125-33	9
1065	WAF1/CIP1 protein expression in human breast tumors. <b>1997</b> , 43, 99-103	30
1064	Apoptosis: a new pharmacodynamic endpoint. <b>1997</b> , 14, 1659-71	32
1063	Association between sucrase-isomaltase and p53 expression in colorectal cancer. <b>1997</b> , 4, 176-83	3
1062	Predictive value of p53, Bcl2 and bax in the radiotherapy of head and neck cancer. <b>1997</b> , 3, 204-10	19
1061	Wild-type p53 gene-induced morphological changes and growth suppression in hepatoma cells. <b>1997</b> , 32, 330-7	4
1060	The role of apoptosis in intestinal disease. <b>1997</b> , 32, 414-23	11
1059	Isolation of a hamster cDNA homologous to the mouse and human cyclin kinase inhibitory protein p27Kip1. <b>1997</b> , 23, 147-51	3

1058	Clinical and genomic influence of sulindac on rectal mucosa in familial adenomatous polyposis. <b>1997</b> , 40, 1156-68; discussion 1168-9	52
1057	WAF1 expression and p53 mutations in human colorectal cancers. <b>1997</b> , 123, 118-23	15
1056	Regulation and significance of apoptosis in the stem cells of the gastrointestinal epithelium. <b>1997</b> , 15, 82-93	244
1055	UV-induced signal transduction. <b>1997</b> , 37, 1-17	233
1054	A closer view of an oncoprotein-tumor suppressor interaction. <b>1997</b> , 4, 791-4	6
1053	Human papillomavirus E6 and E7 oncoproteins alter cell cycle progression but not radiosensitivity of carcinoma cells treated with low-dose-rate radiation. <b>1997</b> , 37, 145-54	61
1052	Regulation of p53 in response to ionizing radiation in ataxia telangiectasia fibroblasts. <b>1997</b> , 37, 417-22	11
1051	Transfection of p53-knockout mouse fibroblasts with wild-type p53 increases the thermosensitivity and stimulates apoptosis induced by heat stress. <b>1997</b> , 39, 197-203	21
1050	Platelet-derived growth factor (PDGF)-signaling mediates radiation-induced apoptosis in human prostate cancer cells with loss of p53 function. <b>1997</b> , 39, 731-6	16
1049	p21: a monitor of p53 dysfunction in ovarian neoplasia. <b>1997</b> , 7, 296-303	19
1048	Genes for a range of growth factors and cyclin-dependent kinase inhibitors are expressed by isolated human hair follicles. <b>1997</b> , 137, 693-698	3
1047	Expression of p53, mdm2, p21/waf1 and bcl-2 proteins in thymomas. <b>1997</b> , 30, 549-55	26
1046	p53 expression in CMV-infected cells: association with the alternative expression of the p53 transactivated genes p21/WAF1 and MDM2. <b>1997</b> , 30, 120-5	13
1045	Reduced p21(WAF1/CIP1) expression and p53 mutation in hepatocellular carcinomas. <b>1997</b> , 25, 575-9	73
1044	p21WAF1/CIP1 and MDM2 expression in non-Hodgkin's lymphoma and their relationship to p53 status: a p53+, MDM2-, p21-immunophenotype associated with missense p53 mutations. <b>1997</b> , 181, 51-61	51
1043	Relationship between abnormal p53 protein and failure to express p21 protein in human breast carcinomas. <b>1997</b> , 181, 140-5	46
1042	Apoptosis induced by gamma-irradiation, but not CD4 ligation, of peripheral T lymphocytes in vivo is p53-dependent. <b>1997</b> , 181, 166-71	13
1041	Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas. <b>1997</b> , 181, 178-82	27

1040	Multiple pathways control cell growth and transformation: overlapping and independent activities of p53 and p21Cip1/WAF1/Sdi1. <b>1997</b> , 183, 134-40	85
1039	p21WAF1/Cip1 expression is associated with cell differentiation but not with p53 mutations in squamous cell carcinomas of the larynx. <b>1997</b> , 183, 156-63	41
1038	Correlations between p21 expression and clinicopathological findings, p53 gene and protein alterations, and survival in patients with endometrial carcinoma. <b>1997</b> , 183, 318-24	47
1037	Expression of p21 and mutant p53 gene products in residual prostatic tumor cells after radical radiotherapy. <b>1997</b> , 32, 99-105	5
1036	Mdm-2: a big brother of p53. <b>1997</b> , 64, 343-352	123
1035	Up-regulated P21CIP1 expression is part of the regulation quantitatively controlling serum deprivation-induced apoptosis. <b>1997</b> , 64, 434-446	44
1034	Post-proliferative cyclin E-associated kinase activity in differentiated osteoblasts: Inhibition by proliferating osteoblasts and osteosarcoma cells. <b>1997</b> , 66, 141-152	19
1033	Roles of p300, pocket proteins, and hTBP in E1A-mediated transcriptional regulation and inhibition of p53 transactivation activity. <b>1997</b> , 66, 277-85	36
1032	Expression of cellular genes in HPV16-immortalized and cigarette smoke condensate-transformed human endocervical cells. <b>1997</b> , 66, 309-321	18
1031	p53 tumor-suppressor gene: clues to molecular carcinogenesis. <b>1997</b> , 173, 247-55	60
1030	Linkage analysis of familial melanoma and chromosome 6 in 14 Australian kindreds. <b>1997</b> , 19, 241-9	4
1029	The effect of different TP53 mutations on the chromosomal stability of a human colonic adenoma derived cell line with endogenous wild type TP53 activity, before and after DNA damage. <b>1997</b> , 20, 44-52	10
1028	Identification of additional complementation groups that regulate genomic instability. <b>1997</b> , 20, 103-112	6
1027	Functional characterization in vivo of mutant p53 molecules derived from squamous cell carcinomas of the head and neck. <b>1997</b> , 18, 78-88	22
1026	Downregulation of Waf1, C2, C3, and major histocompatibility complex class I loci within an 18-cM region of chromosome 17 in adenovirus-transformed mouse cells. <b>1997</b> , 18, 213-20	4
1025	Resistance to apoptosis induced by alkylating agents in v-Ha-ras-transformed cells due to defect in p53 function. <b>1997</b> , 18, 221-231	13
1024	Assessment of mutations in Ki-ras and p53 in colon cancers from azoxymethane- and dimethylhydrazine-treated rats. <b>1997</b> , 19, 137-44	39
1023	Induction of p21/WAF1 and G1 cell-cycle arrest by the chemopreventive agent apigenin. <b>1997</b> , 19, 74-82	126

1022	Differential effects of p53 mutants on the growth of human bronchial epithelial cells. <b>1997</b> , 19, 191-203	5
1021	Screening the p53 status of human cell lines using a yeast functional assay. <b>1997</b> , 19, 243-53	141
1020	Inhibition of cell death by lens-specific overexpression of bcl-2 in transgenic mice. <b>1997</b> , 20, 276-87	41
1019	Molecular pathology of primary and metastatic ductal pancreatic lesions. <b>1997</b> , 79, 700-716	65
1018	p53 and MDM2 alterations in osteosarcomas. <b>1997</b> , 79, 1541-1547	100
1017	Expression of p21 (waf1/cip1/sdi1), but not p53 protein, is a factor in the survival of patients with advanced gastric carcinoma. <b>1997</b> , 79, 2067-72	82
1016	Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. <b>1997</b> , 79, 2424-9	75
1015	The clinical significance of p21(WAF1/CIP-1) and p53 expression in pancreatic adenocarcinoma. <b>1997</b> , 80, 372-81	56
1014	p53-independent response of a human breast carcinoma xenograft to radioimmunotherapy. <b>1997</b> , 80, 2529-2537	20
1013	Mutations of p53 tumor-suppressor gene in angiosarcoma. <b>1997</b> , 71, 952-5	68
1012	Aberrant p21(CIP1/WAF1) protein accumulation in head-and-neck cancer. <b>1997</b> , 74, 383-9	74
1011	Amplification of the mdm-2 gene and p53 abnormalities in uterine sarcomas. <b>1997</b> , 73, 33-7	31
1010	p21/waf1/cip1 and mdm-2 expression in breast carcinoma patients as related to prognosis. <b>1997</b> , 74, 529-34	90
1009	Introduction of p53 induces cell-cycle arrest in p53-deficient human medullary-thyroid-carcinoma cells. <b>1997</b> , 73, 449-55	6
1008	A novel cytostatic process enhances the productivity of Chinese hamster ovary cells. <b>1997</b> , 55, 927-39	101
1007	Use of a membrane-localized green fluorescent protein allows simultaneous identification of transfected cells and cell cycle analysis by flow cytometry. <b>1997</b> , 29, 286-91	99
1006	Activated cell cycle checkpoints in epirubicin-treated breast cancer cells studied by BrdUrd-flow cytometry. <b>1997</b> , 29, 321-7	5
1005	Different mechanisms for inhibition of cell proliferation via cell cycle proteins in PC12 cells by nerve growth factor and staurosporine. <b>1997</b> , 49, 461-474	33

1004	Cyclin-dependent kinase inhibitor p27kip1 is expressed at high levels in cells that express a myelinating phenotype. <b>1997</b> , 50, 373-82	26
1003	Probing protein structure using biochemical and biophysical methods. Proteolysis, matrix-assisted laser desorption/ionization mass spectrometry, high-performance liquid chromatography and size-exclusion chromatography of p21Waf1/Cip1/Sdi1. <b>1997</b> , 777, 23-30	52
1002	Biological significance and molecular mechanisms of p53-induced apoptosis. <b>1998</b> , 3, 237-44	11
1001	Signal transduction and the regulation of apoptosis: roles of ceramide. <b>1998</b> , 3, 317-34	36
1000	Molecular Events and Mechanisms of Apoptosis. <b>1998</b> , 2, 9-19	24
999	The Role of the Tumor Suppressor Gene p53 in Cardiomyocyte Apoptosis. <b>1998</b> , 3, 45-61	2
998	Expression of p53 and p21WAF1/CIP1 proteins in gastric and esophageal cancers: comparison with mutations of the p53 gene. <b>1998</b> , 43, 279-89	18
997	Induction of p21 (CIP1/WAF1/SID1) by estradiol in a breast epithelial cell line transfected with the recombinant estrogen receptor gene: a possible mechanism for a negative regulatory role of estradiol. <b>1998</b> , 47, 181-93	18
996	Therapeutic potential of recombinant p53 overexpression in breast cancer cells expressing endogenous wild-type p53. <b>1998</b> , 48, 273-86	10
995	Detection of p21WAF1/Cip1 in brain metastases. <b>1998</b> , 37, 223-8	8
994	Targeting DNA methyltransferase in cancer. <b>1998</b> , 17, 219-31	22
993	Analysis of the p21 gene in gliomas. <b>1998</b> , 40, 107-11	7
992	Prognostic implications of expression of the cell cycle inhibitor protein p27Kip1. <b>1998</b> , 52, 29-41	45
991	Prognostic and predictive value of p53 and p21 in breast cancer. <b>1998</b> , 52, 79-98	113
990	Biochemical and molecular mechanisms regulating apoptosis. <b>1998</b> , 178, 9-25	37
989	pQuattro vectors allow one-step multigene metabolic engineering and auto-selection of quattrocistronic artificial mammalian operons. <b>1998</b> , 28, 229-35	9
988	Molecular analysis of two mammary carcinoma cell lines at the transcriptional level as a model system for progression of breast cancer. <b>1998</b> , 16, 129-39	25
987	Involvement of p21 in mitomycin C-induced G2 arrest in LP1-1 cells. <b>1998</b> , 44, 1011-1020	



986	Transcription of the rat p53 gene is induced by a 39kDa protein binding to the p53 promoter region during the liver regeneration. <b>1998</b> , 46, 765-74	1
985	p53-inducible human homologue of Drosophila seven in absentia (Siah) inhibits cell growth: suppression by BAG-1. <b>1998</b> , 17, 2736-47	165
984	A homologue of Drosophila aurora kinase is oncogenic and amplified in human colorectal cancers. <b>1998</b> , 17, 3052-65	956
983	Retention of wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can promote cancer formation. <b>1998</b> , 17, 4657-67	316
982	The requirement for the p53 proline-rich functional domain for mediation of apoptosis is correlated with specific PIG3 gene transactivation and with transcriptional repression. <b>1998</b> , 17, 4668-79	223
981	The mammalian Cut homeodomain protein functions as a cell-cycle-dependent transcriptional repressor which downmodulates p21WAF1/CIP1/SDI1 in S phase. <b>1998</b> , 17, 4680-94	122
980	The alternative product from the human CDKN2A locus, p14(ARF), participates in a regulatory feedback loop with p53 and MDM2. <b>1998</b> , 17, 5001-14	867
979	A novel p53-inducible gene coding for a microtubule-localized protein with G2-phase-specific expression. <b>1998</b> , 17, 5015-25	75
978	A link between cell cycle and cell death: Bax and Bcl-2 modulate Cdk2 activation during thymocyte apoptosis. <b>1998</b> , 17, 7209-18	141
977	Induction of DNA synthesis and apoptosis by regulated inactivation of a temperature-sensitive retinoblastoma protein. <b>1998</b> , 17, 1040-52	24
976	Genetic selection of intragenic suppressor mutations that reverse the effect of common p53 cancer mutations. <b>1998</b> , 17, 1847-59	142
975	Leiomyosarcoma of the uterus: A clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 49 cases. <b>1998</b> , 68, 54-61	79
974	Malignant mixed Mullerian tumors of the uterus: a clinicopathologic, DNA flow cytometric, p53, and mdm-2 analysis of 44 cases. <b>1998</b> , 68, 18-24	29
973	Underexpression of cyclin-dependent kinase (CDK) inhibitors in cervical carcinoma. <b>1998</b> , 71, 38-45	39
972	Levels of p53 in Epstein-Barr virus-infected cells determine cell fate: apoptosis, cell cycle arrest at the G1/S boundary without apoptosis, cell cycle arrest at the G2/M boundary without apoptosis, or unrestricted proliferation. <b>1998</b> , 251, 217-26	18
971	DNA-dependent protein kinase acts upstream of p53 in response to DNA damage. <b>1998</b> , 394, 700-4	265
970	Stabilization of wild-type p53 by hypoxia-inducible factor 1alpha. <b>1998</b> , 392, 405-8	742
969	Enhanced responses to a DNA vaccine encoding a fusion antigen that is directed to sites of immune induction. <b>1998</b> , 392, 408-11	226

968	Induction of epithelial tubules by growth factor HGF depends on the STAT pathway. <b>1998</b> , 391, 285-8	447
967	DNA shuffling of a family of genes from diverse species accelerates directed evolution. <b>1998</b> , 391, 288-91	699
966	The candidate tumour suppressor p33ING1 cooperates with p53 in cell growth control. <b>1998</b> , 391, 295-8	255
965	MAP kinase links the transcription factor Microphthalmia to c-Kit signalling in melanocytes. <b>1998</b> , 391, 298-301	535
964	Involvement of p85 in p53-dependent apoptotic response to oxidative stress. <b>1998</b> , 391, 707-10	151
963	p53 and brain tumors: from gene mutations to gene therapy. <b>1998</b> , 8, 599-613	50
962	Signals from Ras and Rho GTPases interact to regulate expression of p21Waf1/Cip1. <b>1998</b> , 394, 295-9	410
961	Higher productivity of growth-arrested Chinese hamster ovary cells expressing the cyclin-dependent kinase inhibitor p27. <b>1998</b> , 14, 705-13	88
960	Molecular regulation of cell-cycle progression and apoptosis in mammalian cells: implications for biotechnology. <b>1998</b> , 14, 807-33	81
959	p53 expression in gastric mucosa with Helicobacter pylori infection. <b>1998</b> , 13, 215-9	13
958	Role of MDM2 overexpression in doxorubicin resistance of breast carcinoma. <b>1998</b> , 89, 221-7	30
957	Inhibition of cyclin D1 expression and induction of apoptosis by inostamycin in small cell lung carcinoma cells. <b>1998</b> , 89, 315-22	21
956	Cell cycle-dependent modulation of promoter activities of RB and WAF1/Cip1 genes. <b>1998</b> , 89, 626-33	1
955	Phenotypic alterations of small cell lung carcinoma induced by different levels of wild-type p53 expression. <b>1998</b> , 5, 148-55	15
954	Differential p53 phosphorylation and activation of apoptosis-promoting genes Bax and Fas/APO-1 by irradiation and ara-C treatment. <b>1998</b> , 5, 584-91	47
953	Irradiation induces G2/M cell cycle arrest and apoptosis in p53-deficient lymphoblastic leukemia cells without affecting Bcl-2 and Bax expression. <b>1998</b> , 5, 687-93	35
952	A new p21waf1/cip1 isoform is an early event of cell response to oxidative stress. <b>1998</b> , 5, 940-5	26
951	Monitoring adenoviral p53 transduction efficiency by yeast functional assay. <b>1998</b> , 5, 339-44	6

950	Inhibition of intimal hyperplasia after vein grafting by in vivo transfer of human senescent cell-derived inhibitor-1 gene. <b>1998</b> , 5, 761-9	45
949	Transcriptional regulation and induction of apoptosis: implications for the use of monomeric p53 variants in gene therapy. <b>1998</b> , 5, 1631-41	2
948	V-myc in a simple, single gene retroviral vector causes rapid induction of leukemia and concomitant apoptosis following bone marrow transplantation. <b>1998</b> , 12, 542-53	8
947	p21Cip1/WAF1 is important for differentiation and survival of U937 cells. <b>1998</b> , 12, 1944-50	51
946	Prognostic significance of allelic losses in primary melanoma. <b>1998</b> , 16, 2213-8	71
945	Synergistic transcriptional activation of the MCK promoter by p53: tetramers link separated DNA response elements by DNA looping. <b>1998</b> , 16, 283-92	33
944	Effects of adenovirus-mediated p16INK4A expression on cell cycle arrest are determined by endogenous p16 and Rb status in human cancer cells. <b>1998</b> , 16, 265-72	111
943	Fine mapping and regulation of the association of p53 with p34cdc2. <b>1998</b> , 16, 105-11	31
942	U.V.C.-induction of p53 activation and accumulation is dependent on cell cycle and pathways involving protein synthesis and phosphorylation. <b>1998</b> , 16, 459-69	15
941	Induction of growth arrest and cell death by overexpression of the cyclin-Cdk inhibitor p21 in hamster BHK21 cells. <b>1998</b> , 16, 369-80	48
940	p21 binding to PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells. <b>1998</b> , 16, 311-20	282
939	p21waf1 can block cells at two points in the cell cycle, but does not interfere with processive DNA-replication or stress-activated kinases. <b>1998</b> , 16, 431-41	145
938	Selective binding of different p53 response elements by p53 containing complexes. <b>1998</b> , 16, 453-8	7
937	p21WAF1 induces permanent growth arrest and enhances differentiation, but does not alter apoptosis in PC12 cells. <b>1998</b> , 16, 443-51	51
936	Mutated p21(WAF1/CIP1/SDI1) lacking CDK-inhibitory activity fails to prevent apoptosis in human colorectal carcinoma cells. <b>1998</b> , 16, 705-12	78
935	Identification of cdk2 binding sites on the p27Kip1 cyclin-dependent kinase inhibitor. <b>1998</b> , 16, 755-62	11
934	Antisense oligonucleotide of WAF1 gene prevents EGF-induced cell-cycle arrest in A431 cells. <b>1998</b> , 16, 797-802	26
933	Regulation of the specific DNA binding activity of <i>Xenopus laevis</i> p53: evidence for conserved regulation through the carboxy-terminus of the protein. <b>1998</b> , 16, 883-90	17

932	Small contribution of G1 checkpoint control manipulation to modulation of p53-mediated apoptosis. <b>1998</b> , 16, 957-66	23
931	Nuclear factor - kappaB-dependent regulation of p53 gene expression induced by daunomycin genotoxic drug. <b>1998</b> , 16, 1187-95	90
930	Human smooth muscle alpha-actin gene is a transcriptional target of the p53 tumor suppressor protein. <b>1998</b> , 16, 1299-308	58
929	p53-dependent induction of WAF1 by cold shock in human glioblastoma cells. <b>1998</b> , 16, 1507-11	51
928	Alternatively spliced forms of cyclin D1 modulate entry into the cell cycle in an inverse manner. <b>1998</b> , 16, 1701-12	97
927	A transforming p53 mutant, which binds DNA, transactivates and induces apoptosis reveals a nuclear:cytoplasmic shuttling defect. <b>1998</b> , 16, 1429-41	21
926	Overexpression of MDM2, due to enhanced translation, results in inactivation of wild-type p53 in Burkitt's lymphoma cells. <b>1998</b> , 16, 1603-10	112
925	Recombinant PML adenovirus suppresses growth and tumorigenicity of human breast cancer cells by inducing G1 cell cycle arrest and apoptosis. <b>1998</b> , 16, 1839-49	87
924	Involvement of p21 and p27 in the regulation of CDK activity and cell cycle progression in the regenerating liver. <b>1998</b> , 16, 2141-50	166
923	SV40 T/t-antigen induces premature mammary gland involution by apoptosis and selects for p53 missense mutation in mammary tumors. <b>1998</b> , 16, 2103-14	30
922	p53 mutations isolated in yeast based on loss of transcription factor activity: similarities and differences from p53 mutations detected in human tumors. <b>1998</b> , 16, 2115-22	35
921	Interferon-alpha-induced G1 phase arrest through up-regulated expression of CDK inhibitors, p19Ink4D and p21Cip1 in mouse macrophages. <b>1998</b> , 16, 2075-86	46
920	Oligomerization of p53 is necessary to inhibit its transcriptional transactivation property at high protein concentration. <b>1998</b> , 16, 2413-8	29
919	Potential role for cathepsin D in p53-dependent tumor suppression and chemosensitivity. <b>1998</b> , 16, 2177-83	189
918	mdm2-P2 transcript levels predict the functional activity of the p53 tumor suppressor in primary leukemic cells. <b>1998</b> , 16, 2249-57	10
917	Human male germ cell tumor resistance to cisplatin is linked to TP53 gene mutation. <b>1998</b> , 16, 2345-9	133
916	Involvement of CPP32/Caspase-3 in c-Myc-induced apoptosis. <b>1998</b> , 16, 387-98	55
915	Functional interplay between p53 and E2F through co-activator p300. <b>1998</b> , 16, 2695-710	108

914	p27Kip1: a key mediator of retinoic acid induced growth arrest in the SMS-KCNR human neuroblastoma cell line. <b>1998</b> , 16, 3337-43	78
913	Absence of p53-dependent cell cycle regulation in pluripotent mouse cell lines. <b>1998</b> , 16, 3003-11	38
912	Overexpression of p21waf1/cip1 arrests the growth of chicken embryo fibroblasts that overexpress E2F1. <b>1998</b> , 16, 3115-22	9
911	p53 deficiency and misexpression of protein kinase CK2alpha collaborate in the development of thymic lymphomas in mice. <b>1998</b> , 16, 2965-74	140
910	Activation of p53 DNA binding activity by point mutation. <b>1998</b> , 16, 3123-31	11
909	Agents that cause DNA double strand breaks lead to p16INK4a enrichment and the premature senescence of normal fibroblasts. <b>1998</b> , 16, 1113-23	381
908	The proliferation of normal human fibroblasts is dependent upon negative regulation of p53 function by mdm2. <b>1998</b> , 16, 3317-22	62
907	Identification of human p53 mutations with differential effects on the bax and p21 promoters using functional assays in yeast. <b>1998</b> , 16, 1369-72	70
906	Expression of a p53 mutant in the epidermis of transgenic mice accelerates chemical carcinogenesis. <b>1998</b> , 17, 35-45	71
905	Expression of a novel form of p21Cip1/Waf1 in UV-irradiated and transformed cells. <b>1998</b> , 16, 1333-43	46
904	p21-induced cycle arrest in G1 protects cells from apoptosis induced by UV-irradiation or RNA polymerase II blockage. <b>1998</b> , 16, 3461-9	131
903	TGF-beta1 effects on proliferation of rat intestinal epithelial cells are due to inhibition of cyclin D1 expression. <b>1998</b> , 16, 3445-54	71
902	Role of p53 in aziridinylbenzoquinone-induced p21waf1 expression. <b>1998</b> , 17, 357-65	7
901	BRCA1 physically associates with p53 and stimulates its transcriptional activity. <b>1998</b> , 16, 1713-21	372
900	Scatter factor protects epithelial and carcinoma cells against apoptosis induced by DNA-damaging agents. <b>1998</b> , 17, 131-41	123
899	Excision of mismatched nucleotides from DNA: a potential mechanism for enhancing DNA replication fidelity by the wild-type p53 protein. <b>1998</b> , 17, 261-70	69
898	p53-mediated transcription induces resistance of DNA to UV inactivation. <b>1998</b> , 17, 401-11	15
897	Favorable prognostic significance of high-level retinoic acid receptor beta expression in neuroblastoma mediated by effects on cell cycle regulation. <b>1998</b> , 17, 751-9	47

896	Uncoupling of p21WAF1/CIP1/SDI1 mRNA and protein expression upon genotoxic stress. <b>1998</b> , 17, 781-7	42
895	p21Waf1 inhibits the activity of cyclin dependent kinase 2 by preventing its activating phosphorylation. <b>1998</b> , 17, 959-69	30
894	Human tumor-derived p53 proteins exhibit binding site selectivity and temperature sensitivity for transactivation in a yeast-based assay. <b>1998</b> , 16, 2527-39	83
893	The E7 protein of human papillomavirus type 16 sensitizes primary human keratinocytes to apoptosis. <b>1998</b> , 17, 1207-14	96
892	Insensitivity to growth inhibition by TGF-beta1 correlates with a lack of inhibition of the CDK2 activity in prostate carcinoma cells. <b>1998</b> , 17, 1549-56	22
891	Reciprocal relationship between the tumor suppressors p53 and BAX in primary colorectal cancers. <b>1998</b> , 17, 2003-8	52
890	Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs. <b>1998</b> , 17, 2235-49	301
889	Post-transcriptional induction of p21 cip1 protein by human papillomavirus E7 inhibits unscheduled DNA synthesis reactivated in differentiated keratinocytes. <b>1998</b> , 17, 2027-38	61
888	Tumour associated mutants of p53 can inhibit transcriptional activity of p53 without heterooligomerization. <b>1998</b> , 17, 2351-8	16
887	Delayed involution of the mammary epithelium in BALB/c-p53null mice. <b>1998</b> , 17, 2305-12	73
886	Fractional allelic loss in gastric carcinoma correlates with growth patterns. <b>1998</b> , 17, 2655-9	32
885	Characterization of a new intrabody directed against the N-terminal region of human p53. <b>1998</b> , 17, 2445-56	53
884	Prevention of mammalian DNA reduplication, following the release from the mitotic spindle checkpoint, requires p53 protein, but not p53-mediated transcriptional activity. <b>1998</b> , 17, 2743-51	48
883	Poly(ADP-ribosyl)ation is required for p53-dependent signal transduction induced by radiation. <b>1998</b> , 17, 2819-25	74
882	Induction of apoptosis in breast cancer cells by TPA. <b>1998</b> , 17, 2915-20	24
881	Activation and repression of p21(WAF1/CIP1) transcription by RB binding proteins. <b>1998</b> , 17, 3463-9	63
880	A targeted disruption of the murine Brca1 gene causes gamma-irradiation hypersensitivity and genetic instability. <b>1998</b> , 17, 3115-24	291
879	Stress-induced secretion of growth inhibitors: a novel tumor suppressor function of p53. <b>1998</b> , 17, 1089-96	130

878	Lovastatin mediated G1 arrest in normal and tumor breast cells is through inhibition of CDK2 activity and redistribution of p21 and p27, independent of p53. <b>1998</b> , 17, 2393-402	173
877	Identification of candidate target genes for EVI-1, a zinc finger oncoprotein, using a novel selection strategy. <b>1998</b> , 17, 1527-38	14
876	Enforced CDK4 expression in a hematopoietic cell line confers resistance to the G1 arrest induced by ionizing radiation. <b>1998</b> , 17, 2961-71	20
875	Regulation of CAK kinase activity by p53. <b>1998</b> , 17, 2733-41	60
874	Mouse models in tumor suppression. <b>1998</b> , 17, 3385-400	71
873	Roles for p53 in growth arrest and apoptosis: putting on the brakes after genotoxic stress. <b>1998</b> , 17, 3287-99	352
872	Gene therapy for prostate cancer. <b>1998</b> , 1, 189-196	3
871	Transient global ischemia triggers expression of the DNA damage-inducible gene GADD45 in the rat brain. <b>1998</b> , 18, 646-57	52
870	Controlled proliferation by multigene metabolic engineering enhances the productivity of Chinese hamster ovary cells. <b>1998</b> , 16, 468-72	250
869	Duplication of ATR inhibits MyoD, induces aneuploidy and eliminates radiation-induced G1 arrest. <b>1998</b> , 19, 39-46	74
868	Inhibition of presenilin 1 expression is promoted by p53 and p21WAF-1 and results in apoptosis and tumor suppression. <b>1998</b> , 4, 835-8	166
867	Cloning and functional analysis of human p51, which structurally and functionally resembles p53. <b>1998</b> , 4, 839-43	465
866	Prognostic significance of cyclin E and p53 protein overexpression in carcinoma of the renal pelvis and ureter. <b>1998</b> , 77, 783-8	31
865	Mutations in the TP53 gene and protein expression of p53, MDM 2 and p21/WAF-1 in primary cervical carcinomas with no or low human papillomavirus load. <b>1998</b> , 78, 69-72	23
864	Frequent and heterogeneous expression of cyclin-dependent kinase inhibitor WAF1/p21 protein and mRNA in urothelial carcinoma. <b>1998</b> , 77, 515-21	42
863	p22/PACAP response gene 1 (PRG1): a putative target gene for the tumor suppressor p53. <b>1998</b> , 865, 27-36	3
862	A novel strategy for inhibiting growth of human pancreatic cancer cells by blocking cyclin-dependent kinase activity. <b>1998</b> , 2, 36-43	13
861	Changes in c-Jun but not Bcl-2 family proteins in p53-dependent apoptosis of mouse cerebellar granule neurons induced by DNA damaging agent bleomycin. <b>1998</b> , 794, 239-47	39

860	Accumulation of genetic alterations and their significance in each primary human cancer and cell line. <b>1998</b> , 400, 421-37	16
859	A comparative analysis of the proteins between the fibroblasts from Werner's syndrome patients and age-matched normal individuals using two-dimensional gel electrophoresis. <b>1998</b> , 100, 133-43	24
858	Ubiquitin, E6-AP, and their role in p53 inactivation. <b>1998</b> , 78, 129-39	77
857	BDNF accelerates gene expression in cultured cerebellar granule neurons. <b>1998</b> , 105, 277-86	17
856	Cellular factors may enable squamous carcinoma cells to overcome TGF beta-mediated repression of CDK2 activity. <b>1998</b> , 34, 52-7	4
855	The papillomavirus E6 proteins. <b>1998</b> , 1378, F1-19	35
854	p21(WAF1/Cip1) retards the growth of human squamous cell carcinomas in vivo. <b>1998</b> , 34, 211-8	28
853	Expression of p21WAF1/CIP1 is unrelated to p53 tumour suppressor gene status in oral squamous cell carcinomas. <b>1998</b> , 34, 198-203	36
852	Expression of cyclin dependent kinase inhibitor p21waf1/cip1 in premalignant and malignant oral lesions: relationship with p53 status. <b>1998</b> , 34, 353-60	31
851	p53- and p21-independent apoptosis of squamous cell carcinoma cells induced by 5-fluorouracil and radiation. <b>1998</b> , 34, 529-37	34
850	Okadaic acid-induced lens epithelial cell apoptosis requires inhibition of phosphatase-1 and is associated with induction of gene expression including p53 and bax. <b>1998</b> , 257, 351-61	37
849	Clinical and molecular prognostic factors in sphincter-preserving surgery for rectal cancer. <b>1998</b> , 8, 54-69	8
848	Molecular aspects of the relationship between cancer and aging: tumor suppressor activity during cellular senescence. <b>1998</b> , 33, 81-94	25
847	Anticancer quinones induce pRb-preventable G2/M cell cycle arrest and apoptosis. <b>1998</b> , 24, 848-54	36
846	Decrease in p53 protein in cultured cardinal ligament fibroblasts from patients with prolapsus uteri. <b>1998</b> , 22, 31-40	11
845	Inhibition of in vivo rat liver regeneration by 2-acetylaminofluorene affects the regulation of cell cycle-related proteins. <b>1998</b> , 27, 691-6	26
844	Loss of butyrate-induced apoptosis in human hepatoma cell lines HCC-M and HCC-T having substantial Bcl-2 expression. <b>1998</b> , 27, 1233-40	33
843	bcl-2 and apoptosis in lymph node positive breast carcinoma. <b>1998</b> , 82, 1296-1302	99



842	Immunohistochemical detection of sex steroid receptors, cyclins, and cyclin-dependent kinases in the normal and neoplastic squamous epithelia of the uterine cervix. <b>1998</b> , 82, 1709-19	54
841	The prognostic significance of the biomarkers p21WAF1/CIP1, p53, and bcl-2 in laryngeal squamous cell carcinoma. <b>1998</b> , 82, 2159-2165	65
840	Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix. <b>1998</b> , 82, 2409-2417	71
839	Alterations of p53, cyclin D1, Rb, and H-ras in human oral carcinomas related to tobacco use. <b>1998</b> , 83, 204-12	77
838	Reduced expression of cyclin-dependent kinase inhibitor p27Kip1 is an indicator of malignant behavior in oral squamous cell carcinoma. <b>1998</b> , 83, 2447-55	43
837	Induction of apoptosis in human keratinocytes containing mutated p53 alleles and its inhibition by both the E6 and E7 oncoproteins. <b>1998</b> , 75, 96-104	40
836	Overexpression of p21WAF1/CIP1 induces cell differentiation and growth inhibition in a human glioma cell line. <b>1998</b> , 75, 643-8	25
835	Acute overexpression of wt p53 facilitates anticancer drug-induced death of cancer and normal cells. <b>1998</b> , 75, 933-40	47
834	Selective down-regulation of human papillomavirus transcription by 2-deoxyglucose. <b>1998</b> , 76, 639-46	32
833	Induction of p53 and melanoma cell death is reciprocal with down-regulation of E2F, cyclin D1 and pRB. <b>1998</b> , 76, 757-60	10
832	Increased level of p21 in human ovarian tumors is associated with increased expression of cdk2, cyclin A and PCNA. <b>1998</b> , 76, 891-6	31
831	Suppression of growth of hepatocellular carcinoma by sodium butyrate in vitro and in vivo. <b>1998</b> , 76, 897-902	48
830	p21/WAF1, p53 and PCNA expression and p53 mutation status in hepatocellular carcinoma. <b>1998</b> , 79, 424-8	51
829	Positive correlation between p27Kip1 expression and progression of human esophageal squamous cell carcinoma. <b>1998</b> , 79, 439-43	53
828	Characterization of p53 mutants identified in human tumors with a missense mutation in the tetramerization domain. <b>1998</b> , 78, 372-6	24
827	pTRIDENT, a novel vector family for tricistronic gene expression in mammalian cells. <b>1998</b> , 57, 1-10	65
826	Increased expression of cyclin G1 and p21WAF1/CIP1 in neurons following transient forebrain ischemia: comparison with early DNA damage. <b>1998</b> , 53, 279-96	48
825	Identification of deletions and insertions in the p53 gene using multiplex PCR and high-resolution fragment analysis: application to breast and ovarian tumors. <b>1998</b> , 12, 250-6	5

824	PCNA binding through a conserved motif. <b>1998</b> , 20, 195-9	288
823	"Isogaba Maware": quality control of genome DNA by checkpoints. <b>1998</b> , 20, 391-9	14
822	Tumor-suppressor p53 is expressed in proliferating and newly formed neurons of the embryonic and postnatal rat brain: comparison with expression of the cell cycle regulators p21Waf1/Cip1, p27Kip1, p57Kip2, p16Ink4a, cyclin G1, and the proto-oncogene Bax. <b>1998</b> , 397, 181-98	101
821	p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. <b>1998</b> , 184, 265-71	44
820	Loss of heterozygosity during the development and progression of differentiated adenocarcinoma of the stomach. <b>1998</b> , 185, 38-43	63
819	Molecular abnormalities in liposarcoma: role of MDM2 and CDK4-containing amplicons at 12q13-22. <b>1998</b> , 185, 188-90	78
818	No evidence for functional inactivation of wild-type p53 protein by MDM2 overexpression in gastric carcinogenesis. <b>1998</b> , 186, 36-40	9
817	Transforming growth factor- $\beta$ induces apoptotic cell death in cultured retinal endothelial cells but not pericytes: Association with decreased expression of p21waf1/cip1. <b>1998</b> , 70, 70-83	40
816	Possible involvement of p21/waf1 in the growth inhibition of HepG2 cells induced by hepatocyte growth factor. <b>1998</b> , 177, 130-6	26
815	Comparison of bax, waf1, and IMP dehydrogenase regulation in response to wild-type p53 expression under normal growth conditions. <b>1998</b> , 177, 364-76	17
814	Identification of allelic loss on chromosome arm 6p in human astrocytomas by arbitrarily primed polymerase chain reaction. <b>1998</b> , 22, 165-70	15
813	Isolation of a novel TP53 target gene from a colon cancer cell line carrying a highly regulated wild-type TP53 expression system. <b>1998</b> , 23, 1-9	47
812	Apoptotic response of spermatogenic cells to the germ cell mutagens etoposide, adriamycin, and diepoxybutane. <b>1998</b> , 31, 133-48	55
811	Growth arrest of immortalized human keratinocytes and suppression of telomerase activity by p21WAF1 gene expression. <b>1998</b> , 21, 26-36	27
810	Cooperation of p53 loss of function and v-Ha-ras in transformation of mouse keratinocyte cell lines. <b>1998</b> , 21, 50-61	20
809	Characterization of rare p53 mutants from carcinogen-treated albumin $\beta$ gimian virus 40 T-antigen transgenic rats. <b>1998</b> , 21, 128-134	11
808	p53-independent WAF1 induction by ACNU in human glioblastoma cells. <b>1998</b> , 21, 171-6	4
807	Relaxed cell-cycle arrests and propagation of unrepaired chromosomal damage in cancer cell lines with wild-type p53. <b>1998</b> , 23, 1-12	18

806	DNA adduct levels associated with p53 induction and delay of MCF-7 cells in S phase after exposure to benzo[g]chrysene dihydrodiol epoxide enantiomers. <b>1998</b> , 23, 115-20	16
805	S-phase arrest in mouse keratinocytes exposed to multiple doses of ultraviolet B/A radiation. <b>1998</b> , 23, 159-167	19
804	Alterations in cyclin-dependent kinase 2 function during differentiation of primary human keratinocytes. <b>1998</b> , 23, 226-33	16
803	Role of cyclin E and p53 expression in progression of early gastric cancer. <b>1998</b> , 1, 160-165	14
802	p53 protein overexpression and response to induction chemoradiation therapy in patients with locally advanced rectal adenocarcinoma. <b>1998</b> , 5, 203-8	37
801	New p53-based anti-cancer therapeutic strategies. <b>1998</b> , 15, 222-8	14
800	Immunohistochemical analysis of p53 and p21 in human primary glioblastomas in relation to proliferative potential and apoptosis. <b>1998</b> , 15, 89-94	10
799	Alteration of bcl-2 and bax expression in embolized meningiomas. <b>1998</b> , 15, 13-7	5
798	The challenge of p53: linking biochemistry, biology, and patient management. <b>1998</b> , 16, 248-60	14
797	Targeting cancer cell death with a bcl-XS adenovirus. <b>1998</b> , 19, 279-88	10
796	Induction of tumour-suppressor phosphoprotein p53 in the apoptosis of cultured rat cerebellar neurones triggered by excitatory amino acids. <b>1998</b> , 10, 246-54	90
795	Prognostic factors in muscle-invasive bladder cancer treated with radiotherapy: an immunohistochemical study. <b>1998</b> , 81, 862-9	23
794	Induction of squamous cell carcinoma in p53-deficient mice after ultraviolet irradiation. <b>1998</b> , 110, 72-5	74
793	Anchorage-dependent expression of the vitamin D receptor in normal human keratinocytes. <b>1998</b> , 111, 551-8	16
792	p53-Dependent DNA repair and apoptosis respond differently to high- and low-dose ultraviolet radiation. <b>1998</b> , 139, 3-10	45
791	Ineffective haemopoiesis and apoptosis in myelodysplastic syndromes. <b>1998</b> , 101, 220-30	76
790	Mutation of p16, p21 or cyclin dependent kinase 4 is rare in acute lymphoblastic leukaemia. <b>1998</b> , 103, 467-72	4
789	Expression of p53, p21/WAF/CIP, Bcl-2, Bax, Bcl-x, and Bak in radiation-induced apoptosis in testicular germ cell tumor lines. <b>1998</b> , 41, 415-24	31

788	Hepatitis C virus core protein represses p21WAF1/Cip1/Sid1 promoter activity. <b>1998</b> , 208, 331-6	135
787	pZ402, an improved SV40-based shuttle vector containing a T-antigen mutant unable to interact with wild-type p53. <b>1998</b> , 211, 229-34	3
786	Action of 1,25(OH) <sub>2</sub> D <sub>3</sub> on the cell cycle genes, cyclin D1, p21 and p27 in MCF-7 cells. <b>1998</b> , 142, 57-65	129
785	p53 suppresses cytokine induced, Stat5 mediated activation of transcription. <b>1998</b> , 143, 143-54	21
784	p53-independent induction of WAF1/Cip1 is correlated with osteoblastic differentiation by vitamin D <sub>3</sub> . <b>1998</b> , 129, 61-8	31
783	Induction of p21 during ceramide-mediated apoptosis in human hepatocarcinoma cells. <b>1998</b> , 129, 215-22	28
782	Induction of cyclin-dependent kinase inhibitor p21 in vesnarinone-induced differentiation of squamous cell carcinoma cells. <b>1998</b> , 133, 35-45	13
781	DNA damage induces p21 protein expression by inhibiting ubiquitination in ML-1 cells. <b>1998</b> , 1404, 405-11	20
780	Cell cycle-related gene expression in the adult rat brain: selective induction of cyclin G1 and p21WAF1/CIP1 in neurons following focal cerebral ischemia. <b>1998</b> , 84, 1097-112	53
779	Oncogene expression in tumour cells of pediatric Hodgkin's disease in Argentina--correlation with Epstein Barr virus presence. <b>1998</b> , 194, 25-31	6
778	Altered topographic expression of p21WAF1/CIP1/SDI1, bcl2 and p53 during gastric carcinogenesis. <b>1998</b> , 194, 309-17	22
777	Expression of p53 and p21 proteins in oral squamous cell carcinoma: correlation with lymph node metastasis and response to chemoradiotherapy. <b>1998</b> , 194, 821-30	21
776	Expression of p21WAF1/CIP1 in soft tissue sarcomas: a comparative immunohistochemical study with p53 and Ki-67. <b>1998</b> , 194, 685-91	17
775	DNA damage activates p53 through a phosphorylation-acetylation cascade. <b>1998</b> , 12, 2831-41	927
774	Recent insights into platinum drug resistance in cancer. <b>1998</b> , 1, 243-54	55
773	Tumor suppressor gene therapy for cancer: from the bench to the clinic. <b>1998</b> , 1, 205-10	2
772	Connections between growth and the cell cycle. <b>1998</b> , 10, 784-90	159
771	Molecular characterisation of a panel of human ovarian carcinoma xenografts. <b>1998</b> , 34, 1432-8	13

770	Cellular and molecular determinants of cisplatin resistance. <b>1998</b> , 34, 1535-42	310
769	G0/G1 cell cycle arrest in the brain of <i>Sarcophaga crassipalpis</i> during pupal diapause and the expression pattern of the cell cycle regulator, proliferating cell nuclear antigen. <b>1998</b> , 28, 83-9	79
768	FDG accumulation and tumor biology. <b>1998</b> , 25, 317-22	271
767	Review article Alterations in cyclin D1, p53, and the cell cycle related elements Implications for distinct genetic pathways of urinary bladder carcinogenesis. <b>1998</b> , 4, 58-72	5
766	Overexpression of ErbB2 blocks Taxol-induced apoptosis by upregulation of p21Cip1, which inhibits p34Cdc2 kinase. <b>1998</b> , 2, 581-91	311
765	p63, a p53 homolog at 3q27-29, encodes multiple products with transactivating, death-inducing, and dominant-negative activities. <b>1998</b> , 2, 305-16	1765
764	The C-terminal domain of p53 catalyzes DNA-renaturation and strand exchange toward annealing between intact ssDNAs and toward eliminating damaged ssDNA from duplex formation through preferential recognition of damaged DNA by a duocarmycin. <b>1998</b> , 409, 147-62	4
763	Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. <b>2000</b> , 14, 981-993	247
762	Cell cycle signaling and cardiovascular disease. <b>2002</b> , 67, 163-70	4
761	Neurogenic differentiation factor 1 promotes colorectal cancer cell proliferation and tumorigenesis by suppressing the p53/p21 axis. <b>2020</b> , 111, 175-185	8
760	The expression of retinoblastoma protein in epidermis is induced by ultraviolet B exposure. <b>1996</b> , 135, 406-411	5
759	Genes for a range of growth factors and cyclin-dependent kinase inhibitors are expressed by isolated human hair follicles. <b>1997</b> , 137, 693-698	26
758	Aging of the human adrenal cortex. <b>2004</b> , 2004, re6	17
757	Inhibition of p53 DNA binding by human papillomavirus E6 proteins. <b>1994</b> , 68, 4262-73	169
756	The kinetics of simian virus 40-induced progression of quiescent cells into S phase depend on four independent functions of large T antigen. <b>1994</b> , 68, 5496-508	58
755	The ability of human papillomavirus E6 proteins to target p53 for degradation in vivo correlates with their ability to abrogate actinomycin D-induced growth arrest. <b>1994</b> , 68, 5698-705	156
754	Cytomegalovirus infection induces high levels of cyclins, phosphorylated Rb, and p53, leading to cell cycle arrest. <b>1995</b> , 69, 6697-704	232
753	Suppression of cellular proliferation by the papillomavirus E2 protein. <b>1995</b> , 69, 7791-9	157

752	Direct interaction of the hepatitis B virus HBx protein with p53 leads to inhibition by HBx of p53 response element-directed transactivation. <b>1995</b> , 69, 1851-9	185
751	Human papillomavirus type 11 and 16 E5 represses p21 (Waf1/Sdi1/Cip1) gene expression in fibroblasts and keratinocytes. <b>1996</b> , 70, 7535-9	51
750	Epstein-Barr virus latent membrane protein 1 blocks p53-mediated apoptosis through the induction of the A20 gene. <b>1996</b> , 70, 8653-9	198
749	Human cytomegalovirus mtrII oncoprotein binds to p53 and down-regulates p53-activated transcription. <b>1996</b> , 70, 8691-700	36
748	In vivo assay of p53 function in homologous recombination between simian virus 40 chromosomes. <b>1996</b> , 70, 737-44	63
747	Alteration of cell cycle kinase complexes in human papillomavirus E6- and E7-expressing fibroblasts precedes neoplastic transformation. <b>1996</b> , 70, 999-1008	62
746	The latency-related gene of bovine herpesvirus 1 encodes a product which inhibits cell cycle progression. <b>1996</b> , 70, 3807-14	73
745	High-risk human papillomavirus E6 protein has two distinct binding sites within p53, of which only one determines degradation. <b>1996</b> , 70, 4509-16	144
744	Epstein-Barr virus nuclear antigen 2 and latent membrane protein independently transactivate p53 through induction of NF-kappaB activity. <b>1996</b> , 70, 4849-53	51
743	A cooperative interaction of human T-cell leukemia virus type 1 Tax with the p21 cyclin-dependent kinase inhibitor activates the human immunodeficiency virus type 1 enhancer. <b>1996</b> , 70, 5731-4	16
742	Cellular aging is a critical determinant of primary cell resistance to v-src transformation. <b>1997</b> , 71, 237-47	8
741	Antioxidant-induced changes of the AP-1 transcription complex are paralleled by a selective suppression of human papillomavirus transcription. <b>1997</b> , 71, 362-70	79
740	Mutation of Tp53 contributes to the malignant phenotype of Abelson virus-transformed lymphoid cells. <b>1997</b> , 71, 8149-56	29
739	The ORF3 protein of hepatitis E virus is a phosphoprotein that associates with the cytoskeleton. <b>1997</b> , 71, 9045-53	197
738	Analysis of the p53-mediated G1 growth arrest pathway in cells expressing the human papillomavirus type 16 E7 oncoprotein. <b>1997</b> , 71, 2905-12	139
737	p300 binding by E1A cosegregates with p53 induction but is dispensable for apoptosis. <b>1997</b> , 71, 3515-25	75
736	Regulation of p53-dependent apoptosis, transcriptional repression, and cell transformation by phosphorylation of the 55-kilodalton E1B protein of human adenovirus type 5. <b>1997</b> , 71, 3620-7	90
735	Perturbation of the p53 response by human papillomavirus type 16 E7. <b>1997</b> , 71, 3710-8	41

734	Initiation of DNA synthesis by human papillomavirus E7 oncoproteins is resistant to p21-mediated inhibition of cyclin E-cdk2 activity. <b>1997</b> , 71, 5570-8	53
733	Simian virus 40 T antigen can regulate p53-mediated transcription independent of binding p53. <b>1997</b> , 71, 5620-3	22
732	Human cytomegalovirus IE2 86-kilodalton protein binds p53 but does not abrogate G1 checkpoint function. <b>1997</b> , 71, 5861-70	68
731	Infection of primary cells by adeno-associated virus type 2 results in a modulation of cell cycle-regulating proteins. <b>1997</b> , 71, 6020-7	50
730	Adenovirus type 12 early region 1B 54K protein significantly extends the life span of normal mammalian cells in culture. <b>1997</b> , 71, 6629-40	21
729	p53 status does not determine outcome of E1B 55-kilodalton mutant adenovirus lytic infection. <b>1998</b> , 72, 9479-90	215
728	Human papillomavirus oncoproteins E6 and E7 independently abrogate the mitotic spindle checkpoint. <b>1998</b> , 72, 1131-7	115
727	p53 and RPA are sequestered in viral replication centers in the nuclei of cells infected with human cytomegalovirus. <b>1998</b> , 72, 2033-9	103
726	Expression of the pRb-binding regions of E1A enables efficient transformation of primary epithelial cells by v-src. <b>1998</b> , 72, 2815-24	4
725	Adenovirus E1B 55K represses p53 activation in vitro. <b>1998</b> , 72, 3146-54	119
724	Evidence of a role for phosphatidylinositol 3-kinase activation in the blocking of apoptosis by polyomavirus middle T antigen. <b>1998</b> , 72, 3221-6	51
723	Perturbation of cell cycle progression and cellular gene expression as a function of herpes simplex virus ICP0. <b>1999</b> , 73, 8245-55	164
722	Overexpression of cyclin A inhibits augmentation of recombinant adeno-associated virus transduction by the adenovirus E4orf6 protein. <b>1999</b> , 73, 10010-9	21
721	The simian virus 40 small-t and large-T antigens jointly regulate cell cycle reentry in human fibroblasts. <b>1999</b> , 73, 3102-7	43
720	Activation of caspases and p53 by bovine herpesvirus 1 infection results in programmed cell death and efficient virus release. <b>1999</b> , 73, 3778-88	97
719	Adenovirus-mediated p21((WAF1/SDI1/CIP1)) gene transfer induces apoptosis of human cervical cancer cell lines. <b>1999</b> , 73, 4983-90	86
718	The Epstein-Barr virus protein BRLF1 activates S phase entry through E2F1 induction. <b>1999</b> , 73, 6540-50	48
717	Simian virus 40 large T antigen J domain and Rb-binding motif are sufficient to block apoptosis induced by growth factor withdrawal in a neural stem cell line. <b>1999</b> , 73, 6791-9	30

7 <sup>16</sup>	The E7 oncoprotein of human papillomavirus type 16 stabilizes p53 through a mechanism independent of p19(ARF). <b>1999</b> , 73, 7590-8	50
7 <sup>15</sup>	Middle T antigen activation of signal transduction pathways does not overcome p53-mediated growth arrest. <b>1999</b> , 73, 7882-5	3
7 <sup>14</sup>	Hot-spot p53 mutants interact specifically with two cellular proteins during progression of the cell cycle. <b>1994</b> , 14, 6764-6772	8
7 <sup>13</sup>	Transactivation of the human p53 tumor suppressor gene by c-Myc/Max contributes to elevated mutant p53 expression in some tumors. <b>1994</b> , 14, 7805-7815	35
7 <sup>12</sup>	Mouse p53 represses the rat brain creatine kinase gene but activates the rat muscle creatine kinase gene. <b>1994</b> , 14, 8483-8492	18
7 <sup>11</sup>	Regulation of cyclin D-dependent kinase 4 (cdk4) by cdk4-activating kinase. <b>1994</b> , 14, 2713-2721	103
7 <sup>10</sup>	An inhibitor of yeast cyclin-dependent protein kinase plays an important role in ensuring the genomic integrity of daughter cells. <b>1994</b> , 14, 3320-3328	71
7 <sup>09</sup>	A novel inhibitor of cyclin-Cdk activity detected in transforming growth factor beta-arrested epithelial cells. <b>1994</b> , 14, 3683-3694	98
7 <sup>08</sup>	Inactivation of a Cdk2 inhibitor during interleukin 2-induced proliferation of human T lymphocytes. <b>1994</b> , 14, 4889-4901	103
7 <sup>07</sup>	p53 domains: structure, oligomerization, and transformation. <b>1994</b> , 14, 5182-5191	55
7 <sup>06</sup>	Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. <b>1994</b> , 14, 6264-6277	181
7 <sup>05</sup>	Protein-protein interactions: methods for detection and analysis. <b>1995</b> , 59, 94-123	628
7 <sup>04</sup>	p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer. <b>2001</b> , 54, 866-70	28
7 <sup>03</sup>	Patterns of p21(waf1/cip1) expression in non-papillomatous nasal mucosa, endophytic sinonasal papillomas, and associated carcinomas. <b>2001</b> , 54, 871-6	16
7 <sup>02</sup>	Molecular pathogenesis of oral squamous carcinoma. <b>2000</b> , 53, 165-72	143
7 <sup>01</sup>	Phenoxodiol, a novel isoflavone, induces G1 arrest by specific loss in cyclin-dependent kinase 2 activity by p53-independent induction of p21WAF1/CIP1. <b>2005</b> , 65, 3364-73	54
7 <sup>00</sup>	Cellular radiosensitivity, radioresistant DNA synthesis, and defect in radioinduction of p53 in fibroblasts from atherosclerosis patients. <b>1997</b> , 17, 947-53	9
699	Diabetic LDL inhibits cell-cycle progression via STAT5B and p21waf. <b>2002</b> , 109, 111-119	19



698	A role for p53 in terminal epithelial cell differentiation. <b>2002</b> , 109, 1021-1030	33
697	Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. <b>2002</b> , 110, 1717-1727	53
696	CTS1: a p53-derived chimeric tumor suppressor gene with enhanced in vitro apoptotic properties. <b>1998</b> , 101, 120-7	26
695	Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. <b>2001</b> , 108, 1321-30	77
694	Posttranscriptional stabilization underlies p53-independent induction of p21WAF1/CIP1/SDI1 in differentiating human leukemic cells. <b>1995</b> , 95, 973-9	103
693	Disappearance of cyclin A correlates with permanent withdrawal of cardiomyocytes from the cell cycle in human and rat hearts. <b>1995</b> , 95, 2275-80	84
692	p53-dependent ceramide response to genotoxic stress. <b>1998</b> , 102, 329-39	132
691	Phorbol esters induce death in MCF-7 breast cancer cells with altered expression of protein kinase C isoforms. Role for p53-independent induction of gadd-45 in initiating death. <b>1995</b> , 96, 1874-86	59
690	Adenovirus-mediated over-expression of the cyclin/cyclin-dependent kinase inhibitor, p21 inhibits vascular smooth muscle cell proliferation and neointima formation in the rat carotid artery model of balloon angioplasty. <b>1995</b> , 96, 2260-8	283
689	Expression of p21(WAF1/CIP1/SDI1) and p53 in apoptotic cells in the adrenal cortex and induction by ischemia/reperfusion injury. <b>1996</b> , 97, 1723-31	46
688	Tumor suppression and inhibition of aneuploid cell accumulation in human brain tumor cells by ectopic overexpression of the cyclin-dependent kinase inhibitor p27KIP1. <b>1996</b> , 97, 1983-8	48
687	Suppression of p53 activity and p21WAF1/CIP1 expression by vascular cell integrin alphaVbeta3 during angiogenesis. <b>1996</b> , 98, 426-33	297
686	Lonidamine induces apoptosis in drug-resistant cells independently of the p53 gene. <b>1996</b> , 98, 1165-73	40
685	Drug-induced apoptosis in hepatoma cells is mediated by the CD95 (APO-1/Fas) receptor/ligand system and involves activation of wild-type p53. <b>1997</b> , 99, 403-13	559
684	p53 and the hypoxia-induced apoptosis of cultured neonatal rat cardiac myocytes. <b>1997</b> , 99, 2635-43	236
683	Ectopic expression of decorin protein core causes a generalized growth suppression in neoplastic cells of various histogenetic origin and requires endogenous p21, an inhibitor of cyclin-dependent kinases. <b>1997</b> , 100, 149-57	169
682	CDKN2B upregulation prevents teratoma formation in multipotent fibromodulin-reprogrammed cells. <b>2019</b> , 129, 3236-3251	10
681	A role for p53 in terminal epithelial cell differentiation. <b>2002</b> , 109, 1021-30	25

680	Induction of p21WAF1/CIP1/SDI1 in kidney tubule cells affects the course of cisplatin-induced acute renal failure. <b>1998</b> , 101, 777-82	220
679	DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. <b>2003</b> , 111, 877-85	48
678	Induction of the Cdk inhibitor p21 by LY83583 inhibits tumor cell proliferation in a p53-independent manner. <b>2002</b> , 110, 1717-27	27
677	Histone deacetylase inhibitors induce remission in transgenic models of therapy-resistant acute promyelocytic leukemia. <b>2001</b> , 108, 1321-1330	224
676	DNA damage is a novel response to sublytic complement C5b-9-induced injury in podocytes. <b>2003</b> , 111, 877-885	101
675	p21Cip1 modulates arterial wound repair through the stromal cell-derived factor-1/CXCR4 axis in mice. <b>2008</b> , 118, 2050-61	48
674	Proliferation of human HCC cells and chemically induced mouse liver cancers requires JNK1-dependent p21 downregulation. <b>2008</b> , 118, 3943-53	247
673	Mammalian target of rapamycin regulates murine and human cell differentiation through STAT3/p63/Jagged/Notch cascade. <b>2010</b> , 120, 103-14	177
672	HIV-1 Rev-binding protein accelerates cellular uptake of iron to drive Notch-induced T cell leukemogenesis in mice. <b>2010</b> , 120, 2537-48	13
671	Enigma negatively regulates p53 through MDM2 and promotes tumor cell survival in mice. <b>2010</b> , 120, 4493-506	36
670	Overexpressed cyclin D3 contributes to retaining the growth inhibitor p27 in the cytoplasm of thyroid tumor cells. <b>1999</b> , 104, 865-74	99
669	Regulation of smooth muscle cell migration and integrin expression by the Gax transcription factor. <b>1999</b> , 104, 1469-80	67
668	Decorin suppresses tumor cell growth by activating the epidermal growth factor receptor. <b>1998</b> , 101, 406-12	226
667	Pretreatment with DNA-damaging agents permits selective killing of checkpoint-deficient cells by microtubule-active drugs. <b>2000</b> , 105, 533-9	80
666	Deletions and Loss of Expression of P16INK4a and P21Waf1 Genes Are Associated With Aggressive Variants of Mantle Cell Lymphomas. <b>1997</b> , 89, 272-280	9
665	Thrombopoietin Upregulates the Promoter Conformation of p53 in a Proliferation-Independent Manner Coincident With a Decreased Expression of Bax: Potential Mechanisms for Survival Enhancing Effects. <b>1997</b> , 90, 4394-4402	1
664	Upregulation of the Elongation Factor-1 Gene by p53 in Association With Death of an Erythroleukemic Cell Line. <b>1997</b> , 90, 1373-1378	2
663	Combined Arsenic and Retinoic Acid Treatment Enhances Differentiation and Apoptosis in Arsenic-Resistant NB4 Cells. <b>1998</b> , 91, 4300-4310	17

662	Regulation of p21(WAF1) Expression During Normal Myeloid Differentiation. <b>1998</b> , 91, 4531-4542	7
661	p21cip-1/waf-1 Deficiency Causes Deformed Nuclear Architecture, Centriole Overduplication, Polyploidy, and Relaxed Microtubule Damage Checkpoints in Human Hematopoietic Cells. <b>1999</b> , 93, 1390-1398 <sup>11</sup>	
660	1,25-Dihydroxyvitamin D3 Induces Differentiation of a Retinoic Acid-Resistant Acute Promyelocytic Leukemia Cell Line (UF-1) Associated With Expression of p21WAF1/CIP1 and p27KIP1. <b>1999</b> , 93, 2225-2233	5
659	Induced Differentiation of U937 Cells by 1,25-dihydroxyvitamin D3 Involves Cell Cycle Arrest in G1 That Is Preceded by a Transient Proliferative Burst and an Increase in Cyclin Expression. <b>1999</b> , 93, 2721-2729	2
658	Subcellular and Cell-Cycle Expression Profiles of CDK-Inhibitors in Normal Differentiating Myeloid Cells. <b>1999</b> , 93, 2907-2917	12
657	Anomalous High p27/KIP1 Expression in a Subset of Aggressive B-Cell Lymphomas Is Associated With Cyclin D3 Overexpression. p27/KIP1-Cyclin D3 Colocalization in Tumor Cells. <b>1999</b> , 94, 765-772	2
656	The Potential of Iron Chelators of the Pyridoxal Isonicotinoyl Hydrazone Class as Effective Antiproliferative Agents III: The Effect of the Ligands on Molecular Targets Involved in Proliferation. <b>1999</b> , 94, 781-792	2
655	Retinoic Acid Prevents Phosphorylation of pRB in Normal Human B Lymphocytes: Regulation of Cyclin E, Cyclin A, and p21Cip1. <b>1999</b> , 94, 1348-1358	2
654	Frequent Methylation Silencing of p15INK4b(MTS2) and p16INK4a (MTS1) in B-Cell and T-Cell Lymphomas. <b>1999</b> , 94, 1773-1781	8
653	SCF and G-CSF lead to the synergistic induction of proliferation and gene expression through complementary signaling pathways. <b>2000</b> , 96, 3422-3430	4
652	Stable expression of Epstein-Barr virus BZLF-1-encoded ZEBRA protein activates p53-dependent transcription in human Jurkat T-lymphoblastoid cells. <b>2000</b> , 96, 625-634	10
651	Bcr-Abl kinase down-regulates cyclin-dependent kinase inhibitor p27 in human and murine cell lines. <b>2000</b> , 96, 1933-1939	9
650	Exploring the multiple roles of guardian of the genome: P53. <b>2020</b> , 21,	16
649	Carbon Monoxide and Vascular Smooth Muscle Cell Growth. <b>2001</b> , 45-65	2
648	p21WAF1 mutation is not a predominant alteration in pediatric bone tumors. <b>1998</b> , 43, 393-5	12
647	Ectopic expression of activated Ras1 induces hyperplastic growth and increased cell death in Drosophila imaginal tissues. <b>1998</b> , 125, 1-9	220
646	Analysis of the early embryonic cell cycles of Xenopus; regulation of cell cycle length by Xe-wee1 and Mos. <b>1998</b> , 125, 237-248	72
645	Interaction of cdc2 and rum1 regulates Start and S-phase in fission yeast. <b>1995</b> , 108, 3285-3294	24

644	In vitro p53 and/or Rb antisense oligonucleotide treatment in association with growth factors induces the proliferation of peripheral hematopoietic progenitors. <b>1995</b> , 108, 1287-1293	7
643	Coupling between gamma irradiation, p53 induction and the apoptotic response depends upon cell type in vivo. <b>1995</b> , 108, 1843-1848	160
642	Accelerated neuronal differentiation induced by p53 suppression. <b>1996</b> , 109, 1509-1516	44
641	Cells from ERCC1-deficient mice show increased genome instability and a reduced frequency of S-phase-dependent illegitimate chromosome exchange but a normal frequency of homologous recombination. <b>1998</b> , 111, 395-404	60
640	Activation of p53-mediated cell cycle checkpoint in response to micronuclei formation. <b>1998</b> , 111, 977-984	42
639	Prolonged arrest of mammalian cells at the G1/S boundary results in permanent S phase stasis. <b>2002</b> , 115, 2829-2838	62
638	Selective impairment of p53-mediated cell death in fibroblasts from sporadic Alzheimer's disease patients. <b>2002</b> , 115, 3131-3138	56
637	Low-energy laser irradiation promotes the survival and cell cycle entry of skeletal muscle satellite cells. <b>2002</b> , 115, 1461-1469	128
636	Five miRNAs Considered as Molecular Targets for Predicting Esophageal Cancer. <b>2015</b> , 21, 3222-30	18
635	Systems analysis of the prostate tumor suppressor NKX3.1 supports roles in DNA repair and luminal cell differentiation. <b>2014</b> , 3, 115	9
634	Constitutive activation of proto-oncogen protein p21 induces cell cycle arrest in the G1 phase in contact-inhibited vascular endothelial cells. <b>2002</b> , 25, 773-8	9
633	Cyclin-dependent kinase inhibitor, p21Waf1, regulates vascular smooth muscle cell hypertrophy. <b>2004</b> , 27, 283-91	13
632	Feedbacks, Bifurcations, and Cell Fate Decision-Making in the p53 System. <b>2016</b> , 12, e1004787	33
631	Inhibition of the de novo pyrimidine biosynthesis pathway limits ribosomal RNA transcription causing nucleolar stress in glioblastoma cells. <b>2020</b> , 16, e1009117	4
630	The LIM-only protein FHL2 mediates ras-induced transformation through cyclin D1 and p53 pathways. <b>2008</b> , 3, e3761	8
629	A large scale shRNA barcode screen identifies the circadian clock component ARNTL as putative regulator of the p53 tumor suppressor pathway. <b>2009</b> , 4, e4798	103
628	p300 alters keratinocyte cell growth and differentiation through regulation of p21(Waf1/CIP1). <b>2010</b> , 5, e8369	31
627	In vivo identification of solar radiation-responsive gene network: role of the p38 stress-dependent kinase. <b>2010</b> , 5, e10776	13

626	Gene profiling of MTA1 identifies novel gene targets and functions. <b>2011</b> , 6, e17135	28
625	Reverse transcriptase-coupled quantitative real time PCR analysis of cell-free transcription on the chromatin-assembled p21 promoter. <b>2011</b> , 6, e23617	5
624	Chemotherapeutic sensitization of leptomycin B resistant lung cancer cells by pretreatment with doxorubicin. <b>2012</b> , 7, e32895	26
623	Cadmium induces p53-dependent apoptosis in human prostate epithelial cells. <b>2012</b> , 7, e33647	60
622	JKA97, a novel benzylidene analog of harmine, exerts anti-cancer effects by inducing G1 arrest, apoptosis, and p53-independent up-regulation of p21. <b>2012</b> , 7, e34303	30
621	Down-regulation of MiR-127 facilitates hepatocyte proliferation during rat liver regeneration. <b>2012</b> , 7, e39151	54
620	Cell cycle regulation by the PRMT6 arginine methyltransferase through repression of cyclin-dependent kinase inhibitors. <b>2012</b> , 7, e41446	45
619	p53 acts as a co-repressor to regulate keratin 14 expression during epidermal cell differentiation. <b>2012</b> , 7, e41742	20
618	p53 inactivation upregulates p73 expression through E2F-1 mediated transcription. <b>2012</b> , 7, e43564	27
617	Vapor of volatile oils from Litsea cubeba seed induces apoptosis and causes cell cycle arrest in lung cancer cells. <b>2012</b> , 7, e47014	34
616	Histone demethylase Jumonji D3 (JMJD3) as a tumor suppressor by regulating p53 protein nuclear stabilization. <b>2012</b> , 7, e51407	80
615	Global effect of inauhzin on human p53-responsive transcriptome. <b>2012</b> , 7, e52172	16
614	Two 4N cell-cycle arrests contribute to cisplatin-resistance. <b>2013</b> , 8, e59848	18
613	PUMA Cooperates with p21 to Regulate Mammary Epithelial Morphogenesis and Epithelial-To-Mesenchymal Transition. <b>2013</b> , 8, e66464	17
612	CD44 expression in intestinal epithelium and colorectal cancer is independent of p53 status. <b>2013</b> , 8, e72849	15
611	Stress-induced alternative splice forms of MDM2 and MDMX modulate the p53-pathway in distinct ways. <b>2014</b> , 9, e104444	15
610	miR-34 and p53: New Insights into a Complex Functional Relationship. <b>2015</b> , 10, e0132767	113
609	A Novel Interaction between FLICE-Associated Huge Protein (FLASH) and E2A Regulates Cell Proliferation and Cellular Senescence via Tumor Necrosis Factor (TNF)-Alpha-p21WAF1/CIP1 Axis. <b>2015</b> , 10, e0133205	7

608	Monitoring the Activation of the DNA Damage Response Pathway in a 3D Spheroid Model. <b>2015</b> , 10, e0134411	5
607	Negative Regulation of p21Waf1/Cip1 by Human INO80 Chromatin Remodeling Complex Is Implicated in Cell Cycle Phase G2/M Arrest and Abnormal Chromosome Stability. <b>2015</b> , 10, e0137411	11
606	TESTIN Induces Rapid Death and Suppresses Proliferation in Childhood B Acute Lymphoblastic Leukaemia Cells. <b>2016</b> , 11, e0151341	9
605	Internal Tandem Duplication in FLT3 Attenuates Proliferation and Regulates Resistance to the FLT3 Inhibitor AC220 by Modulating p21Cdkn1a and Pbx1 in Hematopoietic Cells. <b>2016</b> , 11, e0158290	7
604	miR-24-3p Suppresses Malignant Behavior of Lacrimal Adenoid Cystic Carcinoma by Targeting PRKCH to Regulate p53/p21 Pathway. <b>2016</b> , 11, e0158433	14
603	SOX14 activates the p53 signaling pathway and induces apoptosis in a cervical carcinoma cell line. <b>2017</b> , 12, e0184686	11
602	Tumor suppressor protein p53-mediated repression of human mitotic centromere-associated kinesin gene expression is exerted via down-regulation of Sp1 level. <b>2017</b> , 12, e0189698	5
601	Flow cytometric analysis identifies changes in S and M phases as novel cell cycle alterations induced by the splicing inhibitor isoginkgetin. <b>2018</b> , 13, e0191178	15
600	p53 promotes ZDHHC1-mediated IFITM3 palmitoylation to inhibit Japanese encephalitis virus replication. <b>2020</b> , 16, e1009035	3
599	Overexpression of heat shock protein 70 restores the structural stability and functional defects of temperature-sensitive mutant of large T antigen at nonpermissive temperature. <b>2006</b> , 11, 259-67	4
598	Tumor suppression by p53: making cells senescent. <b>2010</b> , 25, 515-26	50
597	Lack of correlation between DNA strand breakage and p53 protein levels in human fibroblast strains exposed to ultraviolet lights. <b>2000</b> , 72, 562-8	3
596	Molecular aspects of esophageal squamous cell carcinoma carcinogenesis. <b>2003</b> , 40, 256-61	48
595	Prevalence of p21 immunohistochemical expression in esophageal adenocarcinoma. <b>2006</b> , 43, 212-8	3
594	Adenocarcinoma of the esophagogastric junction: relationship between clinicopathological data and p53, cyclin D1 and Bcl-2 immunoexpressions. <b>2009</b> , 46, 315-20	4
593	Marcadores tumorais no c�ncer de pulm�o: um caminho para a terapia biol�gica. <b>2002</b> , 28, 143-149	1
592	Role of the increase in p21 in cisplatin-induced acute renal failure in rats. <b>2001</b> , 12, 900-908	69
591	Influences of TP53 and the anti-aging DDR1 receptor in controlling Raf/MEK/ERK and PI3K/Akt expression and chemotherapeutic drug sensitivity in prostate cancer cell lines. <b>2020</b> , 12, 10194-10210	11

590	Long non-coding RNA NEAT1 promotes non-small cell lung cancer progression through regulation of miR-377-3p-E2F3 pathway. <b>2016</b> , 7, 51784-51814	233
589	Timing of transcription during the cell cycle: Protein complexes binding to E2F, E2F/CLE, CDE/CHR, or CHR promoter elements define early and late cell cycle gene expression. <b>2017</b> , 8, 97736-97748	30
588	Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes. <b>2016</b> , 7, 74846-74859	13
587	Decreased DACH1 expression in glomerulopathy is associated with disease progression and severity. <b>2016</b> , 7, 86547-86560	14
586	SMYD2 lysine methyltransferase regulates leukemia cell growth and regeneration after genotoxic stress. <b>2017</b> , 8, 16712-16727	13
585	Anti-cancer effect of novel PAK1 inhibitor via induction of PUMA-mediated cell death and p21-mediated cell cycle arrest. <b>2017</b> , 8, 23690-23701	10
584	Dependence of p53-deficient cells on the DHX9 DExH-box helicase. <b>2017</b> , 8, 30908-30921	4
583	RECQ1 expression is upregulated in response to DNA damage and in a p53-dependent manner. <b>2017</b> , 8, 75924-75942	8
582	Novel Insights into the Molecular Mechanisms Governing Mdm2 Ubiquitination and Destruction. <b>2010</b> , 1, 685-690	35
581	Identification of kinase inhibitors that target transcription initiation by RNA polymerase II. <b>2011</b> , 2, 18-28	7
580	Klf4 reduces stemness phenotype, triggers mesenchymal-epithelial transition (MET)-like molecular changes, and prevents tumor progression in nasopharyngeal carcinoma. <b>2017</b> , 8, 93924-93941	15
579	Overexpression of HMGB1 in melanoma predicts patient survival and suppression of HMGB1 induces cell cycle arrest and senescence in association with p21 (Waf1/Cip1) up-regulation via a p53-independent, Sp1-dependent pathway. <b>2014</b> , 5, 6387-403	42
578	knock-down in enteric precursors reveals a possible mechanism by which this methyltransferase is involved in the enteric nervous system development and the onset of Hirschsprung disease. <b>2017</b> , 8, 106443-106453	6
577	Array-based genome-wide RNAi screening to identify shRNAs that enhance p53-related apoptosis in human cancer cells. <b>2014</b> , 5, 7540-8	6
576	Potential therapeutic targets of gene in the context of its classically canonical functions and its latest non-canonical functions in human cancer. <b>2018</b> , 9, 16234-16247	15
575	MicroRNA-652 induces NED in LNCaP and EMT in PC3 prostate cancer cells. <b>2018</b> , 9, 19159-19176	19
574	Expression profile and functional role of S100A14 in human cancer. <b>2019</b> , 10, 2996-3012	10
573	The predictive capability of immunohistochemistry and DNA sequencing for determining functional mutation status: a comparative study of 41 glioblastoma patients. <b>2019</b> , 10, 6204-6218	7

572	Protein phosphatase 1 regulatory subunit 1A regulates cell cycle progression in Ewing sarcoma. <b>2020</b> , 11, 1691-1704	1
571	TAF15 contributes to the radiation-inducible stress response in cancer. <b>2020</b> , 11, 2647-2659	2
570	Loss of p21Cip1/CDKN1A renders cancer cells susceptible to Polo-like kinase 1 inhibition. <b>2015</b> , 6, 6611-26	25
569	Simplify p53: just an activator. <b>2015</b> , 6, 3-4	5
568	p53 activates G <sub>2</sub> M checkpoint following DNA damage by doxorubicin during transient mitotic arrest. <b>2015</b> , 6, 4804-15	17
567	DNA-PKCS binding to p53 on the p21WAF1/CIP1 promoter blocks transcription resulting in cell death. <b>2011</b> , 2, 1094-108	39
566	By recruiting HDAC1, MORC2 suppresses p21 Waf1/Cip1 in gastric cancer. <b>2015</b> , 6, 16461-70	28
565	Ataxia-telangiectasia mutated (ATM) silencing promotes neuroblastoma progression through a MYCN independent mechanism. <b>2015</b> , 6, 18558-76	22
564	Initiation and termination of DNA replication during S phase in relation to cyclins D1, E and A, p21WAF1, Cdt1 and the p12 subunit of DNA polymerase $\delta$ revealed in individual cells by cytometry. <b>2015</b> , 6, 11735-50	47
563	Epigenetic inactivation of the candidate tumor suppressor gene ASC/TMS1 in human renal cell carcinoma and its role as a potential therapeutic target. <b>2015</b> , 6, 22706-23	20
562	P73 tumor suppressor and its targets, p21 and PUMA, are required for madin-darby canine kidney cell morphogenesis by maintaining an appropriate level of epithelial to mesenchymal transition. <b>2015</b> , 6, 13994-4004	8
561	Differential targeting of the cyclin-dependent kinase inhibitor, p21CIP1/WAF1, by chelators with anti-proliferative activity in a range of tumor cell-types. <b>2015</b> , 6, 29694-711	12
560	PRMT6 increases cytoplasmic localization of p21CDKN1A in cancer cells through arginine methylation and makes more resistant to cytotoxic agents. <b>2015</b> , 6, 30957-67	27
559	CGK733-induced LC3 II formation is positively associated with the expression of cyclin-dependent kinase inhibitor p21Waf1/Cip1 through modulation of the AMPK and PERK/CHOP signaling pathways. <b>2015</b> , 6, 39692-701	7
558	Mdm2 inhibition confers protection of p53-proficient cells from the cytotoxic effects of Wee1 inhibitors. <b>2015</b> , 6, 32339-52	8
557	Indirect p53-dependent transcriptional repression of Survivin, CDC25C, and PLK1 genes requires the cyclin-dependent kinase inhibitor p21/CDKN1A and CDE/CHR promoter sites binding the DREAM complex. <b>2015</b> , 6, 41402-17	37
556	Human T-cell leukemia virus type-1-encoded protein HBZ represses p53 function by inhibiting the acetyltransferase activity of p300/CBP and HBO1. <b>2016</b> , 7, 1687-706	31
555	Carnitine palmitoyltransferase 1A functions to repress FoxO transcription factors to allow cell cycle progression in ovarian cancer. <b>2016</b> , 7, 3832-46	58



554	Hsa-miR-326 targets CCND1 and inhibits non-small cell lung cancer development. <b>2016</b> , 7, 8341-59	99
553	NRF2 and p53: Januses in cancer?. <b>2012</b> , 3, 1272-83	74
552	Hsa-miR-134 suppresses non-small cell lung cancer (NSCLC) development through down-regulation of CCND1. <b>2016</b> , 7, 35960-35978	79
551	Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor. <b>2016</b> , 7, 27511-26	22
550	Notch1 pathway-mediated microRNA-151-5p promotes gastric cancer progression. <b>2016</b> , 7, 38036-38051	33
549	Down regulation of Chk1 by p53 plays a role in synergistic induction of apoptosis by chemotherapeutics and inhibitors for Jak2 or BCR/ABL in hematopoietic cells. <b>2016</b> , 7, 44448-44461	6
548	Hsa-miR-875-5p exerts tumor suppressor function through down-regulation of EGFR in colorectal carcinoma (CRC). <b>2016</b> , 7, 42225-42240	21
547	The IGF-1R/AKT pathway determines cell fate in response to p53. <b>2016</b> , 5, 664-675	17
546	Epigenetic Metalloenzymes. <b>2019</b> , 26, 2748-2785	7
545	The p53-estrogen receptor loop in cancer. <b>2013</b> , 13, 1229-40	50
544	Role of Unani Medicines in Cancer Control and Management. <b>2019</b> , 14, 92-113	6
543	Role of crocin in several cancer cell lines: An updated review. <b>2020</b> , 23, 3-12	10
542	Effects of 8-hydroxyquinoline-coated graphene oxide on cell death and apoptosis in MCF-7 and MCF-10 breast cell lines. <b>2020</b> , 23, 871-878	4
541	Role of p16(INK4a) in the inhibition of DNA synthesis stimulated by HGF or EGF in primary cultured rat hepatocytes. <b>2013</b> , 34, 269-73	3
540	d-amino acid oxidase promotes cellular senescence via the production of reactive oxygen species. <b>2019</b> , 2,	10
539	Cellular Senescence and Its Effects on Carcinogenesis. <b>2008</b> , 175-193	1
538	A Review on Dietary Intervention in Obesity Associated Colon Cancer. <b>2019</b> , 20, 1309-1319	12
537	Abdominal Irradiation Ameliorates Obesity in ob/ob Mice. <b>2007</b> , 40, 123-30	9

536	Stress-induced Cellular Senescence Contributes to Chronic Inflammation and Cancer Progression. <b>2019</b> , 35, 41-58	3
535	The combination of TRAIL treatment and cancer cell selective expression of TRAIL-death receptor DR4 induces cell death in TRAIL-resistant cancer cells. <b>2006</b> , 47, 55-62	1
534	E1AF Induces Both Matrix Metalloprotease Transcription and Cell Cycle Arrest that Occurs in the Stage of Cancer Cell Invasion. <b>2004</b> , 9, 19-24	1
533	Transcriptomic classification of antitumor agents: application to the analysis of the antitumoral effect of SR31747A. <b>2003</b> , 11, 125-39	4
532	Effects of Radix notoginseng extracts drug-containing serum on expressions of bcl-2, Bax and p21WAF1 proteins in MNNG transformed GES-1 cells. <b>2008</b> , 6, 817-20	3
531	Differentially expressed genes between solitary large hepatocellular carcinoma and nodular hepatocellular carcinoma. <b>2004</b> , 10, 3569-73	35
530	Expression of p21(WAF1) and p53 and polymorphism of p21(WAF1) gene in gastric carcinoma. <b>2004</b> , 10, 1125-31	19
529	p53 negativity, CDC25B positivity, and metallothionein negativity are predictors of a response of esophageal squamous cell carcinoma to chemoradiotherapy. <b>2005</b> , 11, 5696-700	21
528	Regulation of apoptosis by the papillomavirus E6 oncogene. <b>2005</b> , 11, 931-7	24
527	Selective inhibition of cell growth by activin in SNU-16 cells. <b>2006</b> , 12, 3000-5	5
526	Differential effects on apoptosis induction in hepatocyte lines by stable expression of hepatitis B virus X protein. <b>2006</b> , 12, 4673-82	8
525	Expression patterns of cytokine, growth factor and cell cycle-related genes after partial hepatectomy in rats with thioacetamide-induced cirrhosis. <b>2006</b> , 12, 1063	3
524	Expression patterns of cytokine, growth factor and cell cycle-related genes after partial hepatectomy in rats with thioacetamide-induced cirrhosis. <b>2006</b> , 12, 1063-70	7
523	Mechanism of apoptotic effects induced selectively by ursodeoxycholic acid on human hepatoma cell lines. <b>2007</b> , 13, 1652-8	25
522	Genetic alterations in pancreatic cancer. <b>2007</b> , 13, 4423-30	27
521	Survey of molecular profiling during human colon cancer development and progression by immunohistochemical staining on tissue microarray. <b>2007</b> , 13, 699-708	31
520	Association of p53/p21 expression with cigarette smoking and prognosis in esophageal squamous cell carcinoma patients. <b>2010</b> , 16, 4958-67	37
519	Apoptotic pathway induced by diallyl trisulfide in pancreatic cancer cells. <b>2014</b> , 20, 193-203	36

518	Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy. <b>2015</b> , 21, 12150-6	28
517	Overexpression of p27(KIP1) induced cell cycle arrest in G(1) phase and subsequent apoptosis in HCC-9204 cell line. <b>2000</b> , 6, 513-521	19
516	Effects of histone acetylation and DNA methylation on p21( WAF1) regulation. <b>2002</b> , 8, 400-5	79
515	Relationship between the expression of human telomerase reverse transcriptase gene and cell cycle regulators in gastric cancer and its significance. <b>2003</b> , 9, 427-31	13
514	S-phase delay in human hepatocellular carcinoma cells induced by overexpression of integrin beta1. <b>2003</b> , 9, 1689-96	11
513	Cell Cycle Inhibition of Ethylacetate Fraction of . Fruit against T47D Cells. <b>2019</b> , 7, 726-729	4
512	CacyBP/SIP promotes tumor progression by regulating apoptosis and arresting the cell cycle in osteosarcoma. <b>2020</b> , 20, 1397-1404	3
511	IGF-1 induces cellular senescence in rat articular chondrocytes via Akt pathway activation. <b>2020</b> , 20, 49	4
510	Ubiquitination of P53 by E3 ligase MKRN2 promotes melanoma cell proliferation. <b>2020</b> , 19, 1975-1984	6
509	Brother of regulator of imprinted sites inhibits cisplatin-induced DNA damage in non-small cell lung cancer. <b>2020</b> , 20, 251	3
508	Function of p21 and its therapeutic effects in esophageal cancer. <b>2021</b> , 21, 136	3
507	Prognostic significance of p21 and p53 expression in gastric cancer. <b>2003</b> , 18, 98-103	26
506	Epidemiological Trends of Cancer in Older Adults: Implications for Gerontological Nursing Practice and Research. <b>2002</b> , 27, 34-43	6
505	A Fermented Ginseng Extract, BST204, Inhibits Proliferation and Motility of Human Colon Cancer Cells. <b>2011</b> , 19, 211-217	12
504	p53 expression in pterygium in two climatic regions in Turkey. <b>2009</b> , 57, 203-6	7
503	Molecular concept in human oral cancer. <b>2015</b> , 6, 9-15	19
502	Clinical implications of cytosine deletion of exon 5 of P53 gene in non small cell lung cancer patients. <b>2016</b> , 5, 33-6	2
501	p53 prevents immature escaping from cell cycle G2 checkpoint arrest through inhibiting cdk2-dependent NF-Y phosphorylation. <b>2006</b> , 38, 224-8	6

500	Genotypic characteristics of resistant tumors to pre-operative ionizing radiation in rectal cancer. <b>2014</b> , 6, 194-210	10
499	Multifaceted p21 in carcinogenesis, stemness of tumor and tumor therapy. <b>2020</b> , 12, 481-487	21
498	Deacetylase inhibitors - focus on non-histone targets and effects. <b>2010</b> , 1, 55-61	49
497	p53 in stem cells. <b>2011</b> , 2, 202-14	57
496	TGF-beta-dependent cell growth arrest and apoptosis. <b>2002</b> , 35, 47-53	38
495	Suppression of human prostate cancer cell growth by beta-lapachone via down-regulation of pRB phosphorylation and induction of Cdk inhibitor p21(WAF1/CIP1). <b>2003</b> , 36, 223-9	27
494	Activation of apoptotic protein in U937 cells by a component of turmeric oil. <b>2009</b> , 42, 96-100	26
493	THE SIGNIFICANCE OF KEY REGULATORS OF APOPTOSIS IN THE DEVELOPMENT AND PROGNOSIS OF PROSTATE CARCINOMA. I. PROTEINS OF THE BCL-2 FAMILY AND PROTEIN P53. <b>2003</b> , 147, 3-10	6
492	THE SIGNIFICANCE OF KEY REGULATORS OF APOPTOSIS IN THE DEVELOPMENT AND PROGNOSIS OF PROSTATE CARCINOMA. II. PRODUCTS OF SUPPRESSOR GENES RB AND PTEN, CDKI, FAS. <b>2003</b> , 147, 11-17	2
491	Molecular pathology and clinicopathologic features of penile tumors: with special reference to analyses of p21 and p53 expression and unusual histologic features. <b>1999</b> , 123, 895-904	25
490	Multiparameter immunohistochemical analysis of the cell cycle proteins cyclin D1, Ki-67, p21WAF1, p27KIP1, and p53 in mantle cell lymphoma. <b>2000</b> , 124, 1457-62	24
489	Aberrant expression of tumor suppressor proteins in the Ewing family of tumors. <b>2001</b> , 125, 1207-12	32
488	The Dual Role Played by p21 May Influence the Apoptotic or Anti-Apoptotic Fate in Cancer.	37
487	siRNA-mediated silencing of Notch-1 enhances docetaxel induced mitotic arrest and apoptosis in prostate cancer cells. <b>2012</b> , 13, 2485-9	22
486	Overexpression of Cyclin E and its Low Molecular Weight Isoforms Cooperate with Loss of p53 in Promoting Oncogenic Properties of MCF-7 Breast Cancer Cells. <b>2015</b> , 16, 7575-82	3
485	Global analysis of p53-regulated transcription identifies its direct targets and unexpected regulatory mechanisms. <b>2014</b> , 3, e02200	175
484	A distinct p53 target gene set predicts for response to the selective p53-HDM2 inhibitor NVP-CGM097. <b>2015</b> , 4,	57
483	Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance. <b>2020</b> , 9,	16

482	The effect of ribosomal protein S15a in lung adenocarcinoma. <b>2016</b> , 4, e1792	13
481	p53 isoforms differentially impact on the POL $\beta$ -dependent DNA damage tolerance pathway. <b>2021</b> , 12, 941	2
480	Novel chemotherapeutic agent FX-9 activates NF- $\kappa$ B signaling and induces G1 phase arrest by activating CDKN1A in a human prostate cancer cell line. <b>2021</b> , 21, 1088	
479	ACTL6A suppresses p21 tumor suppressor expression to maintain an aggressive mesothelioma cancer cell phenotype. <b>2021</b> , 10, 70	0
478	At a Crossroads to Cancer: How p53-Induced Cell Fate Decisions Secure Genome Integrity. <b>2021</b> , 22,	5
477	Recent Advances of WEE1 Inhibitors and Statins in Cancers With p53 Mutations. <b>2021</b> , 8, 737951	1
476	Non-Clinical In Vitro Evaluation of Antibiotic Resistance Gene-Free Plasmids Encoding Human or Murine IL-12 Intended for First-in-Human Clinical Study. <b>2021</b> , 13,	1
475	A Balancing Act: p53 Activity from Tumor Suppression to Pathology and Therapeutic Implications. <b>2021</b> ,	0
474	The Role of C-type Protein Kinases in Apoptosis. <b>2000</b> , 109-126	
473	THE GROWTH INHIBITORY EFFECT OF p21 ADENOVIRUS ON HUMAN BLADDER CANCER CELLS. <b>2000</b> , 1033	
472	Suppression of primary tumor growth and the progression to metastasis with p53 adenovirus in human prostate cancer. <b>2000</b> , 164, 814-9	9
471	Phosphorylation-deficient Stat1 inhibits retinoic acid-induced differentiation and cell cycle arrest in U-937 monoblasts. <b>2000</b> , 96, 2870-2878	1
470	Pulmonary Malignancies: Pathophysiology and Treatment. <b>2001</b> , 406-432	
469	VASECTOMY IMPAIRS SPERMATOGENESIS THROUGH GERM CELL APOPTOSIS MEDIATED BY THE p53-BAX PATHWAY IN RATS. <b>2001</b> , 1565-1571	
468	Inactivation of Negative Growth Regulators During Neoplastic Transformation. <b>2002</b> , 81-111	
467	Induction of Proliferation-Related Signals by Hepatitis C Virus. <b>2002</b> , 81-98	
466	Apoptosis.	
465	p53 and Its Targets. <b>2002</b> , 77-96	

464 Molekulare Pathologie bösartiger pulmonaler und pleuraler Tumoren. **2002**, 27-86

463 Pankreaskarzinom. **2002**, 187-206

462 CDK Inhibitors. **2002**, 123-143

1

461 Senescence.

460 Vitamin D Regulation of Cell Cycle and Differentiation in Myeloid Cells. **2002**, 147-171

459 5-Fluorouracil Induction of Fas and Apoptosis in Colon Cancer Patients: Relation of Clinical Outcome with Thymidylate Synthase, Mcl-1 and Rb. **2002**, 461-466

458 Difference in the Types of Uterine Tumors between Heterozygous p53-deficient and Wild Type CBA Mice Treated with Ethinylestradiol after N-ethyl-N-nitrosourea Initiation.. **2002**, 15, 203-207

457 Cell Cycle Regulatory Mechanisms in Head and Neck Squamous Cell Carcinoma. **2003**, 101-116

456 Cellular Senescence. **2003**,

455 Development of an In vitro Ubiquitination System for the Cyclin Kinase Inhibitor, p21. **2003**, 15, 79-84

454 The p53 Pathway, Cancer and Aging. **2003**, 121-149

453 Apoptosis and Cancer. **2003**, 177-199

452 Radiation Responses in Drosophila. **2003**, 213-217

451 TP53 in Carcinogenesis and Cancer Prevention. **2003**, 57-81

450 Inhibition of pRB Phosphorylation and Induction of p21WAF1/CIP1 Occur During cAMP-induced Growth Arrest in Human Neuroblastoma Cells. **2003**, 13, 642-650

449 Potential Function of the Werner's Syndrome Homologue in the African Clawed Frog and the Mouse. **2004**, 107-122

448 Organismal aging and phosphorylation of transcription factors. **2004**, 16, 1-14

447 The p53 Transcription Factor as Therapeutic Target in Cancer. **2004**, 209-258

446 Zellzyklus und Apoptose. **2004**, 175-191

445 Genomic Instability, DNA Repair Pathways, and Cancer. **2004**, 491-504

444 Human Papillomavirus Infection in Men and Women: The Impact of Nutrition on Cervical Cancer. **2004**, 796-812

443 Microarray Profiling of Gene Expression Patterns of Genistein in Tumor Cells. **2004**, 77-103

442 DNA Demethylating Agents. **2004**, 183-212

1

441 Induction of Cdk inhibitor p21 and inhibition of cyclooxygenase-2 by resveratrol in human lung carcinoma A549 cells.. **2004**, 14, 800-808

1

440 The Role of Multiple Drug Resistance in Neuroglial Survival. **2004**, 251-261

439 Expression of p53, mdm2 and p21 Proteins in Betel Quid and Tobacco Associated Oral Squamous Cell Carcinoma in Bangladeshi Population. **2005**, 10, 23-31

438 Effect of Resveratrol on the Induction of Cdk Inhibitor p21 and Pro-apoptotic Bax Expression by amyloid- $\beta$  in Astrogloma C6 Cells. **2005**, 15, 169-175

437 Growth Inhibition of Human Hepatoma and Bladder Carcinoma Cells by DNA Topoisomerase Inhibitor Etoposide. **2005**, 15, 323-331

436 Tumor Suppressor Genes. **2005**, 131-150

435 Skin Cancer. **2005**, 379-402

434 Lung Cancer. **2005**, 319-340

433 THE ROLE OF RAD9 IN HEAD AND NECK CANCER. **2006**, 32, 417-422

1

432 Mechanisms of Gastrointestinal Malignancies. **2006**, 477-498

431 Adenovirus-Mediated p53 Treatment Enhances Photodynamic Antitumor Response. **2006**, 060214062855002

430 Cyclin-Dependent Kinase Inhibitors and Vascular Disease. **2006**, 85-100

429 Functional Regulation of CIP/KIP CDK Inhibitors. **2006**, 29-53

- 428 The regulation of Rad9 for therapy of head and neck cancer. **2007**, 33, 425-428
- 427 p53, p21 and bcl-2 Protein Expressions and the Clinical Significance in Papillary Thyroid Carcinoma. **2007**, 22, 98 1
- 426 TP53 Mutation and Li-Fraumeni Syndrome. **2007**, 251-261 1
- 425 1,3-Dichloro-2-Propanol (1,3-DCP) Induced Cell Damage. **2007**, 16, 219-225
- 424 Effects of Histone Deacetylase Inhibitor, Trichostatin A, on the Differentiation of C2C12 Myoblasts and the Expression of Cell Cycle Regulators. **2007**, 17, 976-982
- 423 Apoptotic Cell Death by Pectenotoxin-2 in p53-Deficient Human Hepatocellular Carcinoma Cells. **2007**, 17, 1447-1451
- 422 Chemopreventive Effects of Garlic Extracts on Rat Colonic Aberrant Crypt Foci Induced by 1,2-Dimethylhydrazine. **2007**, 23, 321-330 1
- 421 Application of Genomic, Proteomic, and Metabolomic Technologies to the Development of Countermeasures against Chemical Warfare Agents. **2007**,
- 420 Basics of Radiation Therapy. **2008**, 417-448 1
- 419 Molecular Genetics of Lung and Pleural Neoplasms. **2008**, 47-157 1
- 418 Receptors, Signaling Pathways, Cell Cycle, and DNA Damage Repair. **2008**, 11-21
- 417 Control of the Cell Cycle. **2008**, 49-66
- 416 TP53 Mutation and Li-Fraumeni Syndrome. **2009**, 247-257
- 415 TP53 Mutation and Li-Fraumeni Syndrome. **2009**, 85-96
- 414 Mouse Model: Telomeres and Telomerase in Stem Cell and Cancer. **2009**, 149-167 1
- 413 Involvement of Cdk Inhibitor p21(WIP1/CIP1) in G2/M Arrest of Human Myeloid Leukemia U937 Cells by N-Methyl-N'-Nitro-N-Nitrosoguanidine. **2009**, 19, 1-8
- 412 Inhibition of Apoptosis by Nitric Oxide in MCF-7 Cells. **2009**, 19, 157-162 1
- 411 Chromatin Modifications and Orchestration of Checkpoint Response in Cancer. **2010**, 83-93



410 Cellular Growth and Neoplasia. **2010**, 31-44.e2

409 Role of Jun dimerization protein 2 (JDP2) in cellular senescence. **2010**, 30, 507-519

408 Cyclin D1, p16, and p21 gene product expression as a predictor of outcomes in tongue cancer. **2010**, 56, 401-408

407 Radiation Responses in Drosophila. **2010**, 2159-2163

406 p53 Dilemma in Transcription: Analysis by Microarrays. **2010**, 142-159

405 Nitric Oxide: Monotherapy or Sensitiser to Conventional Cancer Treatments?. **2010**, 387-417

404 Carcinogenetic Pathway of Urothelial Carcinoma. **2010**, 285-293

1

403 p21/Waf1/Cip1 cellular expression in chronic long-lasting hepatitis C: correlation with HCV proteins (C, NS3, NS5A), other cell-cycle related proteins and selected clinical data. **2009**, 47, 385-94

7

402 Analysis of p53-Dependency of Differentially Expressed Genes by Capsaicin in Human Colorectal Cancer Cell. **2010**, 20, 213-218

1

401 Human Papillomaviruses. **2010**, 207-252

400 Molecular Signatures of Bladder Cancer. **2011**, 91-119

399 Apoptosis In Vivo. **2011**, 625-640

398 Methylmercury Effects on Neural Developmental Signaling Pathways. 409-433

397 Analyzing p53 regulated DNA damage checkpoints by flow cytometry. **2011**, 782, 193-203

396 Topoisomerases and Apoptosis. **2012**, 409-435

395 Molecular Genetics and Cancer Biology. **2012**, 530-567.e16

394 Expression of Ski in the Follicles of eCG-primed Immature Hypophysectomized Rat Ovary. **2012**, 54, 151-156

1

393 Stem Cells and Aging. **2013**, 363-373

- 392 Functional Maturation of PAKs from Unicellular to Multicellular Organisms. **2013**, 1-21
- 391 Therapeutic Induction of Apoptosis in Nasopharyngeal Carcinoma. **2013**, 187-199
- 390 *In vivo* effect of 17- $\beta$ -estradiol, progesterone, hCG and expression of P53 and P21 in endometrial Ishikawa cells. **2013**, 03, 105-110
- 389 Gene Expression Profiling in Melanoma. **2014**, 529-545
- 388 DNA Damage Response Pathways and Cancer. **2014**, 142-153.e3 1
- 387 Curcumin Protects SK-N-MC Cells from H<sub>2</sub>O<sub>2</sub>-Induced Cell Death by Modulation of Notch Signaling Pathway. **2014**, 03, 72-86 2
- 386 Control of the Cell Cycle. **2014**, 52-68.e6 0
- 385 p53 in Head and Neck Cancer. **2014**, 227-258
- 384 Control of cell proliferation during plant development. **1994**, 53-67
- 383 Lessons from developmental biology. **1995**, 85-97
- 382 Genetic Changes in Breast Cancer. **1995**, 191-208
- 381 Transfer and Expression of Antioncogenes and Paraneoplastic Genes in Normal and Neoplastic Cells in Vitro and in Vivo. **1995**, 275-VIII
- 380 Death genes in T cells. **1995**, 200, 137-46 4
- 379 Tumour Suppressor Genes in Hodgkin's Disease. **1995**, 209-222
- 378 On the regulation of the p53 tumour suppressor, and its role in the cellular response to DNA damage. **1995**, 79-83 0
- 377 Genetic Alterations in Colon Cancer. **1995**, 139-189
- 376 Target of breeding and canceration of keratinocytes.Cyclin and cdk complex.. **1995**, 57, 687-695 1
- 375 Biophysical and Biochemical Properties of the p53 Protein. **1995**, 55-72

- 374 Lymphocyte death, p53, and the problem of the "undead" cell. **1995**, 200, 123-35 2
- 373 Dysregulation des Zellzyklus (p53, Zyklone). **1995**, 9-16
- 372 The role of the p53 protein in the apoptotic response. **1995**, 41-44 1
- 371 Cell Cycle Regulation in Intestinal Epithelial Cells. **1996**, 73-80
- 370 From Start to S Phase: Early Events in the Yeast Cell Cycle. **1996**, 11-25
- 369 P53-Mediated Apoptosis. **1996**, 83-101 1
- 368 Alterations in cell cycle control during tumor progression: effects on apoptosis and the response to therapeutic agents. **1996**, 213 ( Pt 2), 197-213 2
- 367 Differentiation and proliferation of epidermal cell. (1). Cell cycle and Stem Cell in the proliferation of epidermal cell ( epidermal keratinocyte ).. **1996**, 58, 113-115
- 366 p16 Family Inhibitors of Cyclin-Dependent Kinases. **1996**, 57-82
- 365 Growth Factors and Ageing. **1996**, 111-129
- 364 Ageing and Cancer. **1996**, 15-23
- 363 Genetics of Breast Cancer. **1996**, 197-224
- 362 Neoplastic Transformation: Oncogenes, Tumor Suppressors, Cyclins, and Cyclin-Dependent Kinases. **1996**, 3-41
- 361 Cell Cycle Control. **1996**, 48-58
- 360 A Cell Cycle Regulator and Cancer. **1996**, 59-67
- 359 Oncogenes and Anti-oncogenes : Their Role in the Genesis and Progression of Tumors. **1996**, 5, 111-117
- 358 Mechanisms of developmental cell death. **1996**, 89-122
- 357 Various functions of CDK inhibitor in skin.. **1996**, 58, 561-566

- 356 Fluorescence in Situ Hybridization and Human Cell Cycle Genes. **1996**, 29-45
- 355 Gene Alterations in Glial Tumors. **1996**, 161-172
- 354 Cell Cycle Control of Genetic Stability. **1997**, 33-52
- 353 Signalling to the C-terminus of p53. **1997**, 63-75
- 352 Regulation of p53-Dependent Apoptosis in Human Neuroblastoma Cells by Isoquinolines. **1997**, 71-77
- 351 Novel Approaches to Photoprotection. **1997**, 388-394
- 350 Neoplastic Progression in Barrett's Esophagus. **1997**, 195-214
- 349 WAF1. **1997**, 512-516
- 348 Medical Background: Human DNA Damage Recognition and Processing Disorders. **1997**, 1-30
- 347 E6 Protein. **1997**, 71-102 1
- 346 Nuclear Reactivity Relationship Among p53 and Some of its Downstream Proteins is Predictive of p53 Functional State. **1997**, 715-722
- 345 References. **1997**, 215-326
- 344 p53-Dependent Signaling in Response to DNA Damage or Arrest of DNA Synthesis and its Role in Cell Cycle Control. **1997**, 69-81
- 343 Effects of Natural Antioxidants on the Activation of Transcription Factor NF- $\kappa$ B and p53. **1997**, 468-471
- 342 Molecular Biology of Malignant Brain Tumors (Topics of Malignant Brain Tumors). **1997**, 6, 306-310
- 341 Immunohistochemical Evaluation of Cell Cycle Regulating Proteins in Epithelial Skin Tumors. **1997**, 786-791
- 340 UVB Irradiation, Mismatch Repair and Cutaneous Melanoma. **1997**, 727-737
- 339 Molecular Analysis of the INK4 Family of Genes in Prostate Carcinomas. **1997**, 1995-1999 1

338 Modulation of Idarubicin-Induced Apoptosis in Human Acute Myeloid Leukemia Blasts by All-Trans Retinoic Acid, 1,25(OH)<sub>2</sub> Vitamin D<sub>3</sub>, and Granulocyte-Macrophage Colony-Stimulating Factor. **1997**, 90, 4578-4587

337 Lung Cancer. **1998**, 357-361

336 Therapeutic manipulation of apoptosis in cancer and neurological disease. **1998**, 281-303

335 Prognostic and predictive value of p53 and p21 in breast cancer. **1998**, 169-188

1

334 Gene Therapy for Pancreatic Cancer. **1998**, 295-318

333 Cell Cycle Regulators and Mechanisms of Growth Control Evasion in Lung Cancer. **1998**, 105-116

332 The molecular genetics of colonic cancer. **1998**, 98, 351-82

1

331 The role of p53 in apoptosis. **1998**, 5-35

0

330 Common Mechanisms in Cell Cycle and Cell Death. **1998**, 81-87

329 Tumor Suppressor Gene Therapy for Brain Tumors. **1998**, 205-229

328 Mammalian Cell-Cycle Responses to DNA-Damaging Agents. **1998**, 465-486

327 Maligne proliferierende Trichilemmalzyste mit p53-Defekt. **1998**, 330-332

326 Prognostic implications of expression of the cell cycle inhibitor protein p27kip1. **1998**, 119-131

325 Screening for Pancreatic Cancer Using Techniques to Detect Altered Gene Products. **1998**, 113-136

324 Transcriptional Responses to Damage Created by Ionizing Radiation. **1998**, 223-262

323 Control of Cell Proliferation During Development and Animal Evolution. **1998**, 1-27

322 Promoters for Expression of Gene Products within Neurons and Glia. **1998**, 121-146

321 Molecular Pathological Mechanisms in NSCLC and the Assessment of Individuals with a High Risk of Developing Lung Cancer. **1998**, 247-261

- 320 Potential applications of cell cycle manipulation to clinical response. **1998**, 93, 169-90 1
- 319 Transgenic Animal Models. **1998**, 209-221
- 318 Neurooncology and Cancer Therapy. **1998**,
- 317 Introduction. **1998**,
- 316 Gliale Neoplasien. **1999**, 450-509
- 315 Protein kinase CK2 interacts with a multi-protein binding domain of p53. **1999**, 111-120 1
- 314 Use of Biochemical and Molecular Biomarkers for Cancer Risk Assessment in Humans. **1999**, 81-182 2
- 313 Murine protein kinase CK2: Gene and oncogene. **1999**, 65-74
- 312 Vitamin D and Breast Cancer. **1999**, 411-429
- 311 Regulation of Apoptosis in the Testis. **1999**, 215-224
- 310 Inhibition of Human Umbilical Vein Endothelial Cell Proliferation by the CXC Chemokine, Platelet Factor 4 (PF4), Is Associated With Impaired Downregulation of p21Cip1/WAF1. **1999**, 93, 25-33 4
- 309 Premalignant Lesions. **2015**, 273-292
- 308 Novel Strategies in Chemotherapy for Gliomas. **2015**, 24, 386-398
- 307 SUPPRESSION OF CELLULAR P53 PROMOTES CYTOTOXICITY OF ONCOLYTIC VECTOR AT THE MODELS OF HUMAN GLIOBLASTOMA. **2015**, 14, 25-28
- 306 Structure-Activity-Relationship Study of the Novel p21/waf1 Inhibitor for Anti-Cancer Agents against Renal Cell Carcinoma. **2015**, 11, 387-393
- 305 Radiation Injury in the Gastrointestinal Tract. 2509-2520
- 304 Neoplasia of the Gastrointestinal Tract. 587-616
- 303 Cellular Senescence as a Novel Mechanism of Chronic Inflammation and Cancer Progression. **2016**, 187-200

302 Biomarkers of Replicative Senescence Revisited. **2016**, 203-239

301 Removing a Cystein Group On Interferon Alpha 2b at Position 2 and 99 does Not Diminish Antitumor Activity of the Protein, Even Better. **2016**, 84, 113-30

300 Transcription Factors as Detection and Diagnostic Biomarkers in Cancer. **2017**, 31-58

299 p53 binding sites in normal and cancer cells are characterized by distinct chromatin context.

298 CDKN1A-RAB44 transcript fusion and activation in cancers.

297 Ki-67 contributes to normal cell cycle progression and inactive X heterochromatin in p21 checkpoint-proficient human cells.

296 P53 toxicity is a hurdle to CRISPR/CAS9 screening and engineering in human pluripotent stem cells. 2

295 High-mobility group box 1 is a promising diagnostic and therapeutic monitoring biomarker in Cancers: A review. **2018**, 5, 183-241 2

294 Histone Deacetylase Functions in Epidermal Development, Homeostasis and Cancer. **2018**, 121-157

293 On the design of CRISPR-based single cell molecular screens. 4

292 IL-1Ra Protects Hematopoietic Stem Cells from Chemotoxicity Through Quiescence Induction Via p53.

291 p53 and Ferroptosis. **2019**, 249-256

290 FLIP(L) determines p53 induced life or death.

289 Parallel CRISPR-Cas9 screens clarify impacts of p53 on screen performance.

288 Notch1 regulates breast cancer stem cell function via a non-canonical cleavage-independent pathway.

287 Induction of intracellular wild-type p53 amyloids leading to cellular transformation and tumor formation in mice.

286 Ciliopathic micrognathia is caused by aberrant skeletal differentiation and remodeling.

285 PROFILING OF Y1 CELLS TREATED WITH FGF-2 REVEALS PARALLELS WITH ONCOGENE-INDUCED SENESCENCE.

- 284 Co-expression Patterns Explain how a Basic Transcriptional Role for MYC Modulates Wnt and MAPK Pathways in Colon and Lung Adenocarcinomas.
- 283 Tumor suppressor p53 promotes ferroptosis in oxidative stress conditions independent of modulation of ferroptosis by p21, CDKs, RB, and E2F. **2021**, 297, 101365 4
- 282 Response of human oral mucosal epithelial cells to different storage temperatures: A structural and transcriptional study. **2020**, 15, e0243914
- 281 The Effect of Probiotics on T-2 Mycotoxin Induced Apoptosis in Chicken Liver Tissue. **2020**, 43, 55-60 1
- 280 CDKN1A (p21 gene) polymorphisms correlates with age in esophageal cancer. **2021**, 1
- 279 Altered Expression of the CIP/KIP Family CDK Inhibitors in Tumor Phenotype-Suppressed Human Lung Cancer Cells. **1999**, 347-351
- 278 Oncogenes and Tumor Suppressor Genes in Malignant Mesothelioma. **2005**, 124-140
- 277 Cervical and Endometrial Cancer Prevention. **2005**, 315-347 1
- 276 Molecular Staging of Non-Small-Cell Lung Cancer. **2006**, 159-176 2
- 275 T-Cell Non-Hodgkin's Lymphoma. **2006**, 161-220 0
- 274 Cardiac myocytes and fibroblasts exhibit differential sensitivity to apoptosis-inducing stimuli. **2000**, 189-208
- 273 Cell cycle regulation and apoptotic cell death. **2000**, 101-108 0
- 272 Diabetic LDL inhibits cell-cycle progression via STAT5B and p21(waf). **2002**, 109, 111-9 5
- 271 Proapoptotic Strategy in Cancer Gene Therapy. **2005**, 273-286
- 270 Cell Cycle Regulators and Vascular Proliferative Diseases. **2007**, 199-212
- 269 Cell Cycle, Neurological Disorders, and Reactive Gliosis. **2006**, 163-175
- 268 Aberrations of DNA Damage in Checkpoints in Cancer. **2007**, 119-136
- 267 Impaired p53-mediated DNA damage response contributes to microcephaly in Nijmegen Breakage Syndrome patient-derived cerebral organoids.



266	The chromatin-binding domain of Ki-67 together with p53 protects human chromosomes from mitotic damage.	2
265	Case report: 16-yr life history and genomic evolution of an ER HER2 breast cancer. <b>2020</b> , 6,	0
264	Inhibitory Effect of Ginseng on Breast Cancer Cell Line Growth Via Up-Regulation of Cyclin Dependent Kinase Inhibitor, p21 and p53. <b>2016</b> , 17, 4965-4971	6
263	PERP, an apoptosis-associated target of p53, is a novel member of the PMP-22/gas3 family. <b>2000</b> , 14, 704-18	242
262	Analysis of p53-regulated gene expression patterns using oligonucleotide arrays. <b>2000</b> , 14, 981-93	299
261	Cooperative effects of genes controlling the G(2)/M checkpoint. <b>2000</b> , 14, 1584-8	67
260	Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. <b>2000</b> , 14, 1797-809	56
259	Negative feedback regulation of wild-type p53 biosynthesis. <b>1995</b> , 14, 4442-9	102
258	DNA damage in human B cells can induce apoptosis, proceeding from G1/S when p53 is transactivation competent and G2/M when it is transactivation defective. <b>1995</b> , 14, 4994-5005	39
257	The tumour suppressor gene product APC blocks cell cycle progression from G0/G1 to S phase. <b>1995</b> , 14, 5618-25	51
256	Loss of p53 function through PAX-mediated transcriptional repression. <b>1995</b> , 14, 5638-45	51
255	Physical and functional interactions between p53 and cell cycle co-operating transcription factors, E2F1 and DP1. <b>1995</b> , 14, 6184-92	26
254	A temperature-sensitive mutant of human p53. <b>1994</b> , 13, 2535-44	40
253	Analysis of the most representative tumour-derived p53 mutants reveals that changes in protein conformation are not correlated with loss of transactivation or inhibition of cell proliferation. <b>1994</b> , 13, 3496-504	61
252	The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B. <b>1994</b> , 13, 3772-81	84
251	Cyclin G is a transcriptional target of the p53 tumor suppressor protein. <b>1994</b> , 13, 4816-22	126
250	Wild-type alternatively spliced p53: binding to DNA and interaction with the major p53 protein in vitro and in cells. <b>1994</b> , 13, 4823-30	15
249	Mutation of conserved domain II alters the sequence specificity of DNA binding by the p53 protein. <b>1994</b> , 13, 5393-400	11

248	Transformation by homeobox genes can be mediated by selective transcriptional repression. <b>1994</b> , 13, 5967-76	10
247	p53 oligomerization and DNA looping are linked with transcriptional activation. <b>1994</b> , 13, 6011-20	45
246	Lack of cyclin D-Cdk complexes in Rb-negative cells correlates with high levels of p16INK4/MTS1 tumour suppressor gene product. <b>1995</b> , 14, 503-11	84
245	The dihedral symmetry of the p53 tetramerization domain mandates a conformational switch upon DNA binding. <b>1995</b> , 14, 512-9	39
244	Identification of the active region of the DNA synthesis inhibitory gene p21Sdi1/CIP1/WAF1. <b>1995</b> , 14, 555-63	40
243	Epstein-Barr virus efficiently immortalizes human B cells without neutralizing the function of p53. <b>1995</b> , 14, 1382-91	34
242	Accumulation of wild-type p53 protein upon gamma-irradiation induces a G2 arrest-dependent immunoglobulin kappa light chain gene expression. <b>1995</b> , 14, 1392-401	32
241	A direct effect of activated human p53 on nuclear DNA replication. <b>1995</b> , 14, 2099-105	22
240	Cell type-specific inhibition of p53-mediated apoptosis by mdm2. <b>1996</b> , 15, 1596-606	63
239	Functional interactions between p53 and the TFIID complex are affected by tumour-associated mutations. <b>1996</b> , 15, 1615-24	37
238	Experimental elongation of telomeres extends the lifespan of immortal x normal cell hybrids. <b>1996</b> , 15, 1734-41	35
237	The Epstein-Barr virus bZIP transcription factor Zta causes G0/G1 cell cycle arrest through induction of cyclin-dependent kinase inhibitors. <b>1996</b> , 15, 2748-59	100
236	Specific loss of apoptotic but not cell-cycle arrest function in a human tumor derived p53 mutant. <b>1996</b> , 15, 827-38	85
235	Transcriptional activation by p53, but not induction of the p21 gene, is essential for oncogene-mediated apoptosis. <b>1996</b> , 15, 3693-701	59
234	A novel role for the budding yeast RAD9 checkpoint gene in DNA damage-dependent transcription. <b>1996</b> , 15, 3912-22	54
233	Activation of cyclin E/CDK2 is coupled to site-specific autophosphorylation and ubiquitin-dependent degradation of cyclin E. <b>1996</b> , 15, 4182-93	98
232	E47 activates the Ig-heavy chain and TdT loci in non-B cells. <b>1996</b> , 15, 5014-21	32
231	Loss of Rb activates both p53-dependent and independent cell death pathways in the developing mouse nervous system. <b>1996</b> , 15, 6178-88	104

230	Epidermal growth factor increases the level of the cyclin-dependent kinase (CDK) inhibitor p21/CIP1 (CDK-interacting protein 1) in A431 cells by increasing the half-lives of the p21/CIP1 transcript and the p21/CIP1 protein. <b>1999</b> , 337 ( Pt 3), 599-606	12
229	p21WAF1 expression by an activator of protein kinase C is regulated mainly at the post-transcriptional level in cells lacking p53: important role of RNA stabilization. <b>1999</b> , 337 ( Pt 3), 607-16	18
228	Strategies for manipulating the p53 pathway in the treatment of human cancer. <b>2000</b> , 352 Pt 1, 1-17	28
227	Germ-line p53 mutations in 15 families with Li-Fraumeni syndrome. <b>1995</b> , 56, 608-15	136
226	A gene that regulates DNA replication in response to DNA damage is located on human chromosome 4q. <b>1995</b> , 57, 1095-103	14
225	Genetic alterations and epithelial dysplasia in juvenile polyposis syndrome and sporadic juvenile polyps. <b>1997</b> , 150, 939-47	39
224	Cyclin-dependent kinase inhibitor p27KIP1 in lymphoid tissue: p27KIP1 expression is inversely proportional to the proliferative index. <b>1997</b> , 151, 151-60	92
223	Reduced levels of the cell-cycle inhibitor p27Kip1 in epithelial dysplasia and carcinoma of the oral cavity. <b>1998</b> , 152, 585-90	74
222	Analysis of p21Waf1/Cip1 expression in normal, premalignant, and malignant cells during the development of human lung adenocarcinoma. <b>1997</b> , 151, 461-70	22
221	Differentiation-dependent p53 regulation of nucleotide excision repair in keratinocytes. <b>1997</b> , 150, 1457-64	46
220	Aberrant p27kip1 expression in endocrine and other tumors. <b>1997</b> , 150, 401-7	144
219	WAF1/Cip1 gene polymorphism and expression in carcinomas of the breast, ovary, and endometrium. <b>1997</b> , 150, 167-75	52
218	Decreased DNA repair but normal apoptosis in ultraviolet-irradiated skin of p53-transgenic mice. <b>1996</b> , 148, 1113-23	74
217	Molecular diagnosis of p53 mutations in gastric carcinoma by touch preparation. <b>1996</b> , 148, 405-13	10
216	Characterization of a panel of novel anti-p21Waf1/Cip1 monoclonal antibodies and immunochemical analysis of p21Waf1/Cip1 expression in normal human tissues. <b>1996</b> , 148, 825-35	55
215	Interleukin-11 induces intestinal epithelial cell growth arrest through effects on retinoblastoma protein phosphorylation. <b>1996</b> , 149, 895-902	37
214	Differentiation-associated overexpression of the cyclin-dependent kinase inhibitor p21waf-1 in human cutaneous squamous cell carcinoma. <b>1996</b> , 149, 1139-46	32
213	The MDM2 oncoprotein is overexpressed in rhabdomyosarcoma cell lines and stabilizes wild-type p53 protein. <b>1996</b> , 149, 143-51	53

212	Early alteration of cell-cycle-regulated gene expression in colorectal neoplasia. <b>1996</b> , 149, 381-7	62
211	Association of p53 and WAF1 expression with apoptosis in diffuse alveolar damage. <b>1996</b> , 149, 531-8	53
210	Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. <b>1996</b> , 149, 1813-22	36
209	Genetic evidence in melanoma and bladder cancers that p16 and p53 function in separate pathways of tumor suppression. <b>1995</b> , 146, 1199-206	71
208	Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. <b>1995</b> , 146, 1170-7	36
207	Heterogeneity in intratumor distribution of p53 mutations in human prostate cancer. <b>1995</b> , 147, 92-101	86
206	Human replicative senescence. A molecular study. <b>1995</b> , 147, 1-8	36
205	p53 gene mutations, p53 protein accumulation and compartmentalization in colorectal adenocarcinoma. <b>1995</b> , 147, 790-8	100
204	Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. <b>1995</b> , 147, 545-60	317
203	p53-independent expression of the cyclin-dependent kinase inhibitor p21 in pancreatic carcinoma. <b>1995</b> , 147, 884-8	83
202	The interaction of taxol and vinblastine with radiation induction of p53 and p21 WAF1/CIP1. <b>1996</b> , 27, S82-5	5
201	Cisplatin nephrotoxicity: molecular mechanisms. <b>2003</b> , 1, 47-61	200
200	Regulation of transcription functions of the p53 tumor suppressor by the mdm-2 oncogene. <b>1995</b> , 1, 142-52	71
199	Taxol-induced mitotic block triggers rapid onset of a p53-independent apoptotic pathway. <b>1995</b> , 1, 506-26	76
198	Differential regulation of the p21/WAF-1 and mdm2 genes after high-dose UV irradiation: p53-dependent and p53-independent regulation of the mdm2 gene. <b>1997</b> , 3, 441-51	48
197	Transcription abnormalities potentiate apoptosis of normal human fibroblasts. <b>1997</b> , 3, 852-63	18
196	The molecular biology of colorectal cancer development and the associated genetic events. <b>1999</b> , 81, 312-9	2
195	From here to eternity - the secret of Pharaohs: Therapeutic potential of black cumin seeds and beyond. <b>2008</b> , 6, 495-510	102

194	[The use of p53 as a tool for human cancer therapy]. <b>2007</b> , 41, 947-63	1
193	Stress sensor Gadd45 genes as therapeutic targets in cancer. <b>2009</b> , 7, 268-276	63
192	Analysis of genomic instability in Li-Fraumeni fibroblasts with germline p53 mutations. <b>1996</b> , 12, 2267-78	45
191	[Transcriptional inhibition of human papilloma virus in cervical carcinoma cells reactivates functions of the tumor suppressor p53]. <b>2007</b> , 41, 515-23	11
190	Pleurotus ostreatus inhibits proliferation of human breast and colon cancer cells through p53-dependent as well as p53-independent pathway. <b>2008</b> , 33, 1307-13	19
189	p53-Mediated down-regulation of the human DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) via interaction with Sp1 transcription factor. <b>2009</b> , 29, 3741-50	67
188	Decreasing expression of the G1-phase inhibitors, p21Cip1 and p16INK4a, promotes division of corneal endothelial cells from older donors. <b>2010</b> , 16, 897-906	34
187	Targeting Rb inactivation in cancers by synthetic lethality. <b>2011</b> , 1, 773-86	12
186	Novel insights into the molecular mechanisms governing Mdm2 ubiquitination and destruction. <b>2010</b> , 1, 685-90	23
185	Telomere lengthening and other functions of telomerase. <b>2012</b> , 4, 44-61	21
184	What We Know about the Molecular Genetics of Central Nervous System (CNS) Tumours in Malaysia. <b>2004</b> , 11, 37-43	
183	Research progress on the negative factors of corneal endothelial cells proliferation. <b>2012</b> , 5, 614-9	4
182	Gene Expression upon Proliferation and Differentiation of Hematopoietic Cells with Ph Chromosome ex vivo. <b>2012</b> , 4, 95-114	1
181	BCCIP is required for the nuclear localization of the p21 protein. <b>2009</b> , 8, 3019-24	15
180	Association of TBX2 and P21 expression with clinicopathological features and survival of laryngeal squamous cell carcinoma. <b>2014</b> , 7, 5394-402	6
179	Carboplatin-docetaxel-induced activity against ovarian cancer is dependent on up-regulated lncRNA PVT1. <b>2015</b> , 8, 3803-10	39
178	Clinicopathologic and prognostic significance of p21 (Cip1/Waf1) expression in bladder cancer. <b>2015</b> , 8, 4999-5007	17
177	p53-dependent activation of the mouse MCK gene promoter: identification of a novel p53-responsive sequence and evidence for cooperation between distinct p53 binding sites. <b>1995</b> , 5, 19-33	6

176	Differential upregulation of p53-responsive genes by genotoxic stress in hematopoietic cells containing wild-type and mutant p53. <b>1999</b> , 8, 197-206	10
175	Functional role of p21 during the cellular response to stress. <b>1999</b> , 7, 377-85	51
174	The complexity of radiation stress responses: analysis by informatics and functional genomics approaches. <b>1999</b> , 7, 387-400	48
173	P21 Immunoexpression in Actinic Keratosis and Cutaneous Carcinomas. <b>2017</b> , 43, 226-230	
172	Inhibition of peptidyl-prolyl isomerase (PIN1) and BRAF signaling to target melanoma. <b>2019</b> , 11, 4425-4437	
171	[Role of P21 in Resistance of Lung Cancer]. <b>2020</b> , 23, 597-602	
170	Ginsenoside Rg1 improves pathological damages by activating the p21-p53-STK pathway in ovary and Bax-Bcl2 in the uterus in premature ovarian insufficiency mouse models. <b>2021</b> , 23,	1
169	Effect of metformin on irinotecan-induced cell cycle arrest in colorectal cancer cell lines HCT116 and SW480. <b>2021</b> , 15, 34-41	
168	anticancer activity of a pentacyclic triterpenoid via the mitochondrial pathway in bone-invasive oral squamous cell carcinoma. <b>2021</b> , 25, 313-321	
167	Disruption of the ARF transcriptional activator DMP1 facilitates cell immortalization, Ras transformation, and tumorigenesis. <b>2000</b> , 14, 1797-1809	71
166	Cooperative effects of genes controlling the G2/M checkpoint. <b>2000</b> , 14, 1584-1588	174
165	Coordination between cell proliferation and apoptosis after DNA damage in Drosophila. <b>2021</b> ,	1
164	The Cross Talk Between p53 and mTOR Pathways in Response to Physiological and Genotoxic Stresses. <b>2021</b> , 9, 775507	1
163	Comparatively analyzing the liver-specific transcriptomic profiles in Kunming mice afflicted with streptozotocin- and natural food-induced type 2 diabetes mellitus. <b>2021</b> , 1	
162	Identification of a novel catalytic inhibitor of topoisomerase II alpha that engages distinct mechanisms in p53 or p53 cells to trigger G2/M arrest and senescence. <b>2021</b> ,	0
161	LARP7 ameliorates cellular senescence and aging by allosterically enhancing SIRT1 deacetylase activity. <b>2021</b> , 37, 110038	1
160	. <b>2021</b> ,	0
159	Cell cycle and cancer. <b>2000</b> , 2, 12-22	1

158	Apoptosis and cancer. <b>2000</b> , 2, 180-190	1
157	Ginsenoside Rg1 improves pathological damages by activating the p21-p53-STK pathway in ovary and Bax-Bcl2 in the uterus in premature ovarian insufficiency mouse models. <b>2020</b> , 23, 1-1	3
156	Morphological and functional changes in placentas from prolonged pregnancies.. <b>2022</b> ,	
155	Epigenetic Priming with Decitabine Augments the Therapeutic Effect of Cisplatin on Triple-Negative Breast Cancer Cells through Induction of Proapoptotic Factor NOXA.. <b>2022</b> , 14,	0
154	Cell Cycle Regulation by Heat Shock Transcription Factors.. <b>2022</b> , 11,	0
153	Cancer and cell cycle. <b>2022</b> , 91-102	
152	Down-Regulating HAUS6 Suppresses Cell Proliferation by Activating the p53/p21 Pathway in Colorectal Cancer.. <b>2021</b> , 9, 772077	0
151	MARK2 potentiate aerobic glycolysis-mediated cell growth in breast cancer through regulating mTOR/HIF-1 and p53 pathways.. <b>2022</b> ,	2
150	Advances in the Current Understanding of How Low-Dose Radiation Affects the Cell Cycle.. <b>2022</b> , 11,	4
149	Nucleotide biosynthesis links glutathione metabolism to ferroptosis sensitivity.. <b>2022</b> , 5,	1
148	Design, synthesis, and biological activities of 3-((4,6-diphenylpyrimidin-2-ylamino)methylene)-2,3-dihydrochromen-4-ones.. <b>2022</b> , 120, 105634	1
147	Downregulation of CPT2 promotes proliferation and inhibits apoptosis through p53 pathway in colorectal cancer.. <b>2022</b> , 92, 110267	1
146	A noninvasive iRFP713 p53 reporter reveals dynamic p53 activity in response to irradiation and liver regeneration in vivo.. <b>2022</b> , 15, eabd9099	1
145	Deficiency of ribosomal proteins reshapes the transcriptional and translational landscape in human cells.. <b>2022</b> ,	1
144	ZMAT3 hypomethylation contributes to early senescence of preadipocytes from healthy first-degree relatives of type 2 diabetics.. <b>2022</b> , e13557	3
143	A reference induced pluripotent stem cell line for large-scale collaborative studies.	1
142	Murine protein kinase CK2: gene and oncogene. <b>1999</b> , 191, 65-74	21
141	Protein kinase CK2 interacts with a multi-protein binding domain of p53. <b>1999</b> , 191, 111-20	8

140	Capillaries as a Therapeutic Target for Heart Failure.. <b>2022</b> ,	1
139	Quantitative profiling of adaptation to cyclin E overproduction.. <b>2022</b> , 5,	1
138	Discovery of a potent cytotoxic agent that promotes G/M phase cell cycle arrest and apoptosis in a malignant human pharyngeal squamous carcinoma cell line.. <b>2022</b> , 60,	0
137	Impaired p53-Mediated DNA Damage Response Contributes to Microcephaly in Nijmegen Breakage Syndrome Patient-Derived Cerebral Organoids.. <b>2022</b> , 11,	0
136	.. <b>2022</b> ,	1
135	Zebrafish imaging reveals TP53 mutation switching oncogene-induced senescence from suppressor to driver in primary tumorigenesis.. <b>2022</b> , 13, 1417	2
134	Diet suppresses tumour initiation by maintaining quiescence of mutation-bearing neural stem cells.	
133	Delayed Therapeutic Administration of Melatonin Enhances Neuronal Survival Through AKT and MAPK Signaling Pathways Following Focal Brain Ischemia in Mice.. <b>2022</b> , 1	0
132	Lipids as Regulators of Cellular Senescence.. <b>2022</b> , 13, 796850	2
131	Tumor Suppressor Par-4 Regulates Complement Factor C3 and Obesity.. <b>2022</b> , 12, 860446	
130	Urushiol V Suppresses Cell Proliferation and Enhances Antitumor Activity of 5-FU in Human Colon Cancer Cells by Downregulating FoxM1.. <b>2022</b> ,	
129	Elevated p21 (CDKN1a) mediates $\beta$ -thalassemia erythroid apoptosis but its loss does not improve $\beta$ -thalassemic erythropoiesis.	0
128	Cell cycle regulation: p53-p21-RB signaling.. <b>2022</b> ,	16
127	Molecular Mechanisms of Cutaneous Squamous Cell Carcinoma.. <b>2022</b> , 23,	0
126	Targeted clearance of p21- but not p16-positive senescent cells prevents radiation-induced osteoporosis and increased marrow adiposity.. <b>2022</b> , e13602	3
125	Preferential translation of p53 target genes.. <b>2022</b> , 19, 437-452	0
124	In vitro cytotoxic effects of Smilax aspera L. roots on cancer cell lines. <b>2022</b> , 46, 101501	1
123	The multifaceted mechanisms of Paeoniflorin in the treatment of tumors: State-of-the-Art.. <b>2022</b> , 149, 112800	0



- 122 E6/E7 from Beta-2-HPVs 122, 38b, and 107 possess transforming properties in a fibroblast model in vitro.. **2022**, 414, 113088
- 121 Comparative analysis of mouse embryonic palatal mesenchymal cells isolated by two primary culture methods.. **2022**, 76, 101783
- 120 Syringic and ascorbic acids prevent NDMA-induced pulmonary fibrogenesis, inflammation, apoptosis, and oxidative stress through the regulation of PI3K-Akt/PKB-mTOR-PTEN signaling pathway.. **2022**, 14, 100179 1
- 119 Advances in pathogenesis and therapeutic strategies for osteoporosis.. **2022**, 237, 108168 6
- 118 Transcriptional Regulation of Amino Acid Transport in Glioblastoma Multiforme.. **2021**, 13, 0
- 117 Endoderm development requires centrioles to restrain p53-mediated apoptosis in the absence of ERK activity.. **2021**, 56, 3334-3348.e6 0
- 116 eIF5A-Independent Role of DHPS in p21 and Cell Fate Regulation.. **2021**, 22, 0
- 115 Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53 Uterine Leiomyosarcoma.. **2021**, 14, 1
- 114 Missense variants in ANKRD11 cause KBG syndrome by impairment of stability or transcriptional activity of the encoded protein. 1
- 113 Green Tea () Extract Induces p53-Mediated Cytotoxicity and Inhibits Migration of Breast Cancer Cells.. **2021**, 10, 0
- 112 Loss of peptidase D binding restores the tumor suppressor functions of oncogenic p53 mutants. **2021**, 4, 1373 0
- 111 Endothelial cell dysfunction and senescence: biologic mechanisms and hemodynamic consequences. **2022**, 359-367
- 110 Co-expression patterns explain how a basic transcriptional role for MYC modulates and MAPK pathways in colon and lung adenocarcinomas.. **2022**, 1-20
- 109 The antitumour activity of C steroidal glycosides and their derivatives of Baishouwu: A review.. **2022**, 293, 115300 1
- 108 The First Twenty-Five Years of p53 Research. **2007**, 1-25
- 107 20 Years of DNA Damage Signaling to p53. **2007**, 53-71
- 106 Gatekeepers of the Guardian: p53 Regulation by Post-Translational Modification, MDM2 and MDMX. **2007**, 73-113
- 105 p53, Cell Cycle Arrest and Apoptosis. **2007**, 141-163

104	Focusing Target Discovery and Validation Through Proteogenomics and Molecular Imaging. <b>2005</b> , 151-163	
103	Data_Sheet_1.docx. <b>2018</b> ,	
102	In vitro anticancer activity of a pentacyclic triterpenoid via the mitochondrial pathway in bone-invasive oral squamous cell carcinoma. <b>2021</b> , 25, 313	0
101	Truncating mutations: an insight into the biology of urinary tract carcinomas?. <b>2021</b> , 11, 6214-6217	
100	Long noncoding RNA TLNC1 promotes the growth and metastasis of liver cancer via inhibition of p53 signaling.. <b>2022</b> , 21, 105	1
99	The microRNA-3622 family at the 8p21 locus exerts oncogenic effects by regulating the p53-downstream gene network in prostate cancer progression.. <b>2022</b> ,	
98	Signaling Pathway Reporter Screen with SARS-CoV-2 Proteins Identifies nsp5 as a Repressor of p53 Activity. <b>2022</b> , 14, 1039	2
97	TAFII70 Isoform-Specific Growth Suppression Correlates With Its Ability to Complex With the GADD45a Protein. <b>2004</b> , 2, 442-452	8
96	Inhibitory Effects of Terfezia (Ascomycota) Desert Truffles on PANC-1 Cell Growth Via Upregulation of the Pro-apoptotic Genes TP53, CDKN1A, and BAX, and Downregulation of the Anti-apoptotic Gene BCL2. <b>2022</b> ,	
95	MDM2 E3 ligase activity is essential for p53 regulation and cell cycle integrity.. <b>2022</b> , 18, e1010171	0
94	NF90/NF45 is essential for T cell compensation under obesity-inducing metabolic stress through suppression of p53 signaling pathway. <b>2022</b> , 12,	
93	Changes in 5-fluorouracil-induced external granular cell damage during the time-course of the developing cerebellum of infant rats. <b>2022</b> ,	
92	Defining the molecular underpinnings controlling cardiomyocyte proliferation. <b>2022</b> , 136, 911-934	1
91	SOX9 Protein in Pancreatic Cancer Regulates Multiple Cellular Networks in a Cell-Specific Manner. <b>2022</b> , 10, 1466	
90	BB-reactivator screening as a novel cell-based assay for discoveries of molecular targeting agents including the first-in-class MEK inhibitor trametinib (trade name: Mekinist). <b>2022</b> , 108234	0
89	IDO1 plays a tumor-promoting role via MDM2-mediated suppression of the p53 pathway in diffuse large B-cell lymphoma. <b>2022</b> , 13,	1
88	The Core Splicing Factors EFTUD2, SNRPB and TXNL4A Are Essential for Neural Crest and Craniofacial Development. <b>2022</b> , 10, 29	0
87	Negative regulation of p53 by the poliovirus receptor PVR is a target of a human cytomegalovirus immune evasion molecule.	

86	Missense variants in ANKRD11 cause KBG syndrome by impairment of stability or transcriptional activity of the encoded protein. <b>2022,</b>	0
85	p63p-Regulates the Hsp70 Gene in Human Cancer. <b>2005, 65, 758-766</b>	24
84	Premature Senescence Is a Primary Fail-safe Mechanism of ERBB2-Driven Tumorigenesis in Breast Carcinoma Cells. <b>2005, 65, 840-849</b>	24
83	p53 Codon 72 and p21 Codon 31 Polymorphisms in Prostate Cancer. <b>2004, 13, 2217-2224</b>	13
82	Brain tumor cell lines resistant to O6-benzylguanine/1,3-bis(2-chloroethyl)-1-nitrosourea chemotherapy have O6-alkylguanine-DNA alkyltransferase mutations. <b>2004, 3, 1127-1135</b>	13
81	Different DNA lesions trigger distinct cell death responses in HCT116 colon carcinoma cells. <b>2004, 3, 613-620</b>	3
80	Inhibition of NEDD8 NEDDylation induced apoptosis in acute myeloid leukemia cells via p53 signaling pathway.	1
79	Prognostic Implications of Molecular and Immunohistochemical Profiles of the Rb and p53 Cell Cycle Regulatory Pathways in Primary Non-small Cell Lung Carcinoma. <b>2005, 11, 232-241</b>	9
78	Cell Division/Death: Cell Cycle The Restriction Point. <b>2022,</b>	
77	Inactivation of tumor suppressor TAp63 by hepatitis B virus X protein in hepatocellular carcinoma. Publish Ahead of Print,	
76	From cyclins to CDKs: Cell cycle regulation of skeletal muscle stem cell quiescence and activation. <b>2022, 113275</b>	2
75	Loss of the aryl hydrocarbon receptor increases tumorigenesis in p53-deficient mice. <b>2022, 116191</b>	1
74	Regulation of male germline transmission patterns by the Trp53-Cdkn1a pathway. <b>2022,</b>	
73	Deregulated transcription factors and poor clinical outcomes in cancer patients. <b>2022,</b>	1
72	Isoform-specific Disruption of the TP73 Gene Reveals a Critical Role for TAp73gamma in Tumorigenesis via Leptin.	
71	Paradoxical tumor suppressive role of the musculoaponeurotic fibrosarcoma gene in colorectal cancer.	
70	Knockdown of PRKD2 Enhances Chemotherapy Sensitivity in Cervical Cancer via the TP53/CDKN1A Pathway. <b>2022, 22,</b>	
69	Liposomal formulation of new arsenic schiff base complex as drug delivery agent in the treatment of acute promyelocytic leukemia and quantum chemical and docking calculations. <b>2022, 75, 103600</b>	1

- 68 Cell Division/Death: Cell Cycle â€”Cyclins, Cyclin-Dependent Kinases, and Cyclin-Dependent Kinase Inhibitors. **2022,** 0
- 67 Cell Division/Death: Cell Cycle â€”CDK Inhibitors in Normal and Malignant Cells. **2022,** 0
- 66 Dietary Phytocompounds for Colon Cancer Therapy. **2022,** 0
- 65 p53 positively regulates the proliferation of hepatic progenitor cells promoted by laminin-521. **2022, 7,** 0
- 64 Cell cycle progression defects and impaired DNA damage signaling drive enlarged cells into senescence. 0
- 63 GADD34 activates p53 and may have utility as a marker of atherosclerosis. 0
- 62 p53 pathway inactivation drives SMARCB1-deficient p53-wildtype epithelioid sarcoma onset indicating therapeutic vulnerability through MDM2 inhibition. 0
- 61 p53 amyloid aggregation in cancer: function, mechanism, and therapy. **2022, 11,** 0
- 60 In vitro and in vivo anticancer potential and molecular targets of the new colchicine analog IIM-067. **2022,** 0
- 59 A comprehensive study of p53 protein. 0
- 58 DNA damage response revisited: the p53 family and its regulators provide endless cancer therapy opportunities. 1
- 57 Smp24, a Scorpion-Venom Peptide, Exhibits Potent Antitumor Effects against Hepatoma HepG2 Cells via Multi-Mechanisms In Vivo and In Vitro. **2022, 14, 717** 1
- 56 Exploring CDKs, Ras-ERK, and PI3K-Aktin Abnormal Signaling and Cancer. 11, 63-69 0
- 55 Current insights into the regulation of programmed cell death by TP53 mutation in cancer. 12, 1
- 54 Tumor Suppressor Genes. 1-15 0
- 53 MLOstasis: liquidâ€”liquid phase separation and biomolecular condensates in cell competition, fitness, and aging. **2023, 485-504** 0
- 52 OR2AT4, an Ectopic Olfactory Receptor, Suppresses Oxidative Stress-Induced Senescence in Human Keratinocytes. **2022, 11, 2180** 1
- 51 Ginsenoside Rh2 sensitizes the anti-cancer effects of sunitinib by inducing cell cycle arrest in renal cell carcinoma. **2022, 12,** 0

50	Nip63 transcriptionally represses p53 target genes involved in the radiation-induced DNA damage response. <b>2022</b> , 17,	0
49	Depletion of R270C Mutant p53 in Osteosarcoma Attenuates Cell Growth but Does Not Prevent Invasion and Metastasis In Vivo. <b>2022</b> , 11, 3614	0
48	Splicing factor SRSF3 represses translation of p21cip1/waf1 mRNA. <b>2022</b> , 13,	1
47	Association of RB1 rs9568036 and CDKN1A rs1801270 polymorphisms with retinoblastoma susceptibility. <b>2022</b> , 34, 328	1
46	New human ATM variants are able to regain ATM functions in ataxia telangiectasia disease. <b>2022</b> , 79,	0
45	p90RSK Regulates p53 Pathway by MDM2 Phosphorylation in Thyroid Tumors. <b>2023</b> , 15, 121	1
44	A reference human induced pluripotent stem cell line for large-scale collaborative studies. <b>2022</b> , 29, 1685-1702.e22	0
43	Hepatocyte-derived DPP4 regulates portal GLP-1 bioactivity, glucose production, and its absence alters liver disease progression.	0
42	The Regulatory Mechanisms and Clinical Significance of Lnc SNHG4 in Cancer. <b>2022</b> , 28, 3563-3571	0
41	Isotretinoin treatment upregulates the expression of p53 in the skin and sebaceous glands of patients with acne vulgaris.	0
40	BRD8 maintains glioblastoma by epigenetic reprogramming of the p53 network.	0
39	Epstein-Barr virus miR-BART2-5p and miR-BART11-5p regulate cell proliferation, apoptosis, and migration by targeting RB and p21 in gastric carcinoma. <b>2023</b> , 95,	0
38	Effects of the Omega-3 Fatty Acid DHA on histone and p53 acetylation in Diffuse Large B-Cell Lymphoma.	0
37	Role of Proteasomes in T Cell Activation and Proliferation. <b>1998</b> , 160, 788-801	11
36	TGF- $\beta$ Induces the Cyclin-Dependent Kinase Inhibitor p27Kip1 mRNA and Protein in Murine B Cells. <b>1998</b> , 160, 770-777	9
35	P53 protein and the diseases in central nervous system. 13,	0
34	Functional genomic analysis of adult and pediatric brain tumor isolates.	0
33	Long Non-Coding RNA Generated from CDKN1A Gene by Alternative Polyadenylation Regulates p21 Expression during DNA Damage Response.	0

32	Hyperforin Elicits Cytostatic/Cytotoxic Activity in Human Melanoma Cell Lines, Inhibiting Pro-Survival NF- $\kappa$ B, STAT3, AP1 Transcription Factors and the Expression of Functional Proteins Involved in Mitochondrial and Cytosolic Metabolism. <b>2023</b> , 24, 1263	1
31	Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types.	0
30	Isotretinoin treatment upregulates the expression of p53 in the skin and sebaceous glands of patients with acne vulgaris.	0
29	Pentacyclic Triterpenoids-Based Ionic Compounds: Synthesis, Study of Structure-Activity Relationship, Effects on Mitochondria and Activation of Signaling Pathways of Proliferation, Genome Repair and Early Apoptosis. <b>2023</b> , 15, 756	0
28	Exploiting pivotal mechanisms behind the senescence-like cell cycle arrest in cancer. <b>2023</b> ,	0
27	A Review of the Regulatory Mechanisms of N-Myc on Cell Cycle. <b>2023</b> , 28, 1141	0
26	The Prospects of RNAs and Common Significant Pathways in Cancer Therapy and Regenerative Medicine. <b>2023</b> , 331-390	0
25	Pan-Cancer Biomarker miR-151a Regulates p21 Partially Through p53.	0
24	Aging and Bone Metabolism. 4355-4386	0
23	Encoding and Decoding of p53 Dynamics in Cellular Response to Stresses. <b>2023</b> , 12, 490	1
22	Effects of Goat Meat Extracts on $\alpha$ -Glucosidase Inhibitory Activity, Expression of Bcl-2-Associated X (BAX), p53, and p21 in Cell Line and Expression of Atrogin-1, Muscle Atrophy F-Box (MAFbx), Muscle RING-Finger Protein-1 (MuRF-1), and Myosin Heavy Chain-7 (MYH-7) in C2C12 Myoblasts. <b>2023</b> , 43, 359-373	0
21	PITAR, a DNA damage-inducible Cancer/Testis long noncoding RNA, inactivates p53 by binding and stabilizing TRIM28 mRNA.	0
20	Splicing Modulation Results in Aberrant Isoforms and Protein Products of p53 Pathway Genes and the Sensitization of B Cells to Non-Genotoxic MDM2 Inhibition. <b>2023</b> , 24, 2410	0
19	Potent bromodomain and extraterminal domain inhibitor JAB-8263 suppresses MYC expression and exerts anti-tumor activity in colorectal cancer models. 15, 332-342	0
18	Expression and Clinical Significance of MDM2 in Non-Functioning PitNETs. <b>2023</b> , 59, 373	0
17	Elephant TP53-RETROGENE 9 induces transcription-independent apoptosis at the mitochondria. <b>2023</b> , 9,	0
16	Identification and Characterization of an Ageing-Associated l3-lncRNA Signature That Predicts Prognosis and Immunotherapy in Hepatocellular Carcinoma. <b>2023</b> , 2023, 1-22	0
15	Molekulare Klassifikation beim Endometriumkarzinom. <b>2023</b> , 56, 164-175	0

- 14 Targeting p53 pathways: mechanisms, structures, and advances in therapy. **2023**, 8, ○
- 13 Spontaneous p53 activation in middle-aged C57BL/6 mice mitigates the lifespan-extending adaptive response induced by low-dose ionizing radiation.. ○
- 12 Cell Cycle and Cancer. **2023**, 83-101 ○
- 11 NUDT22 promotes cancer growth through pyrimidine salvage. **2023**, 42, 1282-1293 ○
- 10 Effective-by-method for the preparation of folic acid-coated TiO 2 nanoparticles with high targeting potential for apoptosis induction against bladder cancer cells (T24). 1
- 9 In vivo RNA-seq and CHIP-seq analyses show an obligatory role for the C terminus of p53 in conferring tissue-specific radiation sensitivity. **2023**, 42, 112216 ○
- 8 Shared gene regulatory strategies for the p53 and ATF4-dependent transcriptional networks. ○
- 7 Nanotubes fabricated from a triple helix polysaccharide as a novel carrier delivering doxorubicin for breast cancer therapy. **2023**, 124153 ○
- 6 Tumor-suppressive role of the musculoaponeurotic fibrosarcoma gene in colorectal cancer. **2023**, 26, 106478 ○
- 5 Different impacts of TP53 mutations on cell cycle-related gene expression among cancer types. **2023**, 13, ○
- 4 VprBP/DCAF1 regulates p53 function and stability through site-specific phosphorylation. **2023**, 42, 1405-1416 ○
- 3 DNA damage, demethylation and anticancer activity of DNA methyltransferase (DNMT) inhibitors. **2023**, 13, ○
- 2 Biomarkers of aging. ○
- 1 Diet suppresses glioblastoma initiation in mice by maintaining quiescence of mutation-bearing neural stem cells. **2023**, ○